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Tuberculosis (TB) is responsible for the deaths of 1.6 million people worldwide 
each year and is the leading cause of death by the pathogen Mycobacterium 
tuberculosis. The treatment regimen for M. tuberculosis involves lengthy, 
intensive drug therapy that causes severe side-effects. The antimicrobial para-
aminosalicylic acid (PAS) is used to treat drug-resistant M. tuberculosis 
infections. Despite the use of PAS to treat M. tuberculosis for over 70 years, the 
biochemical mechanisms which govern PAS susceptibility and resistance in M. 
tuberculosis are incomplete. The focus of this dissertation is to determine these 
mechanisms and can be summarized into three interrelated studies: 1) The 
mechanism of action of PAS on the M. tuberculosis folate metabolic pathway; 2) 
Understanding the mechanisms of PAS resistance; and 3) Examining the drug-
drug interactions between PAS and other anti-folate drugs that are used to treat 
opportunistic infections in patients with HIV-M. tuberculosis co-infections. 
 
Chapter 2 shows that PAS is a pro-drug and is converted, via the M. tuberculosis 
folate biosynthetic pathway, to hydroxy-dihydrofolate. The folate biosynthesis 
pathway is an essential metabolic pathway used maintain the production of DNA, 
RNA, and proteins. Results showed that hydroxy-dihydrofolate acted as a potent 
inhibitor for dihydrofolate reductase and confirm the biochemical mode of action 
of PAS. Although PAS was originally found to be effective at inhibiting M. 
tuberculosis and showed no activity against other bacterial species. PAS activity 
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was tested against other bacterial pathogens. While M. tuberculosis was 
extraordinarily sensitive to PAS, other bacteria resisted PAS-mediated killing. 
Chapter 2 found these bacterial species could utilize PAS as a fully functional 
folate analog into one-carbon metabolism. The folate biosynthesis precursor, 
para-aminobenzoic acid (PABA), is a known antagonist of antifolates, namely 
sulfonamides. Since PAS was shown to act similarly to PABA in folate 
biosynthesis, PAS-sulfonamide interactions were tested against a panel of 
bacterial pathogens. PAS could antagonize sulfonamides in all of these 
organisms. HIV-infected individuals are given numerous drugs to both treat the 
HIV infection and prophylactically treat and prevent opportunistic infections. The 
most commonly prescribed prophylactic drugs are the sulfonamides. These 
findings strongly support that PAS and sulfonamides should cease to be used in 
combination in individuals with HIV-M. tuberculosis co-infections. 
  
Many patients discontinue treatment of PAS because of the side effects, namely, 
gastrointestinal distress. Bacteria must make their own folates and many bacteria 
in the human colon excrete folate to supply human enterocytes with folates. All 
rapidly dividing human cells require folates for the synthesis of new DNA, RNA, 
and proteins. All human cells contain folate receptors which recognize the 
metabolites dihydrofolate or folate. Purified human dihydrofolate reductase 
enzyme and could use hydroxy-dihydrofolate but much less effectively than the 
native substrate. Since enterocytes require a large amount of folates for rapid cell 
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growth, enterocytes using hydroxy-dihydrofolate as a source of folates may not 
be able to grow as fast leading to severe gastrointestinal distress. Indeed, 
hydroxy-dihydrofolate, not PAS, was cytotoxic to enterocytes and hepatocytes. 
These findings will allow us to ultimately to design better ways to administer PAS 
to prevent patients from discontinuing PAS treatment.  
 
In Chapter 3, we hypothesized mice could be co-treated with sulfonamides to 
prevent PAS bioactivation and resulting PAS toxicity. Surprisingly, sulfonamides 
antagonized the anti-mycobacterial action of PAS in mice, resulting in the 
unrestricted growth of M. tuberculosis in the lungs and dissemination of M. 
tuberculosis into the liver and spleen. Taken together, these data indicate that 
combining PAS with sulfonamide in the clinic would not be useful, could be 
detrimental to patient outcome, and further highlights the need for mechanistic 
studies of drug-drug interactions. 
. 
Chapter 4 established that PAS resistance in M. tuberculosis primarily mapped to 
the folate biosynthetic pathway. The most prevalent mutations mapped to thyA 
and folC, a thymidylate synthase and dihydrofolate synthase, respectively. We 
hypothesized that folC mediated resistance occurred through an increase in 
PABA biosynthesis. Indeed PABA biosynthesis genes were upregulated in folC 
resistant mutants but not in thyA resistant mutants. The folC mutants had 
restored susceptibility to PAS when PABA biosynthesis was disrupted. 
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Furthermore, it was found that disruptions in PABA biosynthesis were 
bactericidal in M. tuberculosis. These data represent a novel intrinsic mechanism 
of resistance to PAS and highlights a novel drug target in M. tuberculosis. 
 
This dissertation is the first to determine that PAS selectively inhibits M. 
tuberculosis dihydrofolate reductase enzyme and subsequently, the folate 
biosynthetic pathway. The work presented in this dissertation found that using 
PAS and sulfonamides together prevented both drugs from working correctly in 
M. tuberculosis and in other bacterial pathogens. The results generated from this 
dissertation will be used to inform the current clinical practices in combination 
therapy and foster a paradigm shift in the treatment regimen administered to HIV-
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Chapter 1:  
The mechanistic basis for susceptibility and resistance to para- 
aminosalicylic acid and other antifolates 
This chapter is a reprint, with alterations, of a published manuscript. 
Kordus, S.L. and Baughn A. B. 2019. Revitalizing antifolates through 






Impact of Mycobacterium tuberculosis 
Mycobacterium tuberculosis is the causative agent of tuberculosis (TB). TB was 
responsible for 1.6 million deaths and yielded 10 million new active cases in 
2017(WHO, 2018). TB is one of the top 10 causes of death worldwide and is the 
leading cause of death due to a single infectious agent. Although a highly 
effective treatment regimen for TB exists, therapy remains challenging due to the 
protracted treatment duration that requires multiple antibiotics. The minimum 
treatment duration for TB is 6 months with drugs that are associated with adverse 
reactions. Standard treatment can cure 95% of drug susceptible TB cases. Drug 
resistant strains of M. tuberculosis can emerge in the 5% of patients that cannot 
be effectively treated by standard therapy. Drug resistant TB is multifactorial and 
can occur from treatment errors and poor quality or supply of antitubercular 
drugs. Furthermore, drug-resistant strains of TB can only be cured in about 50% 
of patients. Treatment of drug-resistant TB can last more than 2 years with 
chemotherapeutics that are associated with even more adverse side effects. 
Treatment duration and costs make curing drug resistant TB challenging. 
Therefore, there is an increased interest in studying drugs used to treat drug-
resistant TB. 
 
para-aminosalicylic acid (PAS) is an antimicrobial agent used to treat M. 
tuberculosis infections. Despite the use of PAS to treat TB for over 70 years, the 
biochemical knowledge which govern PAS susceptibility and resistance in M. 
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tuberculosis are incomplete. The focus of this dissertation is to determine these 
mechanisms and can be summarized into three interrelated studies: 1) 
Understanding the mechanisms that govern PAS resistance and susceptibility; 2) 
Examining the drug-drug interactions between PAS and other antifolate drugs 
that are used to treat opportunistic infections in patients with HIV-M. tuberculosis 
co-infections; and 3) Probing para-aminobenzoic acid biosynthesis for novel drug 
targets. Determining the mechanisms that govern resistance and susceptibility to 
current anti-tubercular drugs will allow the discovery of new therapeutic 
approaches to shorten treatment times and counter drug-resistant TB. 
 
The disease tuberculosis 
In the 1880s, Robert Koch discovered M. tuberculosis was the causative agent of 
TB. The disease generally affects the lungs and has symptoms that include 
chronic cough, fever, night sweats, and weight loss(WHO, 2018). Historically, TB 
was called consumption or wasting away disease due to the severe weight loss 
patients experienced. The cough is not productive during the initial phase of the 
disease. As the disease progresses, inflammation and tissue necrosis increase, 
and causes a productive cough with blood tinged sputum. The word TB was 
derived from the tubercle lesions people with M. tuberculosis had in their lungs. 
The early period during the infection can be misdiagnosed as other pulmonary 
diseases. TB is thought to latently infect between one-third to one-fourth of the 
world’s population(WHO, 2018). In 5-10% of these infected individuals, the 
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bacterium will cause active disease that can be transmitted via coughing or 
sneezing. Although many pathogenic bacteria have devised strategies to prevent 
immune recognition, M. tuberculosis has evolved multiple mechanisms to be 
recognized by and exploit the host immune system. 
 
M. tuberculosis first emerged in Africa around 70,000 years ago and spread 
across the world by human migration(Hershberg et. al., 2008; M Cristina et. al., 
2005). M. tuberculosis is believed to have evolved from an ancient environmental 
strain of mycobacteria(Gagneux, 2018). A close relative of this ancestral strain 
can be isolated in east Africa. This common ancestor of Mycobacterium is 
thought to have been unable to be transmitted from person to person but was 
capable of causing a chronic infection in an immune-competent person(Supply 
et. al., 2013). In contrast, M. tuberculosis can only spread by human to human 
transmission (Brites and Gagneux, 2012; Ebert and Bull, 2003). Furthermore, M. 
tuberculosis has no known animal or environmental reservoir, unlike many other 
bacterial pathogens. Taken together, these observations suggests that M. 
tuberculosis evolved to become an intercellular pathogen and environmental 
mycobacteria initially evolved to survive inside of a free-living protozoa that fed 
on environmental bacteria(Jang et. al., 2008). Additionally, while this strain 
survived inside of protozoa, it evolved the ability to survive and multiply 
intracellularly in a macrophage; however, this strain could not be transmitted from 
person to person(VanderVen et. al., 2017). This Mycobacterium is thought to 
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have evolved the ability to spread from person to person, via aerosol droplets, 
facilitated by increased human social interactions that resulted from the 
agricultural revolution(Chisholm et. al., 2016).  
 
Some Mycobacteria can also cause disease in animals. These strains of 
Mycobacteria are thought to have evolved similarly to M. tuberculosis after 
domestication of animals. For instance, humans infected with M. tuberculosis 
were able to transmit the pathogen to cattle, this strain of M. tuberculosis evolved 
into the bacterium Mycobacterium bovis(Brosch et. al., 2002). M. bovis has also 
maintained the ability to be transmitted to humans.  
 
The Biology of Mycobacteria  
Mycobacteria are a member of the Actinobacteria phylum. They are non-motile, 
aerobic rods, with a high G+C DNA content (62-70% depending on species). The 
word Mycobacterium describes the fungal, pellicle-like hyphal colony morphology 
when grown on solid medium. Most Mycobacteria are environmental, soil-
dwelling organisms and are generally classified into two groups, fast-growing and 
slow-growing(Fedrizzi et. al., 2017; Gagneux, 2018; Rogall et. al., 1990). Fast 
growing Mycobacteria require less than seven days to form colonies on agar 
plates, while slow-growing Mycobacteria require over seven days. Some slow-
growers are human pathogens including M. tuberculosis (the causative agent of 
TB) and Mycobacterium leprae (the causative agent of leprosy). Although, it is 
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noted that M. leprae cannot be grown in pure culture. M. tuberculosis has a 
doubling time of 18-24 hours while Mycobacterium smegmatis, a fast growing 
Mycobacterium, has a doubling time of roughly 2.5 hours. The mechanistic basis 
for Mycobacterium slow growth is not understood. 
 
The immune response to M. tuberculosis infection 
M. tuberculosis is spread through aerosol droplets released from an infected 
individual either through coughing or sneezing. The aerosols are inhaled by 
another individual and M. tuberculosis is phagocytized by alveolar phagocytic 
cells within the lung. While most research has focused on interaction of M. 
tuberculosis with monocyte derived macrophages, neutrophils and dendritic cells 
can also phagocytize the bacterium, and less is known about the infection of 
these other immune cells. The information in this section will be focused within 
the context of alveolar macrophages. M. tuberculosis is phagocytized by binding 
to receptors on macrophages such as C-type lectin receptors, scavenger 
receptors, and complement receptors(Philips and Ernst, 2012; Schäfer et. al., 
2009; Wolf et. al., 2007). Interestingly, M. tuberculosis binding to distinct 
receptors dictates their intracellular fate. For instance, binding to a C-type lectin 
(specifically, dendritic cell-specific intracellular adhesion molecule 3–grabbing 
nonintegrin) or a complement receptor results in lysosomal delivery of the 
bacteria. Binding to a C-type lectin receptor (specifically, macrophage mannose 
receptor) prevents phagolysosomal maturation(Armstrong and Hart, 1975; Kang 
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et. al., 2005; Philips and Ernst, 2012). Taken together, M. tuberculosis has 
evolved multiple strategies to gain entry into phagocytic cells that serve as a 
niche for replication and persistence within the host. 
 
After gaining entry into the macrophage, there are multiple intracellular fates of 
M. tuberculosis. Once phagocytized, M. tuberculosis employs multiple 
mechanisms to prevent phagosomal maturation and remain in an early 
endosome-like environment(Russell, 2001). In some instances, M. tuberculosis is 
unable to prevent the phagosome-lysosome fusion leading to bacterial death. 
Furthermore, in some instances, the bacterium can replicate in the 
phagolysosome(17, 23). An early endosome environment allows M. tuberculosis 
to acquire nutrients, such as iron, while preventing acidification and fusion with 
the lysosome(Philips, 2008). The early endosome-like environment allows M. 
tuberculosis to replicate and eventually allows transmission to other cells.  
 
Once in the phagosome, M. tuberculosis can express and secrete proteins 
through Esx-1, a type VII secretion system. Esx-1 allows for escape and 
replication of M. tuberculosis into the cytosol. It is only present in pathogenic 
strains of M. tuberculosis and absent in the attenuated vaccine strain M. bovis 
BCG(Philips and Ernst, 2012; van der Wel et. al., 2007). One Esx-1 secreted 
protein of interest is the early secreted antigenic target 6kDa (ESAT-6) that 
inhibits antigen presentation by macrophages(Samten et. al., 2009; Volkman et. 
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al., 2010). ESAT-6 can also bind culture filtrate protein-10 (CFP-10) and allows 
M. tuberculosis to escape the phagosome during acidic conditions(De Jonge et. 
al., 2007). Bacterial escape into the cytosol, allows for growth and transmission 
of M. tuberculosis to neighboring alveolar macrophages. In the closely related 
Mycobacterium, Mycobacterium marinum, a model bacterium for studying the 
immune response to M. tuberculosis, cytosolic bacteria can also be ubiquitinated 
and are killed by autophagy(Collins et. al., 2009). It is not clear whether cytosolic 
ubiquitinated M. tuberculosis are killed by autophagy similar to M. marinum.  
 
M. tuberculosis can replicate inside of resting macrophages. Specific host factors 
(such as interferon gamma, tumor necrosis factor, and vitamin D) can activate 
the resting macrophages which results in the killing of M. tuberculosis(Jouanguy 
et. al., 1999). Interferon gamma can activate production of reactive nitrogen and 
oxygen species. Both reactive nitrogen and oxygen species are toxic to the 
bacterium and can result in the limitation of iron and other metals(Chan et. al., 
1992). Furthermore, in an activated macrophage, M. tuberculosis will switch its 
metabolism to allow for the utilization of host cholesterol, as a primary carbon 
source(Chang et. al., 2009; Pandey and Sassetti, 2008; Schnappinger et. al., 
2003). In an interferon gamma activated macrophage, the bacteria must acquire 
iron through siderophore production. Tumor necrosis factor is essential for 
controlling M. tuberculosis replication and works synergistically with interferon 
gamma to activate macrophages. However, M. tuberculosis can manipulate 
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macrophage production of tumor necrosis factor to enhance lung inflammation in 
mice(Agarwal et. al., 2009). Taken together M. tuberculosis employs multiple 
mechanisms to survive, replicate, and escape death by macrophages to promote 
disease and spread to new phagocytic cells.  
 
Once M. tuberculosis has replicated to a high titer in the macrophage or if they 
have escaped the macrophage, they spread to an uninfected phagocytic cell to 
propagate the infection(30). M. tuberculosis can escape the macrophage through 
two mechanisms, apoptosis and necrosis. Multiple studies found that the bacteria 
promote necrotic death of the macrophage(Keane et. al., 2000a; Molloy et. al., 
1994a). Attenuated and mutant strains of M. tuberculosis promote macrophage 
apoptosis that results in the release of fewer bacteria(Keane et. al., 2000b; 
Molloy et. al., 1994b). Apoptosis allows for the presentation of M. tuberculosis 
antigens to CD8+ T cells that would promote an adaptive immune response and 
limit the spread of infection(Divangahi et. al., 2010). During necrosis, 
macrophages will release signals to recruit additional phagocytic cells allowing 
for the spread of M. tuberculosis. Furthermore, M. tuberculosis infected 
macrophages that promote necrosis are taken up by newly recruited phagocytic 
immune cells causing the infection to spread(Philips and Ernst, 2012). M. 
tuberculosis also has multiple mechanisms to prevent apoptosis, via modulating 
the regulation of pro-and anti-apoptosis and inflammation responses(Balcewicz-
Sablinska et. al., 1998; Kremer et. al., 2007; Oddo et. al., 1998; Sly et. al., 2014). 
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Specifically, M. tuberculosis upregulates the anti-apoptotic genes mcl-1 and A1, 
as well as the protein complex NF-ΚB(Kremer et. al., 2007; Sly et. al., 2014). M. 
tuberculosis can also downregulate pro-apoptotic proteins such as Fas and 
tumor necrosis factor receptor 2(Balcewicz-Sablinska et. al., 1998; Oddo et. al., 
1998).  During this initial phase of the infection, there is little restriction of 
bacterial growth in the lung. This phase of the infection is dynamic and varies 
depending on individual immune response. 
 
Following the initial innate response, a delayed adaptive immune response is 
thought to be a mechanism employed by M. tuberculosis to expand the initial 
bacterial population in the lungs thereby establishing a chronic infection(Wolf et. 
al., 2008). Activation of CD4+ T cells results in the arrest of bacterial growth(Wolf 
et. al., 2008). In most humans, this arrest results in a latent bacterial infection. 
During latency, the cell mediated immune response coupled with the innate 
response forms the granuloma.  
 
Granulomas represent the hallmark histopathological lesions during a TB 
infection. Simply, the granuloma is an ordered assemblage of dendritic cells, T 
cells, B cells and several types of macrophages including mature macrophages, 
foamy macrophages, and multinucleated (Langhans) giant cells. Foamy 
macrophages are found in areas of the necrotic regions of the granuloma and are 
associated with large amounts of lipids(Peyron et. al., 2008). Interestingly, a 
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small proportion of macrophages in the granuloma are infected with M. 
tuberculosis. The granuloma is a “stalemate” between the host immune system 
and the bacterium. Granuloma formation is thought to be beneficial for M. 
tuberculosis survival, as the granuloma allows for the recruitment of additional 
phagocytic cells that allows for bacterial growth(Davis and Ramakrishnan, 2009). 
Similarly, the granuloma is thought to be beneficial to the host because it allows 
for close interactions between the bacterium and the immune system. The cell 
mediated immune response coupled with the innate response maintains the 
bacterial population and prevents dissemination to other areas of the host; 
however, it does not clear the infection. 
 
Although the initial infection primarily involves the innate immune response, the 
adaptive immune response is of paramount importance for controlling the 
infection. One feature of the adaptive immune response is the delay in the T cell 
response during an M. tuberculosis infection in humans and in mice(Grange and 
Yates, 1995). The delay is due to the lag in the migration of antigen presenting 
cells, from the lung to the lymph nodes. M. tuberculosis antigens are recognized 
by CD4+ T cells(Wolf et. al., 2008). These CD4+ T cells are a subset of T-cells 
that recognize antigen bound to major histocompatibility class (MHC) II 
molecules found on antigen presenting cells. Binding of a CD4+ T cell to its 
cognate antigen, via MHC II, allows the CD4+ T cell to activate phagocytic cells 
such as macrophages and dendritic cells. Therefore, CD4+ T cells are essential 
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for protective immunity against M. tuberculosis. CD4+ T cells are equally 
important in preventing reactivation of M. tuberculosis to an active infection, 
especially in the context of an HIV-TB co-infection (see section TB and HIV/AIDS 
Co-infection). M. tuberculosis employs several mechanisms to prevent antigen 
presentation to CD4+ T cells such as down-regulating antigen production, 
preventing antigen loading onto the MHC II, and preventing trafficking of MHC II 
to the membrane(Harding and Boom, 2010). There are multiple subsets of CD4+ 
T cells such as Th1, Th17, and Tregs that are also important for an effective 
immune response against M. tuberculosis(Harding and Boom, 2010; Khader et. 
al., 2005, 2007). CD4+ T cells activate another type of T cell, called CD8+ T cells 
that recognize MHC I molecules. MHC I is expressed on all host cells and 
expresses a peptide from degraded cytosolic proteins and also antigens from 
intracellular pathogens, like M. tuberculosis. When CD8+ T cells, or cytotoxic T 
cells, bind their cognate antigen they release cytotoxins such as perforin, 
granzymes, and granulysins to kill M. tuberculosis infected host cells by 
apoptosis(Lewinsohn et. al., 2003; Philips and Ernst, 2012). CD8+ T cells are 
important in controlling M. tuberculosis infection and, similarly to CD4+ T cells, 
depletion of CD8+ T cells can also cause a latent infection to become active(van 
Pinxteren et. al., 2000).  
 
Although CD4+ and CD8+ T cells are essential to control intracellular infections, 
another important immune cell for controlling infection and for vaccine 
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development are B cells. B cells are a population of white blood cells that are 
both antigen presenting cells and secrete antibodies. B cells recognize antigen 
through a B cell receptor that can bind extracellular antigen. Once antigen is 
bound to a B cell receptor, the B cell can present the antigen to antigen 
presenting cells and secrete cytokines(Blum et. al., 2013). After binding antigen, 
the B cell can undergo a class switch and affinity maturation to ultimately secrete 
high affinity antibodies to target the antigen(Mårtensson et. al., 2010). Antibody 
binding can have outcomes including opsonization of the surface of bacterial cell, 
neutralization of a pathogen, agglutination and precipitation of antigens to allow 
for phagocytosis to occur. One study found treating SCID mice (lacking T and B 
cells) with polyclonal antibodies against M. tuberculosis provided protection 
against disease relapse(Guirado et. al., 2006). During an infection many 
intracellular pathogens, including M. tuberculosis, will become extracellular 
therefore exposing antibodies to potential antigens(Achkar et. al., 2015). As the 
immune response is not capable of eliminating M. tuberculosis, people can be 
reinfected after the disease is treated and cleared.  
 
The complex interplay between M. tuberculosis and the host makes designing 
effective vaccines and discovery of new drugs challenging. The Bacillus 
Calmette-Guérin (BCG) vaccine is the only vaccine approved and given to 
prevent M. tuberculosis infection. The vaccine is given to infants worldwide in 
areas where TB is common(WHO, 2018). The vaccine is derived from an 
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attenuated strain of M. bovis, a strain of Mycobacterium that causes TB in 
bovines. M. bovis can also infect humans and cause TB(JM et. al., 1996). M. 
bovis BCG lacks many virulence factors found in M. tuberculosis such as the RD-
1 locus that encodes for many secreted proteins essential for virulence, such as 
ESX-1(Ganguly et. al., 2008; Stanley et. al., 2003). Children and adults can also 
receive the vaccine if they have not been previously infected with M. tuberculosis 
but are frequently exposed to drug resistant strains of M. tuberculosis(Davenne 
and McShane, 2016). The efficacy of the M. bovis BCG vaccine varies widely 
depending on the study. The vaccine protects an estimated 20% of people from 
getting a latent infection and it prevents an estimated 50% of people from 
developing the disease(Bjartveit, 2003; Hawn et. al., 2014). The vaccine is most 
effective at preventing extrapulmonary disease (Colditz et. al., 1995; Fine, 1995). 
One obstacle in creating new vaccines is the lack of a convenient animal model 
that fully recapitulates various aspects of the human  immune response to M. 
tuberculosis. Standard lab mice do not exhibit the hallmark granuloma within the 
lung and succumb to the disease much slower than humans(Ernst, 2012; 
Ramakrishnan, 2012).  
 
For many years, a diagnosis of latent TB was defined as a reactivity to the 
tuberculin skin test without signs or symptoms of active disease. Briefly, this test 
uses purified protein derivatives that are injected intradermally. The tuberculin 
skin test measures the delayed-type hypersensitivity response elicited to these 
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proteins. Patients could test positive due to the presence or exposure to non-
pathogenic mycobacterial antigens such as those found in the M. bovis BCG 
vaccine(Barry et. al., 2009; Mazurek et. al., 2001). Recently, more specific tests, 
such as QuantiFERON gold and T-spot test have been developed for diagnosis 
M. tuberculosis exposure. QuantiFERON measures the amount of interferon 
gamma level produced by circulating T cells in response to M. tuberculosis 
antigens early secretory antigenic target 6 (ESAT-6), culture filtrate protein 10 
(CFP-10), and TB7.7. Interferon gamma levels are elevated in patients that have 
elicited a cell-mediated immune response to the previously mentioned M. 
tuberculosis antigens. One major drawback to the QuantiFERON gold test is that 
depending upon the level of T cell depletion, HIV-positive individuals may lack an 
effective cell-mediated immune response, to any infection, and will test negative. 
In this patient cohort, an (ELISPOT) assay is performed termed T-spot TB. 
Specifically, the T-spot measures the number of interferon gamma producing T 
cells after exposure to ESAT-6 and CFP-10 (Wang et. al., 2007). As previously 
described both of these proteins are only found in M. tuberculosis and are absent 
in non-pathogenic mycobacteria. Importantly, the T-spot assay can be used to 
evaluate patients who are HIV-positive, as the assay does not require high 
amounts of reactive CD4+ T cells(Lawn et. al., 2007). One problem with all of the 
previously mentioned diagnostic tests is that they do not distinguish between 




The definition of a latent infection is quite diverse. Some define latency as 
metabolically active bacteria contained in the host in the absence of clinical 
symptoms, compared to those who have cleared the infection(Young et. al., 
2009). Similarly, even active TB is broadly characterized by the presence of 
caseous hypoxic lesions with dynamic bacterial burden or liquid cavities with 
massive loads of replicating bacteria. Therefore, TB is thought to be a spectrum 
of disease(Barry et. al., 2009). Recently, there has been a shift in our 
understanding of what a latent infection might be. Several studies have shown 
that TB reactivity can occur even after an M. tuberculosis infection has 
cleared(Behr et. al., 2018). A recent study found individuals who test positive for 
latent TB might never reactivate to an active infection. Furthermore, these 
individuals had no viable bacilli even with sequence positive results in the 
lesions, in the lung. In some individuals considered latently infected, no bacilli 
were found with negative sequencing results(Behr et. al., 2018). 
 
Bacterial reactivation can be influenced by certain genetic or pathophysiological 
factors, such as HIV co-infection, aging, and cancer(WHO, 2018). These factors 
decrease the cell mediated immune response and allow the bacteria to grow and 
breakdown the granuloma structure. Deterioration of the granuloma can allow the 
bacteria to escape the confinement of necrotized host cells allowing for the 
transmission into the airways. Once in the airways M. tuberculosis is able to be 
transmitted person to person. In some cases, the infection can go systemic and 
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spread to other parts of the body such as spleen, liver, bones and central 
nervous system. Approximately 15-20% of new cases of TB are 
extrapulmonary(Lee, 2015; WHO, 2018). Symptoms of extrapulmonary TB are 
similar to pulmonary TB and can include fever, weight loss, anorexia and general 
weakness (WHO, 2018). Systemic infections are associated with higher morbidity 
and mortality rates especially in immunocompromised individuals.  
 
Mycobacterial cell wall 
A distinct feature of Mycobacteria is their unique cell envelopes. Functionally 
similar to Gram-negative bacteria, M. tuberculosis cell envelope consists of an 
asymmetric lipid bilayer made of long chain fatty acids (mycolic acids), a layer of 
peptidoglycan, arabinogalactan, and waxy components that surround the plasma 
membrane (Brennan, 2003; Hett and Rubin, 2008). The mycobacterial cell wall 
inner layer extending from the plasma membrane is composed of, in order, 
peptidoglycan and arabinogalactan, linked together. Peptidoglycan provides a 
scaffold to allow the bacteria to maintain their shape(Brennan, 2003; Hett and 
Rubin, 2008). Arabinogalactan, composed of arabinan and galactan, is the most 
abundant polysaccharide of the mycobacterial cell wall. Arabinogalactans anchor 
the peptidoglycan layer to the mycolic acid layer and is important for 




Lastly, the mycomembrane, is composed of two layers the inner layer and the 
outer layer(Vincent et. al., 2018). The inner layer is composed of mycolic acids 
that are long (between 60 and 90 carbon atoms), branched-chain hydroxy fatty 
acids; therefore, mycolic acids are hydrophobic. Mycolic acids are also primarily 
responsible for mycomembrane impermeability(Vincent et. al., 2018). For 
instance, mycolic acids are impervious to traditional Gram staining, and, for this 
reason, have been termed Gram indeterminate. In order to detect mycobacteria, 
an acid-fast stain is used. Briefly, acid fast staining uses heat and a phenol-basic 
dye which allows the stain to be retained in the membrane. The stain is not easily 
washed out due to the hydrophobic mycolic acid membrane. Notably, the inner 
mycomebrane is a target for many antitubercular drugs (See Treatment of 
tuberculosis, and Table 1.1). 
 
The mycomembrane outer layer is comprised lipids, lipoglycans, and 
proteins(Chiaradia et. al., 2017; Vincent et. al., 2018). The outer layer is not well 
characterized due to its complexity and many low abundance proteins. Some of 
the lipids found in the outer layer include phthiocerol dimycocerosate, phenolic 
glycolipid, and lipooligosaccharides. These lipids also help M. tuberculosis evade 
the host immune response and are virulence factors(Forrellad et. al., 2013; Reed 
et. al., 2004). The outer layer is associated via hydrophobic interactions with the 
inner mycomembrane layer(Grzegorzewicz et. al., 2016). The lipids in the outer 
membrane make mycobacteria more resistant to damage from certain sterilizing 
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chemicals and can prevent hydrophilic antibiotics from diffusing into the 
cell(Brennan and Nikaido, 1995).  
 
 
TB and HIV/AIDS Co-infection 
Opportunistic infections, such as TB, are the leading cause of death in individuals 
with HIV/AIDS. Individuals infected with HIV and latently infected with TB are 20 
times more likely than HIV-negative people to develop active disease(WHO, 
2018). In 2017, 9% of active TB diseases were in individuals who were HIV-
positive and caused an estimated 300,000 deaths among HIV-positive 
individuals(WHO, 2018). Therefore, individuals with HIV are not only placed on 
anti-retroviral therapy, but also a lifetime prophylactic combination of co-
trimoxazole, a broad spectrum anti-folate that is used to prevent opportunistic 
infections. HIV infections are a strong risk factor for developing active TB 
infections and are associated with poorer treatment outcomes. With the increase 
in antiretroviral therapy, the TB incidence rates have decreased among HIV-
positive individuals since 2010 (Williams et. al., 2010).  
 
HIV is a member of the Lentivirus genera of retroviruses. A retrovirus is a type of 
RNA virus that encodes its own reverse transcriptase to produce DNA from its 
RNA genome. The DNA is then integrated into the host DNA and the host 
transcription and translational machinery can express viral protein. HIV infects 
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CD4+ helper T cells. In healthy HIV-negative individuals, proliferating CD4+ T 
cells are long lived (Okoye and Picker, 2013). During HIV infection, these cells 
are quickly turned over either by pyroptosis, the killing of infected cells by CD8+ T 
cells or by apoptosis(Doitsh et. al., 2013; Garg et. al., 2012; Okoye and Picker, 
2013). Without treatment HIV is fatal after 9-13 years and generally results in 
acquired immunodeficiency syndrome (AIDS) when the CD4+ T cell count is 
below 200 cells per µL of blood. Without treatment the mean survival period, of 
people with AIDS is less than 3 years.  
 
As discussed above in The disease tuberculosis, controlling M. tuberculosis 
infection requires both CD4+ T cells and CD8+ T cells. Depletion of both cell 
types results in TB activation and rapid disease progression. Specifically, 
declining CD4+ T cells results in poor granuloma formation and an increase in 
dissemination of M. tuberculosis(Diedrich and Flynn, 2011). The advent of 
effective antiretroviral therapy to treat HIV prevents the rapid decline in CD4+ T 
cells. Although, the CD4+ T cell function is not as robust as in a TB-positive HIV-
negative individual (Chang et. al., 2013; Suthar et. al., 2012). Patients who are 
HIV-positive with diagnosed latent TB are started on a treatment regimen to 
prevent the reactivation of TB. Furthermore, although TB is the leading cause of 
death in HIV-positive individuals, there are a variety of other opportunistic 




To protect against opportunistic infections, HIV-infected individuals are given the 
chemotherapeutic agent co-trimoxazole, a combination of sulfamethoxazole 
(SMX) and trimethoprim (TMP) in a 5:1 ratio, respectively. Co-trimoxazole is 
given as life-long prophylactic therapy to HIV-positive individuals even when the 
viral titers are undetectable. The combination of SMX/TMP is used to treat a 
variety of bacterial infections including respiratory tract infections, urinary tract 
infections, Staphylococcal infections, and cholera. Co-trimoxazole has also been 
given as lifetime prophylactic therapy to treat and prevent Pneumocystis 
pneumonia and Toxoplasma gondii which commonly infect individuals with AIDS. 
When SMX is not well tolerated dapsone is used as a surrogate. Given the 
success and global availability of highly active antiretroviral therapy for HIV, there 
is a debate regarding the need for lifelong co-trimoxazole prophylactic therapy. 
More information on antifolates will be discussed in Folate biosynthesis as a drug 
target.  
 
Treatment for M. tuberculosis 
Treatment of M. tuberculosis is more complex than treatment for any other 
bacterial infection. For drug susceptible M. tuberculosis infections, patients are 
treated with short course antitubercular therapy of rifampicin, isoniazid, 
ethambutol, and pyrazinamide for 2 months followed by treatment with isoniazid 
and rifampicin for an additional 4 months(WHO, 2018). Each drug is associated 
with a unique mechanism of action for targeting different metabolic 
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processes(Table 1.1). Each of the previously mentioned drugs are associated 
with numerous adverse reactions(Table 1.1). Extensive clinical trials have shown 
that this short course therapy will provide a cure to drug susceptible strains of M. 
tuberculosis in more than 95% of cases, if the drugs are taken correctly. 
However, a small subset of M. tuberculosis cells are able to “persist” in low 
numbers for long periods of time despite the presence of antitubercular therapy. 
These “persisters” can take months to fully eradicate and can lead to disease 
relapse if not fully resolved.  
 
Isoniazid is considered the best bactericidal drug while rifampicin is considered 
the best sterilizing drug. If resistance occurs to both of these instrumental agents, 
patients will be infectious longer, proloning treatment from 6 months to possibly 
longer than 24 months. Multiple types of drug resistance are wide spread across 
the globe and must be considered during TB treatment. Multidrug resistant TB 
(MDR-TB) is defined as being resistant to both isoniazid and rifampicin. While 
extensively drug resistant TB (XDR-TB) is defined as being resistant to isoniazid, 
rifampicin, a second-line fluoroquinolone, and an injectable second line drug 
such as amikacin, kanamycin, or capreomycin. In some areas of the world, totally 
drug resistant strains of M. tuberculosis exist that cannot be cured by existing 
drug regimens. The factors that contribute to the emergence of MDR-TB are still 
not fully understoodinclude treatment errors and patient noncompliance. MDR-TB 
drugs are prescribed by the following considerations, (i) the percentage of drug 
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resistance in the local region, (ii) previous anti-tubercular drugs taken by the 
patient and adverse reactions to those drugs, and (iii) patient medical history 
(Lange et. al., 2014).   
 
Drug discovery in M. tuberculosis has been challenging. First, drugs must be 
able to travel to the lung, travel through the granuloma, and ultimately travel into 
a macrophage in high enough dosage to inhibit or, ideally, kill M. tuberculosis. 
These “ideal” drug candidates should inhibit various physiological states of the 
bacterium and M. tuberculosis should have low evolvable resistance to these 
candidates. The bacterium can be found in many diverse environments (such as 
hypoxia and low pH). Therefore, the drug candidates should be stable (not prone 
to degradation). Ideally, the drug candidates should inhibit both replicating and 
non-replicating states of M. tuberculosis. As described above, the cell wall of M. 
tuberculosis is waxy, lipid rich, and can be impenetrable to many drug-like 
compounds. Furthermore, a relatively inexpensive animal model recapitulating 
the various microenvironments inhabited by M. tuberculosis does not exist. Also, 
the drugs must be well tolerated in patients for extended periods of time, be 
inexpensive, and have minimal drug-drug interactions with the current treatment 
regimen and HIV antiretroviral therapy. This coupled with the slow growth rate of 
M. tuberculosis and requiring Biosafety Level 3 culturing and animal facilities 
have resulted in very few drugs entering into the development pipeline and 
ultimately into the clinic(Koul et. al., 2011; Kumar et. al., 2017; Zuniga et. al., 
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2015). There have been numerous recent advances in understanding M. 
tuberculosis biology, including models for understanding bacterial physiology and 
genetics of M. tuberculosis.  
 
para-Aminosalicylic acid inhibits M. tuberculosis 
para-Aminosalicylic acid (PAS) was synthesized in 1902; however, its therapeutic 
potential was not recognized until 1940(Seidel and Bittner, 1902). Frederick 
Bernheim found salicylic acid stimulated oxygen consumption in M. tuberculosis, 
while other structural analogs of salicylic acid decreased oxygen 
consumption(BERNHEIM, 1940). Jörgen Lehmann followed up on these studies 
and screened over 50 benzoic acid structural analogs, synthesized by K. G. 
Rosdahl from Ferrosan Company(Donald and Diacon, 2015). He identified PAS 
as a potent antitubercular agent(Lehmann, 1946). In March 1944, after PAS was 
found to be efficacious in treating TB in animals, it was given to 20 patients with 
pulmonary TB. Although bacterial counts were not reported, patients gained 
weight, had reduced fevers, and decreased erythrocyte sedimentation rates (a 
correlative measure of bacterial burden)(Donald and Diacon, 2015; Lehmann, 
1946). Although, PAS was the first antitubercular agent tested in humans, no 
controls were used in the study. Interestingly, PAS has been shown to only have 
activity against M. tuberculosis, although the mechanistic basis for this high level 
of selectivity is not known(Ivanovics et. al., 1948; Ragaz, 1948; Sievers, 1946; 
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Tobie and Jones, 1949; Wyss, 1943). PAS entered clinical use as a 
bacteriostatic antitubercular agent in 1946(Youmans et. al., 1947b).  
 
While Lehmann was testing the antitubercular activity of PAS, Albert Schatz, a 
PhD student in the laboratory of Selman A. Waksman, isolated the antibiotic 
streptomycin. Streptomycin showed potent antitubercular activity(Schatz et. al., 
1944). Shortly thereafter, streptomycin was used in randomized clinical trials to 
treat patients with TB and showed excellent efficacy.  
 
Before the discovery of PAS and streptomycin, 50-80% of patients who tested 
positive for TB would die within 10 years(Tiemersma et. al., 2011). The discovery 
of streptomycin and PAS had dramatically improved TB survival rates. However, 
resistance to streptomycin in M. tuberculosis emerged shortly after its 
introduction into the clinic. PAS was found to be effective against streptomycin-
resistant strains of M. tuberculosis(Youmans et. al., 1947b). PAS was used in 
combination with streptomycin, which reduced the emergence of drug resistance, 
and is considered the first multi-drug therapy. The antitubercular agent isoniazid, 
discovered in the early 1950s, was highly effective in treating M. tuberculosis and 
was often included in the streptomycin-PAS treatment regimen. The three-drug 
combination was found to be highly effective in curing M. tuberculosis and 




Unfortunately, treatment with PAS was often associated with gastrointestinal (GI) 
distress. During the first clinical trial of PAS 75% of patients taking PAS reported 
severe GI distress, and 20-25% reported nausea, vomiting and diarrhea(Erdei 
and Snell, 1948; Vallentin and Tronell, 1950). Clinical trials in the US resulted in 
almost half of patients discontinuing PAS treatment(Pfuetze and Pyle, 1949). 
During these clinical trials researchers speculated that this GI distress was due to 
impurities during the synthesis or deterioration of PAS by opening storage 
containers(Mitchell et. al., 1954). To counter these severe side effects, PAS was 
given intravenously in Europe and was found to be much bettered 
tolerated(Jones, 1954). Furthermore, PAS was found to be quickly inactivated in 
the liver either through acetylation, to produce mono- or di-acetyl-PAS, or 
carboxylated, to produce glycine-PAS(Jenne et. al., 1961). In addition, the mean 
serum life of PAS is 1hr. With the advent of better tolerated and superior 
antitubercular agents, such as ethambutol, rifampicin, and pyrazinamide, PAS fell 
out of use to treat TB in the 1960s. 
 
In 1994, with the global spread of MDR and XDR strains of M. tuberculosis, PAS 
has re-entered antitubercular drug regimens to treat drug resistant strains of M. 
tuberculosis. Furthermore, PAS was reformulated into a new delayed release 
gastro-resistance formulation, to help prevent GI distress. PAS is given as the 
free base. The acid resistant granules should be taken with acidic food. Once the 
granules enter the small intestines, the coating is dissolved at neutral pH and the 
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coat allows for delayed release of PAS, so that the serum levels do not 
immediately peak. However, patients still must take 10-12g of PAS per day to 
reach inhibitory levels in the lung and still 20% of patients will discontinue PAS 
treatment due to GI distress. In response to the revitalization of PAS, there is a 
need for understanding of the molecular details of susceptibility and resistance of 
M. tuberculosis to PAS. Initial observations suggested that PAS disrupted a 
salicylic acid-linked metabolic pathway; however, recent studies have suggested 
that PAS inhibits folate biosynthesis.  
 
Folate biosynthesis as a drug target  
In prokaryotes and eukaryotes, folate (vitamin B9) is an essential metabolic 
cofactor required for all actively growing cells. Specifically, folate serves as a 
one-carbon carrier in the synthesis of amino acids (such as methionine, serine, 
and glycine), N-formylmethionyl-tRNA, coenzyme A, purines and thymidine 
(Figure 1.1). Many microbes are unable to acquire folates from their environment 
and rely on de novo folate biosynthesis. In contrast, mammals lack the de novo 
folate biosynthesis pathway and must obtain folate from commensal microbiota 
or the environment using proton-coupled folate transporters. The essentiality and 
dichotomy between mammalian and bacterial folate biosynthesis and utilization 
pathways make it an ideal drug target for the development of antimicrobial 




De novo folate biosynthesis begins with the synthesis of para-aminobenzoic acid 
(PABA, Figure 1.2) and 6-hydroxymethyl-7,8-dihydropterin pyrophosphate 
(DHPPP, Figure 1.3). Although both pathways are largely absent in mammals 
and essential in bacteria, protozoa and fungi, there are no antimicrobial agents in 
clinical use that target PABA or DHPPP biosynthesis.  
 
Later steps in folate synthesis involve the conversion of 7,8-dihydropteroate 
(DHP) to 5,6,7,8-tetrahydrofolate (THF) in three ordered steps by DHP synthase 
(FolP), dihydrofolate synthase (FolC), and dihydrofolate reductase (DHFR in 
mammals and FolA in bacteria) (Figure 1.4). The only approved therapeutic 
agents in clinical use that target this portion of the pathway inhibit FolP and 
dihydrofolate reductase.  
 
Antifolates, agents that impair folate biosynthesis, were the first class of 
antimetabolites to enter clinical use. They were used to treat a variety of cancers 
and inflammatory disorders in humans and were among the first antimicrobial 
agents used to treat bacterial infections. Historically, antifolates have targeted the 
enzymes FolP (sulfonamides and sulfones) and DHFR (methotrexate, proguanil 
and trimethoprim). Resistance to antifolates was reported shortly after their 
introduction into clinic use. Since some antifolates can be associated with 
adverse reactions, some have been replaced with safer more effective drugs. 
With the rise in resistance to many chemotherapeutics and antimicrobial agents 
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and with the advent of better-tolerated antifolates, there has been a renewed 
interest in using this drug class to treat many diseases.  
 
Sulfonamides were introduced into the clinic in 1935 to treat a variety of bacterial 
infections. However, some sulfonamides, such as sulfamethoxazole (SMX), were 
associated with rare adverse reactions such as blood dyscrasias, hypoglycemia, 
hyperkalemia, and inhibition of cytochrome P450(KEISU et. al., 1990; Strevel et. 
al., 2006; Wen et. al., 2002). In 1962, TMP was introduced into the clinic as a 
bacterial FolA inhibitor. Shortly after introduction of TMP into clinic use, it was 
noted that SMX and TMP showed potent synergistic activity, permitting the use of 
lower dosages of SMX that resulted in fewer adverse reactions(Smilack, 1999). 
Consequently, co-administration of SMX with TMP (co-trimoxazole) became 
standard of care for treating many infections. Since co-trimoxazole is generally 
well-tolerated, relatively inexpensive and can target a broad spectrum of 
microbes, it is commonly used for prophylactic treatment against opportunistic 
infections in immunocompromised individuals.  
 
Targeting para-Aminobenzoic Acid Biosynthesis in Microbes 
In most bacteria, fungi, protozoans and plants, folates are synthesized from the 
convergence of two pathways, the PABA biosynthesis pathway and pterin 
biosynthesis pathway. The PABA biosynthesis pathway is generally absent in the 
metazoan lineage. The first step of PABA biosynthesis involves the conversion of 
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chorismate to aminodeoxychorismate (ADC) (Figure 1.2). Chorismate is a 
product of the shikimate pathway, the pathway from which aromatic amino acids, 
quinones and salicylic acid are also derived. In the synthesis of PABA, 
chorismate and glutamine are converted to ADC and glutamate by the action of 
ADC synthase. ADC synthase is comprised of two enzymatic subunits PabA and 
PabB encoded by pabA and pabB, respectively. Both enzymes require physical 
interaction for optimal catalysis. PabA catalyzes glutamine lyase activity and is 
typically only active in the presence of stoichiometric amounts of PabB(Roux and 
Walsh, 1993; Viswanathan et. al., 1995). In the absence of PabA and glutamine, 
PabB is able to catalyze the amination of chorismate in the presence of vast 
molar excess ammonia(Roux and Walsh, 1993). Both pabA and pabB are 
predicted to be essential in many bacterial species.  
 
Interestingly, some bacteria do not encode a defined PabA homolog and instead 
there is functional overlap with an analogous enzyme TrpG from the tryptophan 
biosynthetic pathway. In tryptophan biosynthesis TrpG functions in conjunction 
with TrpE to catalyze synthesis of anthranilate from chorismate and glutamine in 
a reaction similar to that for synthesis of ADC(Kaplan et. al., 1984; Knöchel et. 
al., 1999; Morollo and Eck, 2001; Mugumbate et. al., 2015; Slock et. al., 1990). 
As TrpG and PabA show a high degree of sequence conservation and have 
mechanistically identical enzymatic function(Morollo and Eck, 2001; Slock et. al., 
1990), organisms such as Bacillus subtilis, Acinetobacter calcoaceticus and 
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Salmonella enterica express a bi-functional (amphibolic) glutamine ammonium 
lyase that operates as a subunit of both anthranilate synthase and ADC 
synthase.  
 
The last step in PABA biosynthesis is the conversion of ADC to PABA by ADC 
lyase encoded by pabC(Green and Nichols, 1991; Green et. al., 1992). This 
reaction proceeds with the elimination of the pyruvyl moiety of ADC enabling 
subsequent aromatization to PABA. Since elimination of pyruvate from ADC can 
occur spontaneously, disruption of pabC is not predicted to be essential in many 
bacteria.   
 
In M. tuberculosis disruption of PABA biosynthesis, specifically through 
mutagenesis of pabB or pabC, results in enhanced susceptibility to antifolates, 
including sulfa-drugs and the diaminophenylsulfone, dapsone(Thiede et. al., 
2016). There are multiple natural products that inhibit PabB including 
abyssomicin C and anthelminthicin C and their derivatives (Figure 1.5)(Bihelovic 
et. al., 2013; Freundlich et. al., 2010; Keller et. al., 2007a, 2007b; Matovic et. al., 
2014). These compounds show inhibitory activity against M. tuberculosis and 
methicillin resistant Staphylococcus aureus (MRSA) in whole cell assays 
(Bihelovic et. al., 2013; Freundlich et. al., 2010; Matovic et. al., 2014; Riedlinger 
et. al., 2004; Wang et. al., 2010a). Evaluation of their activity in animal models of 
infection has not been reported. Abyssomicin C and some of its derivatives 
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display a high level of cytotoxicity against mammalian cells(Bihelovic et. al., 
2013). Although, atrop-O-benzyl-desmethylabyssomicin C was found to have 
significantly reduced cytotoxicity whilst retaining activity against MRSA and may 
represent a promising lead(Matovic et. al., 2014). In addition to these derivatized 
natural products, the synthetic dichloronitrophenyl propanone, MAC173979, was 
found to inhibit PABA biosynthesis in E. coli both enzymatically and in whole cell 
assays(Zlitni et. al., 2013). MAC173979 exhibited time-dependent inhibition in a 
one-pot assay using purified recombinant PabA, PabB, and PabC, yet, the exact 
target of MAC173979 is not known(Zlitni et. al., 2013). MAC173979 also showed 
potent activity against M. tuberculosis that could be antagonized by exogenously 
supplied PABA (Figure 1.5) (Thiede et. al., 2016). Consistent with genetic studies 
described above, synergistic inhibition of growth was observed when M. 
tuberculosis was treated with MAC173979 in combination with various sulfa-
drugs or dapsone(Thiede et. al., 2016). Taken together, the PABA biosynthesis 
pathway remains a promising drug target especially in combination with sulfa-
drugs. 
 
Targeting Pterin Biosynthesis in Prokaryotes and Eukaryotes 
Prokaryotes and eukaryotes synthesize pterins, albeit, the metabolic functions 
they serve can be quite distinct. For instance, in humans, guanine cyclohydrolase 
(encoded by GCH1) catalyzes GTP hydrolysis, isomerization and cyclization to 
form 7,8-dihydroneopterin triphosphate (Figure 1.3), a precursor in 
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tetrahydrobiopterin synthesis. Tetrahydrobiopterin is a critical co-factor for the 
synthesis of aromatic amino acids and multiple neurotransmitters(Kappock and 
Caradonna, 1996). Deficiencies in the production of tetrahydrobiopterin results in 
dystonia, or sustained muscle contractions. Bacteria, fungi, protozoans and 
plants also encode a guanine hydrolase (FolE, encoded by folE) that performs 
the same biochemical function as GCH1. However, in this context, 7,8-
dihydroneopterin triphosphate is essential for folate biosynthesis (Figure 1.3). 
FolE requires a zinc ion to be bound that allows for subsequent binding of the 
purine ring of GTP. Following binding, GTP is cleaved and isomerized to allow for 
the closure of the dihydropyrazine ring(Auerbach et. al., 2000; Gräwert et. al., 
2013; Tanaka et. al., 2005). Interestingly, 8-aminoguanosine triphosphate and 
other structural analogs of GTP, can competitively inhibit bacterial FolE and 
GCH1 by mimicking the transition state between GTP and 7,8-dihydroneopterin 
triphosphate (Figure 1.6)(Blau and Niederwieser, 1986; Tanaka et. al., 2005).   
 
In the next step of DHPPP synthesis, 7,8-dihydroneopterin triphosphate is 
dephosphorylated by a cytoplasmic Nudix hydrolase to produce 7,8-
dihydroneopterin (Figure 1.3). Nudix hydrolases form a superfamily of 
pyrophosphatases that are often involved in detoxifying toxic metabolites. The 
first 7,8-dihydroneopterin triphosphate pyrophosphatase Nudix hydrolase 
enzyme to be described was YlgG, encoded by ylgG, in Lactococcus lactis(Klaus 
et. al., 2005). Since YlgG did not show sufficient sequence similarity to Nudix 
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enzymes of bacteria with known genome sequences, identifying other Nudix 
hydrolases involved in pterin synthesis has been quite challenging. The product 
of the gene orf17, NudB (or NtpA), was the first dihydroneopterin triphosphate 
pyrophosphatase described in E. coli(Gabelli et. al., 2007; O’Handley et. al., 
1998). Nudix enzymes hydrolyze substrates through the use of a nucleophilic 
substitution and require a metal ion for coordination of GTP, though the specific 
metal varies between Nudix enzymes(Gabelli et. al., 2007; Hill et. al., 2017; 
Klaus et. al., 2005; O’Handley et. al., 1998). Since dihydroneopterin triphosphate 
pyrophosphatases have only been recently discovered, inhibitors of this enzyme 
have yet to be identified. Nevertheless, deletion of nudB in E. coli has been 
shown to dramatically enhance susceptibility to both SMX and TMP (Li et. al., 
2017; Minato et. al., 2018). Thus, these recent discoveries open avenues for 
novel therapeutic development.  
 
Once formed, 7,8-dihydroneopterin is converted to 6-hydroxymethyl-7,8-
dihydropterin by dihydroneopterin aldolase (FolB) yielding glyceraldehyde as a 
byproduct (Figure 1.3). FolB, encoded by folB, is predicted to be essential in 
bacteria. Most aldolases require a Schiff base for the cleavage of the carbon-
carbon double bond and a zinc ion for catalysis, both of these features are 
targets for selective aldolase inhibitors(Daher and Therisod, 2010). FolB is a 
unique aldolase as it requires neither a Schiff base for cleavage nor a zinc ion for 
catalysis(Blaszczyk et. al., 2007; Wang et. al., 2006). Because of its novel 
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characteristics, designing FolB inhibitors has been challenging. In some 
organisms, dihydroneopterin aldolase is a bi-, or in some parasites, a tri-
functional enzyme. For instance, in Streptococcus pneumonia, dihydroneopterin 
aldolase (SulD, encoded by sulD) is a bi-functional enzyme that encodes 6-
hydroxymethyl-7,8-dihydropterin pyrophosphokinase that can convert 6-
hydroxymethyl-7,8-dihydropterin to 7,8-dihydroneopterin(Garçon et. al., 2006; 
Lopez and Lacks, 1993). The opportunistic pathogen Pneumocystis jiroveci 
encodes a tri-functional enzyme that functions not only as a dihydroneopterin 
aldolase and 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase but also as 
a dihydropteroate synthase(Volpe et. al., 1993). These multi-functional enzymes 
have been extensively targeted for development of antimicrobial inhibitors. 
 
Most FolB inhibitors mimic the pterin or pyrimidine moiety of 7,8-dihydroneopterin 
(Figure 1.6) (Zimmerman et. al., 1977). A high-throughput X-ray crystallography 
screen and structure-directed lead optimization discovered multiple potent 
inhibitors of dihydroneopterin aldolase from S. aureus(Sanders et. al., 2004) 
(Figure 1.6). It has not yet been reported whether these compounds possess 
whole cell inhibitory activity against intact bacteria.  
 
The last step in pterin biosynthesis for folates requires the conversion of 6-
hydroxymethy-7,8-dihydropterin to DHPPP via the enzyme 6-hydroxymethyl-7,8-
dihydropterin pyrophosphokinase (FolK, encoded by folK in bacteria) (Figure 
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1.3). In bacteria, disruption of FolK results in a pronounced growth defect. FolK is 
a unique pyrophosphokinase because it transfers a pyrophosphate from the beta 
phosphate of ATP rather than a more conical gamma phosphate yielding 
AMP(Blaszczyk et. al., 2000). FolK has been studied for the development of 
novel bisubstrate analog inhibitors allowing for selective inhibition of this target 
(Figure1.6) (Parang and Cole, 2002; Shi et. al., 2012b, 2012a). Most of the 
bisubstrate inhibitors developed mimic the ATP phosphate donor and acceptor 
(serine, threonine, or tyrosine). Despite these compounds potently inhibiting 
purified FolK, they showed limited whole cell activity. 8-mercaptoguanine has 
also been shown to inhibit S. aureus FolK by acting as a non-competitive inhibitor 
(Figure 1.6) (Chhabra et. al., 2012, 2013). Although 8-mercaptoguanine is a 
potential scaffold for discovery, its activity against S. aureus has not been 
reported and it is likely to show polypharmacology through interaction with other 
proteins with purine binding domains (Figure 1.6). In bacteria, the pterin 
biosynthetic pathway is highly conserved, however, the enzymes are structurally 
distinct and may ultimately allow for selective targeting (Bourne, 2014). 
 
Targeting Folate Biosynthesis in Prokaryotes and Eukaryotes 
DHP is produced from the condensation of PABA and DHPPP with elimination of 
pyrophosphate via DHP synthase (DHPS, FolP in bacteria, encoded by folP) 
(Figure 1.4). FolP is a target of many antimicrobial agents including sulfonamides 
and diaminodiphenyl sulfones (Figure 1.7). Both drug classes are analogs of 
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PABA. Sulfonamides, such as SMX, are broad spectrum antimicrobial agents 
that inhibit FolP by creating the dead-end product sulfamethoxazole-
dihydropterin(Hevener et. al., 2011; Palmer and Kishony, 2014; Zhao et. al., 
2016). Another inhibitor of FolP is 8-mercaptoguanine that has been shown to 
have promiscuous activity by inhibiting many enzymes that have a substrate 
bearing a purine moiety (Figure 1.7) (Dennis et. al., 2018). Since FolP is an 
important drug target, there have been many structural and biochemical studies 
focused on designing more potent FolP inhibitors(Hammoudeh et. al., 2013; Yun 
et. al., 2012) During the catalytic cycle DHPPP binds first, and the pyrophosphate 
is removed in a magnesium dependent reaction(Baca et. al., 2000; Hevener et. 
al., 2011; Yun et. al., 2012; Zhao et. al., 2016). Once the pyrophosphate is 
eliminated, the PABA binding pocket opens and allows for binding of PABA, 
sulfonamides or diaminodiphenyl sulfones(Babaoglu et. al., 2004; Hevener et. al., 
2011; Levy et. al., 2008; Yun et. al., 2012). Sulfonamides and sulfones bind the 
PABA binding pocket that is separate from the pterin binding pocket. To develop 
novel classes of inhibitors, there is an increased interest in targeting the pterin 
binding pocket. Recently, a series of novel compounds were designed to inhibit 
the pterin binding pocket of purified recombinant Bacillus anthracis FolP (Figure 
1.7) (Zhao et. al., 2012). These compounds potently inhibited through binding 
within the pterin binding pocket and provided structure activity relationship 




Many sulfonamides and sulfonylurea-based drugs, such as sulfasalazine, 
sulfathiazole, sulfapyridine, SMX, and chloropropamide, can show toxicity 
through off target effects in humans. These compounds have been found to 
inhibit the NADPH dependent enzyme sepiapterin reductase(Haruki et. al., 2013; 
Yang et. al., 2015). Sepiapterin reductase is an essential enzyme that is required 
for synthesis of tetrahydropterin, a critical co-factor for neurotransmitter synthesis 
in mammals.  
 
DHP is converted to 7,8 dihydrofolate (DHF) by the ligation of L-glutamate using 
the ATP-dependent enzyme DHF-synthase (DHFS, FolC in bacteria, encoded by 
folC) (Figure 1.4). In many organisms, such as E. coli, Corynebacterium sp., and 
P. falciparum, DHFS is a bi-functional enzyme that can catalyze the gamma 
linkage of additional L-glutamate residues to fully reduced folate species(Bognar 
et. al., 1985; Salcedo et. al., 2001; Shane, 1979). Folylpolyglutamates are 
important in bacteria for methionine synthesis(Watson et. al., 2007). In humans, 
folates are polyglutamylated by the enzyme downstream of dihydrofolate 
reductase, folylpolyglutamate synthase (FPGS). In eukaryotes, polyglutamylation 
is important for retaining reduced folates in subcellular compartments. The role of 
polyglutamylation has not been extensively studied in bacteria, but, it is 
conceivable that the negatively charged polyglutamate tail may prevent folate 




Both FolC and FPGS are members of the Mur superfamily of enzymes and both 
contain an ATPase domain(Bourne, 2014; Mathieu et. al., 2005). ATP is 
positioned in a narrow channel and is stabilized by two magnesium ions(Young 
et. al., 2008). In the crystal structure of many apo-FolC enzymes the pterin 
binding site is not well resolved, however, the active site becomes more ordered 
upon the binding of DHP(Mathieu et. al., 2005; Sheng et. al., 2008a; Young et. 
al., 2008). Interestingly, in bacteria, FolC has an induced fit pterin binding pocket 
to allow mono- and poly-glutamylated folates to bind(Sheng et. al., 2008b; Smith 
et. al., 2006a; Sun et. al., 2001a). The conversion of DHP to DHF generates a 
tetrahedral intermediate through the transfer of a phosphate from ATP to 
DHP(Smith et. al., 2006b; Sun et. al., 2001b). Glutamate will react with the 
intermediate to produce DHF. Attempts to target the tetrahedral transition state 
have yielded initial hits against purified FolC but none have shown whole cell 
activity(Banerjee et. al., 1988; Wang et. al., 2010b).  
 
The last step in folate biosynthesis is the reduction of DHF to THF by the NADPH 
dependent enzyme dihydrofolate reductase (Figure 1.4) (DHFR, FolA in bacteria 
encoded by folA) (Figure 3). DHFR is a small 18kDa protein containing 8 β-
sheets and 4 α-helices and has no disulfide bonds. Although most enzymes in 
the folate biosynthesis pathway are essential, FolA in bacteria can be 
conditionally essential. In E. coli, folA can be deleted following disruption of the 
gene for thymidylate synthase (Howell et. al., 1988), a folate-dependent enzyme 
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required for thymidine synthesis. Unlike other folate-dependent enzymes 
thymidylate synthase yields DHF rather than THF. Thus, while elimination of this 
activity confers thymidine auxotrophy, it decreases the demand for folate 
reduction which can be inefficiently catalyzed by FolM(Giladi et. al., 2003).  
 
DHFR reduces DHF using NADPH as an electron donor to THF and with the 
release of NADP+ (Figure 1.8 and Figure 1.9). Under steady state reaction 
conditions, the catalytic mechanism of DHFR is stepwise (Figure 1.8) (Fierke et. 
al., 1987; Schnell et. al., 2004). The reaction begins with NADPH bound to the 
enzyme (E:NADPH), next DHF binds which creates the Michaelis complex 
(E:NADPH:DHF) (Figure 1.8). Once DHF binds, the hydride transfer occurs 
(E:NADP+:THF). The exact biochemical mechanism of the hydride transfer is not 
well understood. To date there are two proposed mechanisms, the first states the 
hydride transfer is pH dependent and occurs by an ionizable side chain in the 
active site(Cannon et. al., 1997). The second mechanism states the pH 
dependent hydride transfer is solvent dependent(Chen et. al., 1994). NADP+ is 
released (E:THF), another NADPH binds (E:NADPH:THF), and finally THF is 
released in the rate determining step to prime the enzyme for another catalytic 
cycle.  
 
DHFR is a highly dynamic enzyme and multiple structures of DHFR exist with 
multiple ligands bound. Therefore, the movement of DHFR has been extensively 
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studied using x-ray crystallography, NMR and neutron diffraction(Schnell et. al., 
2004). The protein is made up of two structural domains, the adenosine binding 
domain and the major subdomain. The adenosine binding domain allows for the 
adenosine moiety of NADPH to bind. The major subdomain is made up of other 
smaller domains that are located around the active site. These subdomains 
consist of the Met20 loop (residues 1-20), the F-G loop, and the G-H loop. The 
subdomains movement is controlled by Lys38 and Val88, in E. coli(Behiry et. al., 
2014). Both amino acids act as hinges to allow the adenosine binding domain to 
move relative to the major subdomain upon ligand binding. 
 
The Met20 loop lies over the active site preventing solvent exposure, as both 
NADPH and DHF bind in a hydrophobic binding pocket. The Met20 loop allows 
both DHF and NADPH to bind in close proximity of one another. Specifically, the 
NADPH is within van der Waals contact of the hydride acceptor DHF(Schnell et. 
al., 2004). The Met20 loop is important for the structure of the active site by 
stabilizing hydrogen bonding between the F-G loop and the G-H loop. The Met20 
loop forms four different confirmations based on X-ray studies: occluded, closed, 
open, and disordered (Figure 1.8). The occluded and closed have also been 
observed in solution NMR studies(Schnell et. al., 2004). The confirmation is 
determined by a specific ligand that is bound. The loop is considered open when 
NADPH is bound and forms a wide binding area to allow DHF to bind and allow 
for subsequent release of NADP+. When THF is only bound in the active site, 
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DHFR forms an occluded conformation to allow for increased binding affinity to 
NADPH. When NADPH binds the Met20 domain moves to “pack” the NADPH 
into the closed active site confirmation allowing for the release of THF. Lastly, the 
Met20 loop has not been resolved in crystallized apo-enzyme structures or in 
structures where methotrexate, a DHFR inhibitor, is bound(Schnell et. al., 2004). 
 
DHFR is an important folate biosynthesis chemotherapeutic target. There are 
many drugs that selectively inhibit DHFR in humans, bacteria, fungi, and 
protozoa. DHFR inhibitors in humans and protozoans generally mimic the 
substrate folate (Figure 1.7). One class of inhibitors, the diaminopteridines, 
include methotrexate (MTX) and aminopterin, both are used to treat cancers and 
autoimmune disorders (Figure 1.7) (Cronstein, 2005). Diaminopteridines are 
transported into human cells by folate receptors. Since, folate receptors are 
highly upregulated by as much as 100-fold in cancer cells, MTX and other 
diaminopteridines potently target these cells compared to non-cancerous 
cells(Sudimack and Lee, 2000). Not only do folate receptors recognize folate and 
folate analogs but they also recognize polyglutamylated folate species. As 
described above, polyglutamylated species are retained within cellular 
compartments. Thus, this mechanism for retention of folates has been co-opted 
to promote accumulation of DHFR inhibitors, such as pralatrexate, within target 




Aminopterin was the first human DHFR inhibitor to enter clinical use for the 
treatment of childhood lymphocytic leukemia (Figure 1.7) (Figure 3). Aminopterin 
was associated with high toxicity and was quickly replaced with MTX which was 
found to be as effective, but less toxic. MTX is known to inhibit all purified 
DHFRs, including those from bacteria, fungi and protozoans, and is 
characterized as a slow, time-dependent, tight-binding competitive inhibitor 
(Figure 3)(Morrison and Walsh, 1988; Williams et. al., 1979). Binding of MTX 
results in a slow conformational change in the enzyme active site and is known to 
bind almost identically to folate by forming similar hydrogen bonding within the 
active site. One notable difference occurs when the pterin ring of MTX is flipped 
180º with respect to DHF. This flip allows hydrogen bonding with the ionizable 
group in the active site(Bennett et. al., 2006).  
 
Since most pathogenic bacteria lack folate receptors and cannot actively take up 
this cofactor, antibacterial FolA inhibitors are not close structural analogs of 
folate. In general, bacterial FolA inhibitors must diffuse across the cell envelope 
or require folate independent transport(Floyd et. al., 2010; Kok et. al., 1996). The 
structure of many of these inhibitors leaves them vulnerable to numerous efflux 
pumps (Figure 1.10) (Floyd et. al., 2010; Kok et. al., 1996). One notable bacterial 
FolA inhibitor, trimethoprim (TMP), contains a 2,4-diaminopyrimidine ring that 
allows for critical hydrogen bonding in the active site. TMP binds much more 
tightly (about 105) to bacterial FolA than mammalian DHFR (Figure 1.7)(Burchall 
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and Hitchings, 1965). The benzyl ring of TMP undergoes a thermodynamically 
unfavorable flip in the apo-enzyme. However, in the presence of NADPH the 
flipping of the benzyl ring is decreased. Therefore, in bacteria, TMP is a 
competitive inhibitor with respect to DHF and a non-competitive inhibitor with 
respect to NADPH. Conversely, mammalian DHFR can bind TMP but cannot 
form key hydrogen bond contacts within the active site(Matthews et. al., 1985).  
 
TMP was first introduced into the clinic in 1962. Resistance was described as 
early as 1968, therefore, TMP derivatives were synthesized and explored for 
antimicrobial activity. Two notable TMP derivatives are tetroxoprim used for the 
treatment of Pneumocystis pneumonia and iclaprim for treatment of methicillin 
and vancomycin resistant strains of Staphylococcus aureus as well as drug 
resistant strains of Streptococcus species (Figure 1.7) (Aschhoff and Vergin, 
1979; Sincak and Schmidt, 2009). Trimetrexate is a quinazoline derivative and is 
a chimera of pterin moiety of methotrexate and contains the benzyl ring of TMP. 
Iclaprim, like TMP, is a diaminopyrimidine that contains a chromene ring in place 
of the benzyl ring of TMP. The chromene ring allows for additional hydrogen 
bonding to occur within the active site of FolA(Sincak and Schmidt, 2009). 
 
The first anti-malarial antifolate drug discovered was the biguanide proguanil 
which is one of the components of the widely used malaria prophylactic drug 
malarone (Figure 1.7). Shortly after its discovery, proguanil was found to be a 
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pro-drug that is metabolized by the host CYP2C19 to cycloguanil (Figure 
1.7)(Carrington et. al., 1951; Desta et. al., 2002). This activated form was found 
to inhibit Plasmodium falciparum, the most prevalent causative agent of malaria, 
through targeting of DHFR. Many proguanil derivatives, including the cycloguanil 
structural analog pyrimethamine, have since been developed to counter drug 
resistant strains of P. falciparum (Figure 1.7) (Hitchings et. al., 1950). 
Pyrimethamine showed excellent efficacy in humans because of the low dosage 
required for treatment and paucity of side effects(Hoekenga, 1954). However, 
pyrimethamine resistance quickly emerged which diminished its use in treatment 
of malaria. Pyrimethamine has been repurposed to treat toxoplasmosis and is 
used in combination with dapsone to treat Pneumocystis pneumonia in HIV 
infected individuals.  
 
The dihydrotriazine, WR99210, is an anti-malarial DHFR inhibitor that was 
developed after emergence of resistance to pyrimethamine and cycloguanil 
(Figure 1.7). WR99210 potently inhibits DHFR at very low concentrations, in the 
nano- to picomolar range. Unfortunately, in human clinical trials, daily 
administration of 200 mg of WR99210 for three days resulted in severe 
gastrointestinal distress. As a result, further clinical investigation into WR99210 
was abandoned. To counter WR99210 toxicity, the biguanide pro-form PS-15 
((N-(3-(2,4,5-trichlorophenoxy)propyloxy)-N'-(1-methylethyl)-imidocarbonimidic 
diamide hydrochloride) was synthesized based on proguanil that could be 
46 
 
activated in vivo (Figure 1.7) (Canfield et. al., 1993). PS-15 showed improved 
antimalarial activity and it is anticipated that it will be better tolerated than 
WR99210. Importantly, PS-15 was found to selectively inhibit P. falciparum 
DHFR and had little activity against mammalian DHFR. Unfortunately, large-
scale synthesis of PS-15 is challenging for drug production and has caused its 
development to lag. However, with this scaffold, other WR99210 analogs have 
been explored as novel DHFR inhibitors not only in Plasmodia species, but also 
in M. tuberculosis, Mycobacterium avium and P. jiroveci(Gerum et. al., 2002; 
Kumar et. al., 2015).  
 
Antifolate Synergy 
Currently, TMP and SMX are rarely given in monotherapy. When used in 
combination, TMP and SMX (co-trimoxazole) exhibit highly synergistic 
antimicrobial activity. For several decades it was presumed that the basis for 
synergy between SMX and TMP was exclusively due to the ability of SMX to 
prevent DHF synthesis and enhance the ability of TMP to inhibit FolA (Bushby 
and Hitchings, 1968; Minato et. al., 2018; Wormser et. al., 1982). While this 
model explains how SMX is able to enhance microbial susceptibility to TMP, it is 
not sufficient to explain the ability of TMP to enhance susceptibility of microbes to 
SMX(Harvey, 1978). It was recently demonstrated that TMP treatment results in 
depletion of DHPPP through impairment of GTP synthesis and is the basis for 
potentiation of SMX susceptibility (Minato et. al., 2018). Thus, it is the cyclic 
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nature of the folate biosynthetic pathway that enables the potent synergy 
between SMX and TMP (Minato et. al., 2018).  
 
Antifolates for treating drug resistant M. tuberculosis 
Although the folate biosynthesis pathway is not the current target of first line 
therapy, there is renewed interest in targeting folate biosynthesis to treat drug 
resistant strains of M. tuberculosis. Shortly after the discovery of the broad 
spectrum antifolates, sulfonamides were used to treat M. tuberculosis; however, 
they were found to be ineffective(Freilich et. al., 1939). Recently, with the 
increasing challenge of treating MDR- and XDR-TB there has been a renewed 
interest of using co-trimoxazole, because both are well tolerated drugs and are 
cost effective for long term use. Several studies have found that co-trimoxazole is 
a viable treatment option for treating MDR- and XDR-TB(Alsaad et. al., 2013; 
Forsman et. al., 2014; Vilchèze and Jacobs, 2012). Although, these studies also 
suggest that co-trimoxazole should only be given during the initial treatment of M. 
tuberculosis. SMX have limited intracellular activity in macrophages 
(MIC90=76µg/ml) compared to extracellular treatment (MIC90=23µg/ml) 
suggesting that the therapeutically relevant concentrations may not be reached in 
the macrophages. Therefore, this drug combination should be used during the 
initial infection when M. tuberculosis is more extracellular.    
 
PAS targets folate metabolism 
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PAS is a structural analog of PABA, possessing a hydroxyl-group in the ortho-
position to the carboxylic acid. Soon after its discovery, PAS was thought to 
disrupt folate biosynthesis based on the observation that exogenous PABA could 
antagonize its inhibition of M. tuberculosis growth(Youmans et. al., 1947a). 
Initially, PAS was thought to act as a FolP inhibitor similar to sulfonamides. 
However, no cross-resistance between PAS and sulfonamides in M. tuberculosis 
was observed(Yegian and Long, 1951). Further, in contrast to sulfonamides, PAS 
was found to only weakly inhibit purified FolP enzymatic activity and was later 
demonstrated to be converted to a hydroxylated version of DHP, hydroxy-DHP 
(Figure 1.4, Figure 1., and Figure 1.11) (Chakraborty et. al., 2013; Zhao et. al., 
2014; Zheng et. al., 2013). FolC was found to catalyze the glutamylation of 
hydroxy-DHP to hydroxy-DHF (Figure 1.4 and Figure 1.11), which suggested that 
FolC is not the target of bioactivated PAS and the target was likely downstream 
within the folate pathway (Chakraborty et. al., 2013; Zhao et. al., 2014; Zheng et. 
al., 2013). Indeed, it was predicted and later confirmed that hydroxy-DHF could 
potently inhibit FolA (Figure 1.4, Figure 1., and Figure 1.11), (Chakraborty et. al., 
2013; Dawadi et. al., 2017; Zheng et. al., 2013).  
 
Antifolate Resistance 
While folate metabolism remains a powerful target for drug discovery and 
development, there has been a surge in resistance to many antifolates. There 
are multiple mechanisms that can confer broad resistance to sulfonamides and 
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were found to emerge shortly after entrance of this drug class into clinical use. 
One such resistance mechanism involves single amino acid point mutations in 
the chromosomal folP (Figure 1.10). Among clinically resistant isolates, many 
have been characterized that have mutations that result in alteration of the 
ternary structure and prevent productive interaction with 
sulfonamides(Padayachee and Klugman, 1999). In the case of the respiratory 
pathogen S. pyogenes, clinical resistance to sulfonamides emerged much faster 
than in most other organisms and was the result of horizontal acquisition of a 
plasmid encoding a sulfonamide resistant FolP variant (Swedberg et. al., 1998). 
Similarly, in many Gram-negative bacteria, resistance to sulfonamides has been 
traced to mobile genetic elements bearing sul genes that encode fully functional 
FolP variants that fail to interact with sulfonamides (Figure 1.10)(Sköld, 2000). In 
early reports of this resistance mechanism, E. coli was found to transfer 
sulfonamide resistance to Shigella species via a Tn21 family transposon 
encoding sul1 or sul2(Akiba et. al., 1960). Tn21 family transposons have since 
been found to be broadly distributed amongst enteric bacteria that are resistant 
to sulfonamides(Shin et. al., 2014). Recent evidence suggests that the sul genes 
originated in the Gram-negative bacterial orders Rhodobiaceae and 
Leptospiraceae prior to the development of sulfonamides and were subsequently 
distributed amongst human associated microbes with broad clinical use of 




Another factor that limits the use of sulfonamides is intrinsic resistance through 
methionine-associated metabolism. Shortly after discovery of the sulfonamides, it 
was found that exogenously supplied methionine could potently antagonize the 
antimicrobial action of these drugs in numerous bacterial species(Henry, 1944). 
While the mechanism governing this antagonism has not been fully elucidated, it 
has been presumed to occur through methylation-dependent inactivation. In the 
context of M. tuberculosis, sulfonamides are known to inhibit purified 
recombinant FolP, yet, they show poor activity against intact bacilli (Nopponpunth 
et. al., 1999). The related drug dapsone was initially developed as an 
antitubercular agent and also inhibits purified recombinant M. tuberculosis FolP, 
but, like sulfonamides shows limited activity against whole cells(Nopponpunth et. 
al., 1999). In support of a model for methyl inactivation, it has been demonstrated 
that M. tuberculosis rapidly metabolizes sulfonamides and dapsone to N-methyl 
and N,N-dimethyl species(Chakraborty et. al., 2013). In addition to methyl 
inactivation, it has recently been demonstrated in E. coli and M. tuberculosis that 
methionine also mediates antagonism of antifolates through affecting synthesis 
of folate precursors(Howe et. al., 2018; Minato et. al., 2018). Beyond the problem 
of intrinsic resistance, sulfonamides show limited activity against intracellular 
bacilli, suggesting that it may be difficult to achieve therapeutically relevant 
concentrations needed to target organisms like M. tuberculosis in their in vivo 




Like SMX, TMP resistance can occur by a variety of mechanisms including 
intrinsic resistance, target modification or overexpression, and acquisition of 
mobile genetic elements (Figure 1.10). Many bacterial species are naturally 
resistant to therapeutically relevant concentrations of TMP including M. 
tuberculosis, Bacteroides species, Clostridium species, and Neisseria 
species(Huovinen et. al., 1995; Minato et. al., 2015). In the case of M. 
tuberculosis, it was found that the native FolA Tyr100 residue was responsible for 
the weak binding of TMP(Dias et. al., 2014). Modification of Tyr100 to 
phenylalanine resulted in increased affinity for TMP(Dias et. al., 2014). It has 
been reported that some strains of E. coli, S. aureus, and Haemophilus 
influenzae harbor spontaneous mutations in the promoter region of folA that 
confer resistance through increased expression of FolA(de Groot et. al., 1996; 
Huovinen et. al., 1995; Nurjadi et. al., 2014). In addition, it has been shown that 
TMP resistance in S. aureus, S. pneumonia and H. influenzae can arise from 
mutations that result in a single amino acid substitution in FolA(Dale et. al., 1997; 
de Groot et. al., 1996; Pikis et. al., 1998). The mechanism that is primarily 
associated with TMP resistance in Gram-negative bacteria involves acquisition of 
mobile genetic elements encoding variants of FolA (encoded by dfr). To date 
there are over 30 different mobile genetic elements encoding unique dhfr genes 
and are classified as either type I or type II variants (Seputiene et. al., 2010). The 
type I variants share sequence similarity with bacterial folA and are typically 
located on the site-specific integron Tn7 (Heikkila et. al., 1991). In contrast, type 
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II variants are often found on conjugal R plasmids and that lack discernable 
sequence similarity to folA(Stone and Smith, 1979).  
 
In mammalian cells, resistance to MTX can arise and can lead to treatment 
failure. Several MTX resistance mechanisms have been described to date. One 
common mechanism for acquired MTX resistance stems from a defect in 
transport of the drug into target cells and is frequently observed in the context of 
acute lymphocytic leukemia (Figure 1.10) (Trippett et. al., 1992). Another 
observed MTX resistance mechanism associated with acute non-lymphoblastic 
leukemia involves impaired polyglutamylation, a process that is normally 
associated with cytosolic retention of folates (Figure 1.10) (Li et. al., 1992; Lin et. 
al., 1991; Rhee et. al., 1993; Visentin et. al., 2013). To overcome this resistance 
mechanism, analogs of MTX that show better intracellular retention independent 
of polyglutamylation, such as pralatrexate, have been employed(Gonen and 
Assaraf, 2012) Other mammalian antifolate resistance mechanisms involve 
overexpression and missense mutations in DHFR (Figure 1.10) (Göker et. al., 
1995; Schimke, 1988).  Interestingly, increased DHFR expression has been 
linked to mutations in p53 (a tumor suppressor gene), E2F (a transcription factor 
in cell cycle regulation), and genes that are involved in regulation of thymidylate 
synthase(Banerjee et. al., 2002; Göker et. al., 1995; Li et. al., 1995). Similar to 
that which is observed for PAS resistance in M. tuberculosis, DHFR active site 
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mutations that confer MTX resistance are rare but have been observed in the 
laboratory(Ercikan-Abali et. al., 1996; Srimatkandada et. al., 1989). 
 
Resistance to PAS 
Resistance to PAS in M. tuberculosis arises exclusively through occurrence of 
spontaneous mutations in genes related to folate synthesis and metabolism. 
Most frequently, PAS resistance mutations are identified in folC, ribD and thyA 
(Mathys et. al., 2009; Zhang et. al., 2015; Zhao et. al., 2014).  
 
Mutations in folC are the most prevalent mutations identified in PAS resistant 
clinical isolates(Mathys et. al., 2009; Zhang et. al., 2015). folC mutations typically 
map to positions corresponding to substrate binding and nucleoside binding 
pockets of the ATP domain in FolC(Mathys et. al., 2009; Zhang et. al., 2015; 
Zhao et. al., 2014). Both of these positions are essential for proper enzymatic 
function. Purified recombinant FolC variants from resistant strains were found to 
have reduced enzymatic activity (10 to 20% of wild type activity)(Zhao et. al., 
2014). When these variants were analyzed for the ability to glutamylate hydroxy-
DHP, no detectable hydroxy-DHF was observed (Zhao et. al., 2014). Similarly, 
PAS resistant M. tuberculosis folC mutant strains were found to produce 
substantially less hydroxy-DHF than the wild type control(Zhao et. al., 2014). 




Another common PAS resistance mechanism involves loss-of-function mutations 
in thyA, encoding a non-essential thymidylate synthase (ThyA) in M. tuberculosis 
that is responsible for the 5,10-methylene-tetrahydrofolate dependent conversion 
of dUMP to dTMP (Mathys et. al., 2009; Zhang et. al., 2015; Zhao et. al., 2014). 
When functional, ThyA releases DHF that must be re-reduced to be utilized in 
folate metabolism. M. tuberculosis encodes an alternate thymidylate synthase 
(ThyX, encoded by thyX) that regenerates THF from 5,10-methylene-THF 
following catalysis (Myllykallio et. al., 2002). Thus, in contrast to ThyA, ThyX 
places limited demand of FolA for maintaining reduced folate pools. In contrast to 
other pathogens that do not encode a ThyX ortholog and are attenuated mutation 
of thyA (Cersini et. al., 1998; Kok et. al., 2001), M. tuberculosis thyA loss-of-
function mutants are not compromised for fitness growth and survival in vivo.  
 
To date, few folA missense mutations associated with PAS resistance have been 
reported(Myllykallio et. al., 2002). Numerous studies have reported that 
alterations in the FolA active site can be highly deleterious to the overall enzyme 
function. Thus, it could be rare for folA point mutations to confer resistance to 
PAS without compromising FolA enzymatic activity. One paper recently 
described five independent clinical PAS resistant isolates containing a deletion of 
the folA-thyA coding sequence(Moradigaravand et. al., 2016). These strains were 
26 times more resistant to PAS than susceptible control strains. Unlike many 
bacteria, M. tuberculosis does not encode a FolM ortholog that would be 
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expected to compensate for loss of FolA activity. Instead, this compensation 
likely comes from weak DHF reductase activity that can be catalyzed by the 5-
amino-6-(5-phosphoribosylamino)uracil reductase RibD that normally functions in 
riboflavin synthesis(Salcedo et. al., 2001; Zhao et. al., 2014). Consistent with this 
model, ribD promoter mutations have been described that confer PAS resistance 
and were shown to render folA as non-essential in M. tuberculosis(Zhang et. al., 
2015; Zhao et. al., 2014).   
 
Like TMP, PAS is prone to exclusion from the cytoplasm by the action of efflux 
pumps (Figure 1.10). Overexpression of the major facilitator superfamily protein 
Tap (Rv1258c) in Mycobacterium bovis BCG was found to confer resistance to 
PAS(Ramón-García et. al., 2012a). Furthermore, overexpression of Tap in M. 
tuberculosis, M. fortuitum and M. bovis BCG was found to confer resistance to a 
variety of other antimicrobial agents that do not target folate biosynthesis 
including streptomycin, vancomycin, and tetracycline(Aínsa et. al., 1998; Ramón-
García et. al., 2012b),(Siddiqi et. al., 2004). 
 
Main hypothesis 
Numerous groups have shown PAS is converted to hydroxy-dihydrofolate via the 
folate biosynthesis pathway to inhibit dihydrofolate reductase. Due to the lack of 
analytically pure compound, hydroxy-dihydrofolate has never evaluated for 
inhibitory activity against purified recombinant FolA from M. tuberculosis. We 
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hypothesize that hydroxy-dihydrofolate potently inhibits dihydrofolate reductase 
in M. tuberculosis. Furthermore, although PAS was discovered to be specific for 
M. tuberculosis, we propose that bacteria which are resistant to PAS can utilize 
PAS in lieu of PABA in folate biosynthesis. Since antifolates work better in 
combination, such as TMP and SMX, we hypothesize that PAS and SMX will 
also work better in combination. The mechanism by which this occurs is similar to 
TMP and SMX. As such PAS will decrease flux through PABA biosynthesis and 
SMX will decrease metabolic flux through pterin biosynthesis. Since PAS has 
been described to be toxic and many patients discontinue PAS therapy, we 
propose to find novel ways to shorten PAS treatment or find drug combinations to 
use smaller dosages of PAS. Furthermore, we propose that by blocking PABA 
biosynthesis we can potentiate the antitubercular activity of PAS. The ultimate 





TABLE 1. Prescription, adverse reaction and mechanism of actions of anti-
TB drugs. 
Name of Drug 
(abbreviation) 
WHO Guidelines for 
treatment 
Mechanism of action Adverse reactions 
Rifampicin 
(RIF) 
First line  
6 months for DS TB 
Inhibits RNA 
polymerase(CALVORI 








6 months for DS TB 
Inhibits InhA and 











2 months for DS TB 
Inhibits arabinosyl 
transferase and thereby 
arabinogalactan 
synthesis(Takayama 








First line  
2 months for DS TB 
Not known. Many have 
been proposed but the 
Baughn group and 
others keep disproving 
them(Boshoff et. al., 
2002; Dillon et. al., 
2017; Peterson et. al., 
2015; Shi et. al., 2011; 







Streptomycin First or second line 
2+months 
Protein synthesis 
inhibitor specifically the 
30S ribosomal 
subunit(Luzzatto et. al., 
1968) 







Kanamycin A Second line 
12+months 
Protein synthesis 









Moxifloxacin Second line 
12+months 
DNA replication 
specifically by inhibiting 

















Figure 1.1. Folate biosynthesis and one carbon metabolism in bacteria. Blue 
indicates pterin biosynthesis. Red indicates PABA biosynthesis. Green indicates 











                                                 






























Figure 1.8. Catalytic mechanism of FolAMtb. Water molecules are indicated in  





























































Chapter 2:  
 




This chapter is a reprint, with alterations, of a published manuscript. 
 
Dawadi S*, Kordus SL*, Baughn AD, Aldrich CC. Synthesis and analysis of 
bacterial folate metabolism intermediates and antifolates. Org Lett. 2017;19(19).  
 
*Denotes equal contribution. 
 
 
Specific contributions from Organic Letters manuscript 
 
Dawadi, S devised synthetic route for hydroxy-dihydrofolate (Figure 2.1) and 
wrote methods for synthesis 
 
Kordus, SL tested inhibitory activity of hydroxy-dihydrofolate against purified 
recommbinant dihydrofolate reductase from Mycobacterium tuberculosis (Figure 
2.2) wrote the methods for the purification and inhibitory concnetration.  
 
The rest of the chapter has not published when the thesis was submitted. All 
experiments, experimental design, intellectual contributations were performed by  
Shannon Lynn Kordus. One exception is the docking studies were performed in 






para-Aminosalicylic acid (PAS) was one of the first drugs to enter clinical use for 
treatment of tuberculosis. Despite for over 70 years of study, the precise mode of 
action of PAS is still not fully understood. PAS is known to selectively inhibit 
Mycobacterium tuberculosis and has limited to no activity against other 
microorganisms. Previous studies have shown that PAS can be incorporated in 
lieu of PABA by the M. tuberculosis folate biosynthetic pathway. PAS is ultimately 
converted to hydroxy-dihydrofolate that is predicted to inhibit M. tuberculosis 
dihydrofolate reductase. Using a biochemical approach, we demonstrate for the 
first time, that hydroxy-dihydrofolate potently inhibits dihydrofolate reductase. 
Furthermore, we show that other bacteria can also utilize PAS for synthesis of 
hydroxy-dihydrofolate. In contrast to M. tuberculosis, these organisms are 
capable of using PAS-containing folate species as a co-factor for one carbon 
metabolism. One previously unforeseen consequence of this selectivity is that 
PAS can antagonize the activity of sulfa-drugs in many bacterial species. Since 
sulfa-drugs are used as prophylactic therapy to treat and prevent opportunistic 







In 1940, Frederick Bernheim discovered that salicylic acid stimulated oxygen 
consumption in Mycobacterium tuberculosis(Bernheim, 1940). Following up on 
these studies, Jörgen Lehmann performed a screen of 50 structural analogs of 
salicylic acid for compounds that could potently inhibit growth of M. tuberculosis. 
From this screen PAS was identified as the most potent salicylic acid analog and 
was found to be safe and effective in treatment of human tuberculosis in a small 
scale clinical trial (Lehmann, 1946)..PAS entered clinical use for treatment of 
tuberculosis in 1946 and was typically given with streptomycin to prevent the 
emergence of drug resistance. 
 
PAS was given orally and often associated with gastrointestinal distress. By the 
mid-1960s, PAS was replaced with the better-tolerated and more efficacious 
companion drug ethambutol (Ferebee et. al., 1966) With the increased incidence 
of drug resistant strains of M. tuberculosis, PAS has regained more frequent 
clinical use. Consequently, there has been renewed interest in understanding the 
mechanisms that govern susceptibility and resistance to PAS. 
 
Multiple studies have shown that PAS disrupts folate metabolism. PAS is a 
structural analog of the folate precursor, para-aminobenzoic acid (PABA). Like 
PABA, PAS is a substrate for the M. tuberculosis folate biosynthesis pathway 
(Chakraborty et. al., 2013; Dawadi et. al., 2017; Rengarajan et. al., 2004; Zhao 
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et. al., 2014; Zheng et. al., 2013). In this pathway, PAS is ligated to 6-
hydroxymethyl dihydropterin pyrophosphate by the enzyme dihydropteroate 
synthase (FolP) to produce hydroxy-dihydropteroate (Chakraborty et. al., 2013; 
Zhao et. al., 2014; Zheng et. al., 2013). Hydroxy-dihydropteroate is then 
converted to the dihydrofolate analog hydroxy-dihydrofolate (hydroxy-DHF) via 
dihydrofolate synthase (FolC)(Chakraborty et. al., 2013; Zhao et. al., 2014; 
Zheng et. al., 2013). In normal folate metabolism, the native substrate 
dihydrofolate is reduced by the enzyme dihydrofolate reductase (encoded by 
DfrA in M. tuberculosis, herein referred to as FolAMtb for simplicity) to produce 
tetrahydrofolate, a critical cofactor for the synthesis of DNA, RNA, and proteins. 
Although multiple studies have suggested that hydroxy-DHF inhibits FolAMtb, 
there has been no biochemical validation due to the lack of analytically pure 
hydroxy-DHF. In this study, hydroxy-dihydrofolate was synthesized by the 
coupling of N2-acetyl-6-formylpterin obtained from the degradation of folic acid 
and appropriately functionalized arylamines. The sequential chemoselective 
reduction of the imine and pterin ring led to the formation of hydroxy-DHF. Using 
this pure hydroxy-DHF, we have confirmed it to be a potent inhibitor of FolMtb, 
 
PAS has been shown to only have inhibitory activity against M. tuberculosis, 
although the mechanistic basis for this exquisite selectivity is not 
known(Ivanovics et. al., 1948; Ragaz, 1948; Sievers, 1946; Tobie and Jones, 
1949; Wyss, 1943). Previous studies of the selectivity of PAS were extended to 
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test a variety of organisms including Gram positive, Gram negative, and non-
tuberculous mycobacteria. Next, PABA auxotrophic strains of Escherichia coli, 
Acinetobacter baumannaii, and Mycobacterium smegmatis were used to 
determine if PAS could be utilized in folate synthesis and one carbon 
metabolism. In addition, purified recombinant E. coli and M. smegmatis 
dihydrofolate reductase (FolAEc and FolAMs, respectively) were tested for the 
ability to utilize hydroxy-dihydrofolate as a substrate.  
 
To understand if FolAMtb is the principal target for hydroxy-DHF, folAMtb and folAMs 
were expressed in trans in PABA auxtrophic strains of M. tuberculosis and were 
grown in the presence of PAS. A similar experiment was performed in E. coli 
using strains that lacked folA but contained plasmid borne copies of folAMtb or 
folAEc and grown in the presence of PAS. (Howell et. al., 1988a). The structure of 
both FolAEc and FolAMtb bound to hydroxy-DHF was analyzed using molecular 
docking and evolutionary coupling was performed to predict important residues 
for binding of DHF compared to hydroxy-DHF. 
 
If PAS can act as a fully functional PABA analog in one carbon metabolism then 
PAS, like PABA, would be predicted to antagonize FolP inhibitors. Antagonism of 
FolP inhibitors, including sulfa-drugs and sulfones, was tested in the presence of 
exogenously supplied PAS for a variety of bacterial species. The present study 
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Materials and Methods 
Bacterial strains, media, and growth conditions 
All information regarding primers, plasmids and bacterial strains used in this 
study can be found in Tables 2.1-2.3. 
 
M. tuberculosis and M. abscessus strains were grown at 37 ºC in 7H9 broth 
(Difco) supplemented with 0.2% (wt/vol) glycerol (Fisher Scientific), 10% oleic 
acid-albumin-dextrose-catalase (OADC) (BD), and 0.05% tyloxapol (Sigma) or on 
7H10 agar (Difco) supplemented with 0.2% (wt/vol) glycerol (Fisher) and 10% 
oleic acid-albumin-dextrose-catalase (OADC) (Difco). E. coli, S. enterica, B. 
cenocepacia, Stenotrophomonas maltophilia, and A. baumannii were grown at 37 
ºC in either lysogeny broth (LB) (Difco) or M9 minimal media supplemented with 
0.2% (wt/vol) glucose (Fisher Scientific). M. smegmatis was grown at 37 ºC in 
7H9 supplemented with 0.05% tyloxapol, and 0.2% (wt/vol) glucose. S. aureus 
was grown as previously described (Minato et. al., 2018). S. parasanguinis was 
grown at 37 ºC in Mueller-Hinton Broth (Difco) and Iso-sensitest broth (Oxiod) 
both supplemented with 5% laked sheeps blood (BD). B. fragilis was grown at 37 
ºC in an anaerobic chamber (Bactron IV, Sheldon Manufacturing, Inc.) with an 
atmosphere of 5% CO2, 10% H2, and 85% N2 (Matheson, PA) in brain heart 
infusion broth (BHIS) (Difco) supplemented with 0.5% yeast extract (Fisher) and 
15 µg/mL hematin (Sigma) and anaerobic minimal medium (AMMGluc) with 0.5% 
glucose with modifications described in Baughn and Malamy (Baughn and 
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Malamy, 2002). All media and plastics used to cultivate B. fragilis were 
equilibrated anaerobically for a minimum of 48 hrs to ensure minimal oxygen 
contamination. E. coli ΔthyA ΔfolA strains were grown as described 
previously(Howell et. al., 1988b). 
 
All antibiotics were purchased from Sigma and added, when appropriate, to final 
concentrations of 50 µg/mL for kanamycin, 150 µg/mL for penicillin G, and 150 
µg/mL for hygromycin. PABA free media was created by baking glassware for a 
minimum of one hour at 180 ºC. PAS, PABA, trimethoprim (TMP), 
sulfamethoxazole (SMX), dapsone (DDS) sulfanilamide (SNL) were all 
purchased from Sigma and were dissolved in 100% DMSO (Sigma). 
Sulfathiazole (STZ) was purchased from Tokyo Chemical Industry and was 
dissolved in 100% DMSO (Sigma). 
 
Synthesis of hydroxy-dihydrofolate 
The following text was written and synthesis was performed by Dr. Surendra 
Dawadi. To a solution of N2-acetyl-6-formylpterin (141 mg, 0.603 mmol, 1.0 
equiv) in glacial acetic acid (6 mL) was added dimethyl-(4-amino-2- 
(benzoyloxy)benzoyl)glutamate, (275 mg, 0.664 mmol, 1.1 equiv) and the mixture 
was stirred briefly for 15 min at room temperature (rt) (Freisleben et. al., 2002; 
Thijssen, 1973). A solution of dimethylamine borane (56 mg, 0.950 mmol, 1.6 
equiv) in glacial acetic acid (1 mL) was added and stirring was continued at rt for 
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20 min. The suspension was warmed to 60 °C for 10 min and cooled to rt. Acetic 
acid was evaporated under reduced pressure and the residue was dissolved in 
20% methanol in methylene chloride and residual acetic acid was neutralized by 
adding a few drops of trimethylamine. The crude product was purified by column 
chromatography (silicon dioxide, 0:100 to 10:90 methanol/methylene chloride) 
yielding dimethyl-N2-acetyl-2’-benzoyloxyfolate (220 mg, 57%) as a yellow solid. 
 
A solution of dimethyl-N2-acetyl-2’-benzoyloxyfolate (110 mg, 0.174 mmol) in 0.5 
N sodium hydroxide (NaOH) (1 mL) was heated at 70 °C for 1.5 h and cooled to 
rt. In a separate flask, deoxygenated water (6 mL) was prepared by bubbling 
nitrogen for 15-20 min. Ascorbic acid (368 mg, 2.088 mmol) was added in one 
portion into the deoxygenated water and pH of the solution was adjusted to 6.5 
by adding 1 N NaOH dropwise. Sodium dithionite (400 mg, 2.30 mmol) was 
added followed by the previously prepared solution of dimethyl N2-acetyl-2’-
benzoyloxyfolate in 0.5 N NaOH and pH of the solution was re-adjusted to 6.5 by 
adding 1N hydrochloric acid (HCl) (or 1N NaOH as needed) dropwise. An 
another portion of sodium dithionite (200 mg, 1.15 mmol) was added and the 
mixture was warmed to 40 °C and stirred at that temperature for 3 h. The mixture 
was cooled to rt and the pH was adjusted to ~2 by adding 1N HCl dropwise while 
S7 stirring. At that pH, precipitation occurred and the mixture was stored at 4 °C 
for overnight. The mixture was centrifuged, the supernatant was discarded and 
the residue was washed by vortex and centrifugation cycle twice with water, 
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twice with ethanol, and once with diethyl ether. The residue was dried under 
reduced pressure for 3-4 hr to obtain the product (69 mg, 86%) as a brown solid. 
The amber colored vial containing the product was filled with argon and stored at 
–80 °C. Hydroxy-DHF was resuspended in DMSO at a final concentration of 10 
mg/mL. 
 
Biochemical characterization of FolAMtb 
Cloning of M. tuberculosis folA was performed similarly as described with the 
exception pET28b(+) (Novagen) was used instead of pET28a(+) (Argyrou et. al., 
2006; Dias et. al., 2014). M. tuberculosis folAMtb (Rv2763c) was amplified from 
H37Ra genomic DNA by PCR using the primers found in Table 2.1. The resulting 
DNA was cut with the restriction enzymes NdeI and HindIII and ligated into an 
already digested pET28b(+) using the same restriction enzymes. Expression and 
purification of FolAMtb was similarly performed as previously described (Argyrou 
et. al., 2006; Dias et. al., 2014). Briefly, sequence-verified pET28b(+):folAMtb was 
used to transform chemically competent E. coli BL21 (DE3) cells. E. coli BL21 
pET28b(+):folAMtb was inoculated into LB and grown overnight at 37 ºC. The cells 
were diluted 1:1000 into fresh LB (4 L) and were grown until mid-exponential 
phase (optical density at 600 nm (OD600) 0.4–0.6) at 37 ºC. The cells were 
equilibrated to 18 ºC for 1 h. Next, 1 mM Isopropyl β-D-1-thiogalactopyranoside 
(IPTG) (GoldBio) was added to induce protein expression at 18 ºC for 20 h. The 
cells were collected by centrifugation at 5,000 rpm (Beckman Coulter, Avanti 
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JXN-30) at 4 ºC. The pellet was resuspended in 40 mL of lysis buffer (20 mM 
triethanolamine (TEA), 50 mM KCl, pH 7) and was disrupted by ultrasonication 
(Branson Sonifier 450) three times using 20 sec burst and 20 sec cooling (4 ºC). 
40 mg chicken egg white lysozyme (MP Biomedicals, LLC) was added and 
incubated on ice for 30 min. The insoluble fraction was removed by centrifugation 
(Beckman Coulter, Avanti JXN-30) at 11,000 rpm at 4 ºC for 45 min. The 
supernatant was applied to a 4 ml of Ni-NTA Agarose (Qiagen) equilibrated with 
lysis buffer. The column was washed with 40 mL of wash buffer (20 mM TEA, 50 
mM KCl, 50 mM imidazole (GoldBio), pH 7). The protein was eluted with 5 ml of 
elution buffer (20 mM TEA, 50 mM KCl, 500 mM imidazole (GoldBio), pH 7). 
Fractions containing pure FolAMtb (>90% as judged by an SDS-PAGE gel) were 
pooled, and concentrated using an ultra-centrifugal filter (Millipore) into storage 
buffer (20 mM potassium phosphate, 50 mM KCl, pH 7.0) to 500 µg/ml. The 
protein was stored at –80 ºC.  
 
Inhibition of FolAMtb by hydroxy-DHF 
All enzymatic assays were performed in storage buffer. 2.5 nM FolAMtb was 
added to 50 µM NADPH (Sigma), 0.01% Triton X-100, and varying 
concentrations of hydroxy-DHF previously dissolved in 100% DMSO, and the 
mixture was incubated for 5 min at 25 ºC. The reaction was initiated with the 
addition of 25 µM DHF (Sigma). The reaction was performed under initial velocity 
conditions and monitored by following oxidation of NADPH through measuring 
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decrease in absorbance at 340 nm (BioTek Synergy H1) every 10 sec for 10 min. 
The percent activity was normalized to a no drug control. The Cheng-Prushoff 
equation was used to determine the Ki from the initial IC50 value (2.9 ± 1.2 µM) 
using the Km of DHF of 1.6 µM as determined by Czekster and 
coworkers(Czekster et. al., 2011). The data represents 3 independent 
experiments using the average of 3 technical replicates. Biochemical 









Purification of FolAEc and FolAMs 
E. coli BW25113 folA was amplified using primers in Table 2.1. The resulting 
DNA was cut with the restriction enzymes NdeI and BamHI and ligated into an 
already digested pET28b(+) using the same restriction enzymes. Expression and 
purification of FolAEc was similarly performed as previously described(Lee et. al., 
2010). Briefly, sequence-verified pET28b(+):folAMtb was transformed into 
competent E. coli BL21 (DE3) cells. E. coli BL21 pET28b(+)-folAEc was 
inoculated into LB and grown overnight at 37 ºC. The cells were diluted 1:1000 
into fresh LB (1 L) and were grown until mid-exponential phase (OD600 0.4–0.6) 
at 37 ºC and 1 mM IPTG was added to induce protein expression at 37 ºC for 4 
h. The cells were collected by centrifugation at 5,000 rpm at 4 ºC. The pellet was 
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resuspended in 10 mL of lysis buffer (50 mM NaH2PO4, 300 mM NaCl, and 10 
mM imidazole (pH 8.0)) containing 10 mg chicken egg white lysozyme was 
added and incubated on ice for 30 min. The insoluble fraction was removed by 
centrifugation at 11,000 rpm at 4 ºC for 45 min. The supernatant was applied to a 
1 mL of Ni-NTA Agarose (Qiagen) equilibrated with lysis buffer. The column was 
washed with 10 mL of wash buffer (50 mM NaH2PO4, 300 mM NaCl, and 20 mM 
imidazole (pH 8.0)). The protein eluted and collected in 5-1mL aliquots of elution 
buffer (50 mM NaH2PO4, 300 mM NaCl, and 250 mM imidazole (GoldBio) (pH 
8.0)). Fractions containing pure FolAEc (>90% as judged by an SDS-PAGE gel) 
were pooled, concentrated (Millipore) into storage buffer (25 mM Tris buffer (pH 
7.5) with 10% glycerol and 1 mM DTT) to 10 mg/mL. The protein was stored at –
80 ºC.  
 
FolAMs was purified similarly as the purification of FolAMtb. Briefly, M. smegmatis 
folAMs was amplified using M. smegmatis genomic DNA by PCR. The resulting 
DNA was cut with the restriction enzymes NdeI and BamH1 and ligated into an 
already digested pET28b(+) using the same restriction enzymes. Briefly, 
sequence-verified pET28b(+):folAMs was transformed into competent E. coli BL21 
(DE3) cells. E. coli BL21 pET28b(+):folAMtb was inoculated into LB and grown 
overnight at 37 ºC. The cells were diluted 1:1000 into fresh LB (1 L) and were 
grown until mid-exponential phase (optical density at 600 nm 0.4–0.6) at 37 ºC 
and 1 mM IPTG was added to induce protein expression at 37 ºC for 4 h. The 
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cells were collected by centrifugation at 5,000 rpm (Beckman Coulter, Avanti 
JXN-30) at 4 ºC. The pellet was resuspended in 10 mL of lysis buffer (20 mM 
triethanolamine (TEA), 50 mM KCl, pH 7) and was ultrasonicated (Branson 
Sonifier 450) three times using 20 sec burst (4 ºC) and 20 sec cooling. 10 mg 
chicken egg white lysozyme (MP Biomedicals, LLC) was added and incubated on 
ice for 30 min. The insoluble fraction was removed by centrifugation (Beckman 
Coulter, Avanti JXN-30) at 11,000 rpm at 4 ºC for 45 min. The supernatant was 
applied to a 1 mL of Ni-NTA Agarose (Qiagen) equilibrated with lysis buffer. The 
column was washed with 40 mL of wash buffer (20 mM TEA, 50 mM KCl, 50 mM 
imidazole (GoldBio), pH 7). The protein was eluted with 5 mL of elution buffer (20 
mM TEA, 50 mM KCl, 500 mM imidazole (GoldBio), pH 7). Fractions containing 
pure FolAMs (>90% as judged by an SDS-PAGE gel) were pooled, concentrated 
(Millipore) into storage buffer (20 mM potassium phosphate, 50 mM KCl, pH 7.0) 
to 5 mg/ml. The protein was stored at –80 ºC.  
 
Biochemical utilization of DHF and hydroxy-DHF 
All enzymatic assays were performed in flat bottom 96 well plates (Corning), with 
200 µL reaction volume, and measured in a BioTek Synergy H1 
spectrophotometer at 25 ºC. FolAEc enzymatic assays were performed using 5 
nM enzyme in MTEN buffer [50 mM 2-morpholinoethanesulfonic acid, 25 mM 
tris(hydroxymethyl)aminomethane, 25 mM ethanolamine, and 100 mM NaCl (pH 
7.0)] containing 1 mM DTT and 0.01% (vol/vol) Triton-X 100. The enzyme was 
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preincubated with 67 µM of NADPH at room temperature for 5 min. The reaction 
was initiated with varying concentrations of dihydrofolate or hydroxy-
dihydrofolate. The decrease in absorbance corresponding to NADPH oxidation 
was monitored at 340 nm every 10 sec for 10 min. Kinetic measurements for 
FolAMs were performed identically as FolAEc except the reaction was performed in 
20 mM potassium phosphate, 50 mM KCl, pH 7.0 with 0.01% (vol/vol) Triton-X 
100. The Km were determined from 4 independent experiments performed in 
biological triplicate and analyzed using GraphPad Prism software. 
 
Construction of PABA auxotrophic strains 
E. coli ΔpabB and A. baumannii ΔpabC strains were constructed as previously 
described (Baba et. al., 2006). M. smegmatis pabB gene was replaced with a 
hygromycin resistance and sacB cassette using the specialized transduction 
method (Bardarov et. al., 2002). Briefly, ~1,000 bp regions upstream and 
downstream of pabB were amplified via PCR, digested with Van91I and ligated 
into previously digested p0004S. The resulting plasmid was sequenced to verify 
amplicons. The resulting plasmid was digested with PacI and ligated into 
previously digested phAE159. The resulting temperature sensitive phage was 
propagated at 30 ºC in M. smegmatis to high titer and used to transduce M. 
smegmatis. The resulting transductants were plated on 10 µg/mL PABA and 
hygromycin and incubated at 37 ºC. The deletion was verified by PCR. H37Rv 
ΔpabB was created identically to M. smegmatis ΔpabB except using primers 
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found in Table 2.1 and the transduced H37Rv was plated on 1 µg/mL PABA and 
hygromycin. 
 
PABA auxotroph growth curves 
E. coli ΔpabB and A. baumannii ΔpabC were grown to mid-exponential phase 
(OD600 0.4-0.6) in LB medium and washed three times with PABA-free M9 
medium. The cells were subcultured in PABA-free M9 medium to OD600 0.001 in 
the presence of 10 µg/mL PABA, 10 µg/mL PAS, or no addition, in technical 
triplicate, in round bottom 96-well plates (Corning). The cells were incubated at 
37 ºC, with 200 rpm shaking, and OD600 were read every hour for 24 hrs. M. 
smegmatis ΔpabB was grown in PABA-free supplemented 7H9 containing 10 
µg/mL PABA to mid-exponential phase (OD600 0.4-0.6) and washed three times 
with PABA-free 7H9. The cells were subcultured in PABA-free 7H9 to an OD600 
of 0.001 in the presence of 10 µg/mL PABA, 10 µg/mL PAS, or no addition, in 
technical triplicate, in round bottom 96-well plates (Corning). The cells were 
incubated at 37 ºC without shaking. Absorbance (OD600) was read every 6 and 




E. coli ΔthyA ΔfolA containing pUC19 constructs 
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E. coli folA was amplified using primers in Table 2.1 using PCR. The resulting 
DNA was cut with the restriction enzymes BamHI and XmaI and ligated into an 
already digested pUC19. The resulting plasmid was sequence verified and 
electroporated into E. coli ΔthyA ΔfolA. M. tuberculosis folA was amplified from a 
codon optimized G Block (Invitrogen) using primers in Table 2.1 for PCR. The 
resulting DNA was cut with restriction enzymes BamHI and EcoRI and ligated 
into an already digested pUC19. The resulting plasmid was sequence verified 
and electroporated into E. coli ΔthyA ΔfolA. 
 
H37Rv ΔpabB containing pUMN002 constructs 
M. smegmatis folA and M. tuberculosis folA were amplified using primers in 
Table 2.1 for PCR. The resulting amplicons were cut with the restriction enzymes 
HindIII and EcoRI and ligated into an already digested pUMN002. The resulting 
plasmids was sequence verified and electroporated into H37Rv ΔpabB. The 
strains were plated on 7H10 containing 1 µg/mL PABA, hygromycin, and 
kanamycin.  
 
folA swap growth curves  
E. coli ΔthyA ΔfolA containing either pUC19-folAEc or pUC19-folAMtb was grown in 
M9 medium supplemented with 200 µg/mL thymine (Sigma) and 50 µM IPTG to 
mid-exponential phase (OD600 0.4-0.6) and washed three times in M9 medium. E. 
coli containing pUC19-folAEc was subcultured to OD600 0.001 and E. coli 
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containing pUC19-folAMtb was subcultured to OD600 0.01, in M9 supplemented 
with 200 µg/mL thymine (Sigma) and 50 µM IPTG, either alone or with 50 µg/mL 
PAS, in round bottom 96-well plates (Corning), in technical triplicate. The cells 
were incubated at 37 ºC with shaking at 200rpm. Absorbance (OD600) was read 
every hour for 50 hours. All growth curves were performed in biological triplicate.  
 
H37Rv ΔpabB containing pUMN002, pUMN002-folAMtb or pUMN002-folAMs was 
grown with 10 ng/mL PABA to mid-exponential phase and was subcultured to 
OD600 0.01 with 10 ng/mL PABA. The strains were grown to mid-exponential 
phase and streaked on PABA-free 7H10 plates containing 5 µg/mL PAS or 5 
µg/mL PABA. The plates were incubated for 3 weeks at 37 ºC. 
 
Computational docking (Written by William McCue) 
 
Dihydrofolate and hydroxy-DHF were each docked into the crystal structures of 
analogous FolAEc and FolAMtb. Docking was performed using the Schrödinger 
Maestro suite [Schrödinger, LLC, New York, NY, 2018]. The X-ray crystal 
structures of E. coli DHFR with methotrexate and NADPH (PDB 4P66) and Mtb 
DHFR with methotrexate and NADPH (PDB 1DF7) were retrieved from the 
RCSB PDB (Berman et. al., 2000; Li et. al., 2000; Liu et. al., 2014). The PDB 
structures were prepared for docking studies using the Maestro Protein 
Preparation Wizard to assign bond orders, create disulfide bonds, fill-in gaps in 
the protein structure, and add in hydrogens. Waters greater than 5 Å away from a 
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ligand or amino acid hetero group were removed and then an energy 
minimization was completed using the OPLS3 force field. The Maestro Receptor 
Grid Generation module was used to define a 25 × 25 × 25 Å grid centered on 
the methotrexate position in both structures. Dihydrofolate and hydroxy-DHF 
ligand structures for docking were prepared by adaptation from the methotrexate 
structure of 4P66 using the Maestro 3D Build Module. Docking was performed 
using the Maestro Glide module with extra precision and flexible ligand sampling, 
but no additional constraints. 10 initial poses were generated for each molecule 
and subjected to a post-docking minimization using an OPLS3 force field. The 
resulting poses were ranked according to their Glide score, which is an 




The evolutionary coupling between pairs of residues in FolAMtb was determined 
using EVcouplings (http://www.EVfold.org) (Marks et. al., 2012; Sander et. al., 
2011). The amino acid sequence used was UniProt ID P9WNX1 and the PDB 
1DG8 was used for the structural comparisons (Li et. al., 2000). All other default 
parameters were used. The majority of coupling pairs are required for structural 
folding of the protein and map outside of the active site. The only coupling pair 




Testing of evolutionary coupling pairs with site directed mutagenesis and enzyme 
assays 
pET28b(+)-folAMtb described previously was mutated with primers described in 
Table 2.1 using QuikChange II Site-Directed Mutagenesis Kit (Agilent). Primers 
were designed according to the Agilent website using QuikChange II parameters 
To create the double mutant pET28b-folAMtb I20M Q28L, pET28b-folAMtb I20M 
was mutated with primers used to create pET28b-folAMtb Q28L. The enzymes 
were induced and purified as previously described for pET28b(+)-folAMtb, with 
some alterations. Once the cells were grown to mid-exponential phase, they 
were incubated at 25 ºC for 2 hours and then induced at 18 ºC for 18hrs. The 
enzyme assays were performed similarly as described previously. One 
modification noted was the enzyme assays were performed in quartz cuvettes in 
a spectrophotometer (Genesys 10S) with a final volume of 500 µL. Variations in 
enzyme concentration, or substrate concentration were noted.  
 
Determination of minimum inhibitory concentrations of antifolates for bacterial 
strains 
Minimum inhibitory concentration (MIC90) is defined as the minimum 
concentration of antimicrobial agent required to inhibit ≥90% of growth compared 
to a no drug control. MIC50 is defined as the minimum concentration of drug 
required to inhibit ≥50% of growth compared to a no drug control. Growth was 
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assessed spectrophotometrically (OD600) (BioTek Synergy H1) or visually, when 
noted.  
 
M. tuberculosis was grown to mid-exponential phase and subcultured to OD600 
0.01 in inkwell bottles. The MIC90 of PAS was determined using log2 serial 
dilutions. The MIC90 was determined after 14 days of incubation. The MIC90 and 
checkerboards of PAS and SMX for E. coli and S. aureus were performed as 
previously described(Minato et. al., 2018) using log2 serial dilutions. M. 
smegmatis was grown to mid-exponential phase and subcultured to OD600 0.001 
in a round bottom 96-well plate (Corning). The MIC90 and checkerboards for PAS 
and SMX were performed using log2 serial dilutions and the MIC90 was 
determined after 3 days of static incubation. A. baumannii, S. enterica, S. 
maltophilia, and B. cenocepacia were grown in LB to mid-exponential phase and 
washed 3 times with M9 medium. The cells were diluted to OD600 0.001 in M9 
medium in round bottom 96-well plates (Corning). The MIC and checkerboards 
for PAS and SMX were performed using log2 serial dilutions and the MIC (or MIC 
for B. cenocepacia) was determined visually after 24 hrs (or 3 days for B. 
cenocepacia) of static incubation. B. fragilis was grown in BHIS to mid-
exponential phase and washed three times with AMMGluc. The cells were diluted 
to OD600 0.001 in AMMGluc in round bottom 96-well plates (Corning). The MIC 
and checkerboards for PAS and SMX were performed using log2 serial dilutions 
and the MIC was determined visually after 3 days of static incubation. S. 
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parasanguinis was grown in Mueller-Hinton broth to mid-exponential phase and 
washed three times with Iso-Sensitest broth. The cells were diluted to OD600 
0.001 in Iso-Sensitest broth in flat bottom 96-well plates (Corning). The MIC90 and 
checkerboards for PAS and SMX was performed using log2 serially dilutions and 
the MIC50 was determined visually after 24 hrs of static incubation. All MICs were 




















Hydroxy-dihydrofolate inhibits FolAMtb but can be utilized as a substrate in other 
organisms 
We were able to synthesize analytically pure hydroxy-DHF and tested whether it 
had inhibitory activity against purified recombinant M. tuberculosis FolA (FolAMtb) 
(Figure 2.1). Hydroxy-DHF was able to potently inhibit FolAMtb with an IC50 of 2.9 
± 1.2 µM and a Ki of 74 nM (Table 2.4 and Figure 2.2).  
 
We determined the minimum inhibitor concentration (MIC) of PAS required to 
inhibit growth in multiple bacteria including enteric commensal bacteria, Gram 
positive pathogens, Gram negative pathogens, non-pathogenic and non-
tuberculosis mycobacteria were all resistant to PAS (Table 2.5). To determine if 
FolA from these bacteria could utilize hydroxy-DHF, we purified the FolA from 
Escherichia coli (FolAEc) and Mycobacterium smegmatis (FolAMs), and found that 
each of these enzymes could use both DHF and hydroxy-DHF as substrates 
(FolAEc Km DHF 2.1 µM and Km hydroxy-DHF 17.2 µM, FolAMs Km DHF 4.2 µM and Km 
hydroxy-DHF 22.5 µM) (Figure 2.3). Taken together, the data suggest that PAS is 
selective for M. tuberculosis, and its activated form hydroxy-DHF can be utilized 
as a substrate by FolA in M. smegmatis and E. coli.  
 
To determine if PAS can be converted to hydroxy-DHF and utilized for folate 
metabolism, we used PABA auxotrophic strains E. coli ΔpabB, M. smegmatis 
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ΔpabB, and Acetinobacter baumannii ΔpabC. These strains cannot grow without 
addition of supplemental PABA to the growth medium (Figure 2.4). When the 
strains were supplemented with PAS, the growth defects of all of the strains were 
chemically complemented (Figure 2.4). These data indicate that PAS can be 
used in lieu of PABA in folate synthesis to support one carbon metabolism. 
 
FolAMtb is the principle target for hydroxy-DHF 
To further understand if FolAMtb is the principal target for hydroxy-DHF, we 
determined if PAS could be utilized in a M. tuberculosis ΔpabB expressing folAMs 
or folAMtb in trans. M. tuberculosis ΔpabB expressing folAMtb could only grow in 
the presence of PABA, not PAS (Figure 2.5). Interestingly, M. tuberculosis 
ΔpabB expressing folAMs could grow in the presence of both PAS and 
PABA(Figure 2.5). However, it is worth noting that growth on PAS was not as 
robust as growth on PABA, indicating that PAS-containing folates are not used 
as efficiently as native folates in this strain. Furthermore, these strains could not 
grow reliably in liquid medium in the presence of PAS (data not shown) but could 
grow on solid medium containing PAS. These observations indicate that FolA the 
molecular determinant for microbial PAS susceptibility and resistance.  
 
We performed the converse experiment using E. coli ΔfolAEc ΔthyA expressing 
folAMtb and folAEc in trans. The strain cannot grow without supplemental 
thymidine because the strain also lacks thymidylate synthase (encoded by thyA), 
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a key enzyme in thymidine synthesis pathway(Howell et. al., 1988a). E. coli 
ΔfolAEc ΔthyA expressing folAEc could grow in the presence of thymidine and 
PAS (Figure 2.6). As expected, E. coli ΔfolAEc ΔthyA expressing folAMtb could 
grow in the presence of supplemental thymidine, but could not grow in the 
presence of thymidine and PAS (Figure 2.6). However, the strain has a much 
longer lag phase compared to the strain with expressing folAEc. Taken together, 
these data demonstrate that folAMtb is the principal target of activated PAS. 
 
FolAMtb forms additional hydrogen bonds with hydroxy-DHF compared to other 
bacterial FolAs 
DHF and hydroxy-DHF was docked into crystal structures of FolAMtb and FolAEc. 
The docking score was determined for each confirmation of DHF and hydroxy-
DHF. The docking score corresponds to the theoretical binding affinity Kd. The 
more negative binding score the higher binding affinity the enzyme has for the 
substrate. FolAMtb formed an additional hydrogen bond with hydroxy-DHF 
compared to DHF (Figures 2.7 and 2.8). This additional hydrogen bond resulted 
in a more negative docking score (Figure 2.8). In contrast, FolAEc could not form 
any additional hydrogen bonding with hydroxy-DHF and the docking score of 
hydroxy-DHF is similar to DHF (Figures 2.7 and 2.9). The addition of one 





We also used evolutionary coupling as an approach to discover which residues 
were important in the selective binding of hydroxy-DHF. Evolutionary coupling 
predicted many residues to be conserved in FolA, however, only two residues 
were found to be coupled in the active site of FolAMtb I20 and Q28 (Figure 2.10). 
Although the hydrophobic I20 position is conserved among FolA orthologs, Q28 
is unique to FolAMtb and could also hydrogen bond with hydroxy-DHF in the 
molecular docking studies (Figures 2.7 and Figure 2.10).  
 
Based on the results from the molecular docking and evolutionary coupling 
experiments, we performed site directed mutagenesis to create the following 
variants FolAMtb I20M, FolAMtb Q28L, and FolAMtb I20M Q28L, to determine if 
these enzymes could utilize hydroxy-DHF. FolAMtb I20M was found to be 
enzymatically active in its ability to utilize DHF, however, it could not utilize 
hydroxy-DHF (Figures 2.11 and 2.12). FolAMtb Q28L was not able to utilize DHF 
even at higher enzyme concentrations (Figure 2.11). FolAMtb I20M Q28L did not 
show any enzymatic activity using DHF or hydroxy-DHF (Figure 2.12). Taken 
together, this data suggests FolAMtb Q28 is predicted to be an important residue 
in conferring susceptibility to hydroxy-DHF. Although, mutations to Q28 could be 
detrimental to enzyme activity, additional compensatory mutations in FolAMtb 
could be required to utilize hydroxy-DHF  
 
Exogenous PAS can antagonize antifolates in various bacteria 
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Exogenous PABA can antagonize the activity of many FolP inhibitors such as 
sulfonamides and diaminodiphenyl sulfones (Figures 2.13 and 2.14). Since we 
have demonstrated that PAS can act in lieu of PABA in folate biosynthesis, we 
hypothesized that PAS can also antagonize the activity of sulfonamides and 
diaminodiphenyl sulfones. In E. coli, addition of exogenous PAS can antagonize 
the activity of sulfamethoxazole (SMX), sulfanilamide, sulfathiazole and the 
diaminodiphenyl sulfone dapsone (Figures 2.13 and 2.14). Exogenous PABA 
cannot antagonize the activity of TMP(Minato et. al., 2018). We examined the 
interaction, if any, between PAS and TMP and found exogenous PAS had no 
interaction with TMP in E. coli (Figures 2.13 and 2.14). Since SMX and TMP are 
most frequently given in combination, we tested if PAS could antagonize the 
activity of SMX and TMP given in a clinical 5:1 ratio. For E. coli, the MIC of SMX 
alone is 0.2 µg/mL and for TMP alone is 0.5 µg/mL (Figure 2.15). Since SMX and 
TMP work synergistically, the MIC of SMX and TMP in a 5:1 ratio is 0.194/0.0388 
µg/mL, respectively (Figure 2.15). Surprisingly, PAS could antagonize the 
synergistic activity of SMX and TMP until the MIC of TMP (0.0388 µg/mL)  is 
reached. (Figure 2.15). 
 
SMX and TMP are used to treat a wide range of bacterial infections. We also 
determined if exogenous PAS could antagonize SMX activity in a variety of other 
bacterial species. Exogenous PAS did antagonize the activity of SMX in M. 
smegmatis, Staphylococcus aureus, Streptococcus parasanguinis, Bacteroides 
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fragilis, Salmonella enterica and Burkholderia cenocepacia (Figures 2.13 and 








Hydroxy-DHF inhibits FolAMtb but can be utilized as a substrate in other 
organisms. 
Herein, we tested the hypothesis that hydroxy-DHF selectively inhibits FolAMtb 
while other organisms can utilize hydroxylated folate species as a cofactor for 
one carbon metabolism. To test this hypothesis, we first needed to synthesize 
hydroxy-DHF, as no source for analytically pure material exists. We were able to 
develop a synthetic scheme and were able to subsequently demonstrate that 
hydroxy-DHF inhibits FolAMtb. We found that hydroxy-DHF potently inhibits 
FolAMtb with an IC50 of 2.9 ± 1.2 µM and a Ki of 74 nM. The inhibitory data is 
similar to other reported dihydrofolate reductase inhibitors such as methotrexate, 
TMP and WR99210 (Burchall and Hitchings, 1965; Milhous et. al., 1985).  
 
Previous work noted that PAS was selective at inhibiting M. tuberculosis. We 
followed up on these studies and found in most organisms tested PAS did not 
exhibit any inhibitory activity (>500 µg/mL). Although one organism, S. 
parasanguinis, did have a measurable PAS MIC of 250 µg/mL. The serum 
concentration of PAS ranges from 9-35 µg/mL with an average time to peak 
serum concentration levels of 6 hrs. Therefore, although PAS did display 
inhibitory activity against S. parasanguinis, the serum concentrations of PAS 
would be far below this MIC. Since PAS is given orally 3-4 times per day in 4 
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gram doses, it is possible that this level could be reached in the stomach or 
intestines. Although, one remaining question is, why does S. parasanguinis have 
a measurable MIC to PAS while the other bacteria tested do not? On explanation 
could be that hydroxy-DHF or a downstream hydroxy-folate species could be 
inhibitory at very high concentrations. 
 
We extended this study and tested purified recombinant FolA from E. coli and M. 
smegmatis for utilization of hydroxy-DHF. We found that both enzymes could 
utilize hydroxy-DHF as a substrate, however, at a higher Km. Since Km is related 
to binding affinity, both enzymes cannot bind hydroxy-DHF as well as DHF. 
Interestingly, although they have a higher Km for hydroxy-DHF, the amount of 
hydroxy-DHF required for growth must be very low.  
 
To determine if the previously tested bacteria were utilizing PAS for folate 
biosynthesis, we used PABA auxotrophic strains of E. coli and M. smegmatis to 
test if these strains could utilize PAS. All strains could grow in the presence of 
both PABA and PAS. Thus, PAS can be utilized for folate biosynthesis and 
resulting folates can serve as cofactors for one carbon metabolism.   
 
FolAMtb is the principle target for hydroxy-DHF 
In order to determine if FolA is the principle target for PAS, we used a strain of E. 
coli that lacked folA and thyA, an essential enzyme to make thymidine. Using this 
102 
 
strain we could express FolAEc and FolAMtb from a plasmid and determine 
whether these strains could grow in the presence of thymidine alone or in the 
presence of thymidine and PAS.. In order to ensure the enzyme was able to fold 
properly, we first grew both strains in the presence of thymidine. Although the 
strain containing FolAMtb had a delayed growth phenotype it could still grow using 
thymidine. This suggests that when FolAMtb  is expressed in E. coli, it may not 
have the same kinetics as FolAEc. The fast growth rate of E. coli, relative to M. 
tuberculosis, likely demands an increased abundance of reduced folates. When 
we grew both strains in the presence of PAS, only the strain expressing FolAEc 
was capable of growth, suggesting that we could transfer PAS susceptibility to E. 
coli with the expression of FolAMtb. 
 
We performed a similar experiment in a PABA auxotrophic strain of M. 
tuberculosis. Instead of expressing folA from E. coli, we used folAMs from M. 
smegmatis. We reasoned that expression of an ortholog from a more closely 
related bacterial species would have a greater chance of proper folding in M. 
tuberculosis. FolAMs has more sequence identity with FolAMtb then FolAEc (~60% 
compared to ~30%). We grew both strains with the minimum amount of PABA to 
support growth so that the exogenous PABA would not antagonize the activity of 
PAS. We used plates containing 5 µg/mL of PABA or PAS, as previous literature 
has shown that PAS could have an alternative mechanism of action at high 
concentrations of 10 µg/mL or more(Moradigaravand et. al., 2016). We found that 
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the strain expressing FolAMs could grow in the presence of both PABA and PAS. 
In contrast, the strain expressing FolAMtb could grow in the presence of PABA, 
but could not grow in the presence of PAS. The ability of M. tuberculosis to utilize 
PAS in lieu of PABA when expressing FolA from a resistant organism 
demonstrates that FolAMtb is the exclusive target and basis for the exquisite 
selectivity of activated PAS. 
 
FolAMtb can form an additional hydrogen bond to hydroxy-DHF from the residue 
Q28 
To pinpoint the exact mechanisms of this selectivity, we used molecular docking 
to dock DHF and hydroxy-DHF into previously crystallized FolAMtb and FolAEc. 
FolAMtb is predicted to bind both DHF and hydroxy-DHF, however, hydroxy-DHF 
had a more negative docking score (-11.6 DHF compared to -12.6 hydroxy-DHF). 
This score correlates to a log order higher affinity binding of hydroxy-DHF 
compared to DHF in FolAMtb. Furthermore, this more negative docking score is 
likely attributed to an additional hydrogen bond with hydroxy-DHF at position 
Q28. Conversely, FolAEc had a less negative binding score to DHF (-9.4 DHF 
compared to -9.1 hydroxy-DHF), suggesting that FolAEc can bind to both 
substrates, but has a slightly higher affinity to DHF. This observation could 
explain the higher Km of FolAEc for utilization of hydroxy-DHF compared to DHF. 
Notably, FolAEc had a residue L28 that could not hydrogen bond with hydroxy-
DHF. This lack of hydrogen bonding at position 28 in FolAEc could explain the 
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less negative binding score between DHF and hydroxy-DHF.  Furthermore, the 
alpha helix, that binds DHF and hydroxy-DHF in FolAMtb and FolAEc are different. 
The alpha helix in FolAMtb contains much more hydrophilic residues compared to 
FolAEc. Therefore, hydroxy-DHF undergoes a much more thermodynamically 
unfavorable rotation, in FolAEc, to place the hydroxyl-group on hydroxy-DHF into 
a more favorable environment. 
 
Evolutionary coupling was performed using FolAMtb to determine which amino 
acid residues on FolA had a larger evolutionary pressure to mutate. Interestingly, 
Q28 was predicted to be evolutionary coupled with I20. Q28 is the same residue 
that can hydrogen bond with hydroxy-DHF in the molecular docking studies. We 
constructed and purified these enzymes and tested the ability to utilize DHF or 
hydroxy-DHF as a substrate. We found that FolAMtb I20M had reduced enzymatic 
activity compared to the wild type enzyme but could not utilize hydroxy-DHF as a 
substrate. The FolAMtb Q28L mutant and FolAMtb I20M Q28L double mutant could 
not utilize either DHF or hydroxy-DHF.  One avenue of future research could be 
to exchange the alpha helix from FolAEc with the alpha helix from FolAMtb. This 
modification could overcome any detrimental mutations in the active site. Another 
assay to address any overall structural changes to the enzyme, would be to 
perform an enzyme evolution assay using random mutagenesis where active 




PAS, like PABA, can antagonize antifolates 
We have previously demonstrated that PAS can act similarly to PABA in folate 
biosynthesis. Since PABA can antagonize the activity of sulfa-drugs, we tested 
drug-drug interactions between PAS and sulfa-drugs. Specifically, we tested if 
PAS could antagonize SMX, DDS, STZ and SNL. We found that in E. coli PAS 
could antagonize these drugs. Furthermore, PAS could antagonize SMX in a 
variety of bacterial species. Since previous studies have found that PABA cannot 
antagonize TMP activity, we also tested if PAS could antagonize TMP activity. 
Not surprisingly, PAS could not antagonize TMP activity. Since SMX and TMP 
are rarely given in monotherapy, we tested if PAS could antagonize SMX and 
TMP given in a clinical 5:1 ratio. Indeed PAS could antagonize SMX and TMP 
activity, however, once the MIC of TMP is reached the antagonism is abolished. 
This observation indicates that only SMX activity is being antagonized by PAS 
and that co-treatment with PAS and SMX/TMP may be similar to treating with 
TMP in monotherapy. 
 
From a clinical perspective, these data suggest that PAS and sulfa drugs should 
not be used in combination. Patients who are HIV positive are given lifelong 
prophylactic therapy of SMX/TMP to prevent and treat opportunistic pathogens. 
In some areas of the world there is a high prevalence of HIV-TB co-infection. 
Therefore, treatment with PAS and SMX/TMP needs to be reevaluated as PAS 





Table 2.1. Oligonucleotide primers used in this study 
Primer 
name 

































































































































































1Underline corresponds to the restriction enzyme cut site. All primers are written in 5’ to 3’ 
orientation 
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Table 2.2. Plasmids used in this study 
Plasmid Relevant characteristics Source 
pET28b+ Bacterial high copy plasmid for protein overexpression 
containing C- and N-terminal 6X histidine tags inducible with 
lacI, Kanr 
Novagen 
pET28b-folA-Mtb pET28b+ containing folAMtb with an N-terminal 6x-histidine 
tag, Kanr  
This work 
pET28b-folA-Ec  pET28b+ containing folAEc with an N-terminal 6x-histidine 
tag, Kanr  
This work 





pET28b+ containing folAMtb containing the Q28L mutation 




pET28b+ containing folAMtb containing the I20M mutation with 




pET28b+ containing folAMtb containing the I20M and Q28L 
double mutation with an N-terminal 6x-histidine tag, Kanr 
This work 
p0004S Plasmid used for allelic exchange, Hygror, sacB (Baughn et. al., 
2010) 
phAE159 Phasmid used for specialized transduction, Penr (Bardarov et. al., 
2002) 
pUC19 E. coli complementation plasmid, inducible with lacI, Penr Lab stock 
pUC19-folA-Ec pUC19 containing folAEc, Penr This work 
pUC19-folA-Mtb pUC19 containing folAMtb that has been codon optimized for 
expression in E. coli, Penr 
This work 
pUMN002 Mycobacterial low copy number constitutively replicating 
plasmid, Kanr 
Lab stock 
pUMN002- folAMs pUMN002 containing folAMs, Kanr This work 





Table 2.3. Strains used in this study 
Strain Name Relevant characteristics Source 
E. coli   
 DH5α Cloning strain Lab stock 
 BL21 (DE3) Protein purification strain Lab stock 
 pET28b-folA-Mtb BL21 containing pET28b-folA-Mtb for overexpression of 
FolAMtb 
This work 
 pET28b-folA-Ec BL21 containing pET28b-folA-Ec for overexpression of 
FolAEc 
This work 





BL21 containing pET28b-folA-Mtb-Q28L for 




BL21 containing pET28b-folA-Mtb-I21M for 




BL21 containing pET28b-folA-Mtb-I21M for 
overexpression of FolAMb I20M Q28L 
This work 
 BW25113 Wild-type lab stock Lab stock 
 ΔpabB BW25113 pabB::kan, Kanr Keio 
collection(Baba 
et. al., 2006) 
 ΔthyA ΔfolAEc LH18, ΔthyA ΔfolAEc::kan, Kanr (Howell et. al., 
1988c) 
 ΔthyA ΔfolAEc- 
pUC19-folAEc 
ΔthyA ΔfolAEc containing pUC19-folAEc, Penr, Kanr This work 
 ΔthyA ΔfolAEc- 
pUC19-folAMtb 
ΔthyA ΔfolAEc containing pUC19-folAMtb, Penr, Kanr This work 
M. tuberculosis    
 H37Rv Wild-type strain Lab stock 
 H37Ra Wild-type attenuated strain derived from H37Rv Lab stock 
 ΔpabB H37Rv pabB::hygro-sacB cassette, Hygror This work 
 ΔpabB-pUMN002 ΔpabB  containing pUMN002, Kanr, Hygror  This work 
 ΔpabB-
pUMN002- folAMs 
ΔpabB  containing pUMN002-folAMs, Kanr, Hygror This work 
 ΔpabB-
pUMN002-folAMtb 
ΔpabB  containing-pUMN002 folAMtb, Kanr, Hygror This work 
M. smegmatis   
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 mc2155 Wild-type strain (Baughn et. al., 
2010) 
 ΔpabB mc2155 pabB::hygro-sacB cassette, Hygror This work 
M. abscessus  ? 
B. fragilis G38A wild-type lab stock ? 
B. cenocepacia B7, Cystic fibrosis clinical isolate (Tomich and 
Mohr, 2004) 
S. enterica Wild-type lab stock (Adamowicz et. 
al., 2018) 
S. maltophilia   
S. aureus USA300 clinical isolate strain (Minato et. al., 
2018) 










E. coli 2.1 17.2 
M. smegmatis 4.2 22.5 
Table 2.4. Mechaelis-Menten kinetics of utilization of dihydrofolate and 
hydroxy-DHF in FolA 
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 Table 2.5. PAS Inhibitory concentrations against various bacterial species 
  Organism PAS Inhibitory Concentration 
(µg/mL) 
Mycobacterium tuberculosis 0.3 
Mycobacterium smegmatis >500 
Mycobacterium abscessus >500 
Staphylococcus aureus >500 
Streptococcus parasanguinis 250 
Salmonella enterica >500 
Bacteroides fragilis >500 
Escherichia coli >500 
Burkholderia cenocepacia >500 
Stenotrophomonas maltophilia >500 
































1.CbzCl, 10% Na2CO3 
THF, rt, 1 h, 64% 
2. BzCl, Py Et2O, 0 ºC 
to rt 4 h, 63% 
 
EDC, Et3N, DCM 0 ºC 
to rt, 15 h, 46% 
 
H2, Pd/C 
EtOh, rt, 2h 67% 
AcOH, (Me)2N BH3 rt 
to 60 ºC, 1 h 
1. 0.5N NaOH 70 ºC,     
    1.5h 
2. Na2S2O4 ascorbic 
acid, H2O pH 6.5, 40 
ºC, 3h      
    1.5h 
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Figure 2.2. Hydroxy-DHF inhibits FolAMtb. An IC50 curve was generated using 2.5 
nM of purified FolAMtb against varying concentrations of hydroxy-DHF. The data 
shown represents 3 independent experiments using the average of 3 technical 
replicates. The IC
50
(2.9 ± 1.2 µM) was calculated using GraphPad Prism 
software and K
i
 (74 nM) was calculated based on the Cheng-Prushoff equation. 











Figure 2.3. Mechaelis-Menten kinetics utilization of DHF or hydroxy-DHF. DHF 
or hydroxy-DHF utilization was measured in the presence of dihydrofolate or 
hydroxy-dihydrofolate using purified recombinant dihydrofolate reductase from 
E. coli and M. smegmatis. The data represents the average error of the mean 




































E. coli BW25113 ΔpabB 




Figure 2.4. PAS can be utilized in lieu of PABA for folate biosynthesis and is 
function in one carbon metabolism. a) E. coli or b) M. smegmatis PABA 
auxotrophs were grown in the presence of PABA or PAS (10 µg/mL). Both strains 
















Figure 2.5. The mechanistic basis for PAS selectivity in M. tuberculosis. H37Rv 
ΔpabB pUMN002 expressing folAMtb or folAMs or empty vector were grown in the 
presence of a) no addition, 5 µg/mL of b) PABA or c) PAS. Plates were 








































   




   
a 
b 
Figure 2.6. The mechanistic basis for PAS selectivity in E. coli. a) E. coli ∆thyA 
∆folAEc pUC19-folAEc can grow in the presence of thymidine and 
thymidine+PAS (50 µg/mL) in M9 minimal media. b) E. coli ∆thyA ∆folAEc 
pUC19-folAMtb can only grow in the presence of thymidine and not in the 






FolAMtb DHF FolAMtb Hydroxy-DHF 
FolAEc DHF 
Figure 2.7. Molecular docking of DHF and hydroxy-DHF into FolAMtb and FolAEc. 
Previously crystallized FolAMtb (PDB:1DF7) was used to dock a) DHF or b)hydroxy-
DHF. Previously crystallized FolAEc (PDB 4P66) was used to dock c) DHF or d) 
hydroxy-DHF. Dashed lines represent key hydrogen bonds formed during the 
docking simulation. Red dots represent water molecules found in the crystal 
structures of the molecules used for docking. Circle indicated hydrogen bond 










































Figure 2.8. Molecular docking scores and positions of DHF and hydroxy-DHF in FolAMtb. 



























Figure 2.9. Molecular docking scores and positions of DHF and hydroxy-DHF in FolAEc. 








Figure 2.10. Evolutionary coupling predicts key contacts between Q28 and 
I20 uniquely found in FolAMtb. a) Evolutionary coupling was performed on 
FolAMtb, although multiple residues were considered coupled (green) the 
only residues in the active site found to be coupled were Q28 and I20. b) 
Amino acid sequence alignment of the M20 shows conservation of I20 
amino acid among FolA (box). Q28 is only found in is the only residue not 
conserved in the amino acid sequence comparison (box). 
M. tuberculosis MTMVGLIWAQATSGVIGRGGDIP WRLPEDQAHFREITM 
M. smegmatis MSMRLIWAQSTSGIIGRDNSIP WRLPEDLARFKEMTM 
E. coli MISLIAALAVDRVIGMENAMP WNLPADLAWFKRNTL 
S. enterica MISLIAALAVDRVIGMENAMP WNLPADLAWFKRNTL 
B. cenocipacia MTTLTLIVARARNGIIGRDNQLP WKLPEDLAFFKRTTM 
B. fragilis MSRISIIAAVDSRMAIGFQNKLLFW  PNDLKRFKALTT 
S. aureus MTLSIIVAHDKQRVIGYQNQLP WHLPNDLKHIKQLTT 






























































Figure 2.11. Progress curves of FolAMtb I20M and FolAMtb Q28L utilizing DHF. 
a) 10 nM of FolAMtb and FolAMtb I20M utilizing DHF as a substrate. b) Varying 
concentrations of FolAMtb Q28L utilizing DHF as a substrate. All enzymes 
were preincubated with saturating concentrations of NADPH (90 µM)  for 5 
min. The reaction was initiated with saturating concentrations of DHF (76 
µM) and the reaction was read by the depletion of NADPH at 340 nm every 
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10nM FolAMtb Q28L 
 
20nM FolAMtb Q28L 
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40nM FolAMtb Q28L 
 
























































Figure 2.12. Progress curves of FolAMtb I20M, FolAMtb Q28L and FolAMtb I20M 
Q28L utilizing hydroxy-DHF. a) 10 nM of FolAMtb and FolAMtb I20M Q28L 
utilizing DHF as a substrate. b) 10 nM FolAMtb I20M, FolAMtb Q28L and 
FolAMtb I20M Q28L utilizing 25µM or 50µM of hydroxy-DHF. All enzymes 
were preincubated with saturating concentrations of NADPH (90µM)  for 5 
min. The reaction was initiated with saturating concentrations of DHF (25µM) 
or indicated amounts of hydroxy-dihydrofolate and the reaction was read by 
the depletion of NADPH at 340nm every 10 sec for 700 sec. Results are 
shown as the average of three independent experiments. 
Fol Mtb  
Fol Mtb I20M Q28L 
FolAMtb I20M  
25µM hydroxy-DHF 
FolAMtb I20M  
50µM hydroxy-DHF 
FolAMtb I20M Q28L 
25µM hydroxy-DHF 
























Figure 2.13. PAS, like PABA, can antagonize antifolates. E. coli (Ec), M. 
smegmatis (Ms), Staphylococcus aureus (Sa), and Bacteroides fragilis (Bf) were 
grown in minimal media in the presence of varying concentrations of PAS and 
either sulfamethoxazole (SMX), sulfanilamide (SNL), sulfathiazole (STZ), 
dapsone (DDS), trimethoprim (TMP), or a 5:1 ratio of SMX/TMP. The heat map 







































































































































































































































































































Figure 2.14. PAS, like PABA, can antagonize antifolates in E. coli. E. coli were 
grown in minimal M9 medium in the presence of varying concentrations of a) 
PABA and sulfamethoxazole (SMX). E. coli were grown in minimal M9 medium in 
the presence of varying concentrations of PAS and either b) sulfamethoxazole 
(SMX), c) trimethoprim (TMP), d) dapsone (DDS), e) sulfanilamide (SNL), f) 
sulfathiazole (STZ) for 24hrs at 37 ºC. The data represents the minimum 
concentration of drug required to inhibit growth in varying PAS concentrations. 
Each experiment represents an average of three biological replicates, error bar 







Figure 2.15. PAS can only partially antagonize a clinical combination of SMX and 
TMP. E. coli were grown in minimal media in the presence of varying 
concentrations of PAS and a 5:1 ratio of sulfamethoxazole (SMX) trimethoprim 
(TMP), respectively, for 24hrs at 37 ºC. The data represents the minimum 
concentration of drug required to inhibit growth in varying PAS concentrations. 
Each experiment represents an average of three biological replicates, error bar 































































Figure 2.16. PAS, like PABA, can antagonize antifolates in various bacterial 
species. a) S. enterica, b) B. fragilis, c) S. aureus, d) S. parasanguinis, and e) M. 
smegmatis were grown in minimal media, or isosentist broth for S. parasanguinis, 
in the presence of varying concentrations of PAS and SMX at 37 ºC. The data 
represents the minimum concentration of drug required to inhibit growth in 
varying PAS concentrations. Each experiment represents an average of three 






















































































































































































































Chapter 3:  
The mechanistic basis for para-aminosalicylic acid toxicity and  
resulting antagonism by sulfa-drugs 
 
Specific contributions  
 
Kordus, SL concieved cytotoxicity assay study. Lamont, EA performed the 
cytotoxicity assays (TABLE 3.4 and 3.5) and wrote the methods for the 
cytotoxcity assays. 
 
The rest of the chapter has not published when the thesis was submitted. All 
experiments, experimental design, intellectual contributations were performed by  






Many chemotherapeutic agents cause gastrointestinal distress. These side 
effects are a result of disturbances within the gut microbiota or off-target effects 
to the host. para-Aminosalicylic acid (PAS) was one of the first chemotherapeutic 
agents used to treat Mycobacterium tuberculosis infections, and its use was 
highly associated with severe gastrointestinal distress. Consequently, PAS use 
fell out of favor and it was replaced with better tolerated antitubercular agents. 
With the emergence of drug-resistant strains of M. tuberculosis, PAS has 
regained clinical use. Thus, there is a renewed interest in understanding the 
mechanisms that govern PAS toxicity. Human-associated microbiota produce 
many vitamins and co-factors that are accessible by human cells. Folate, for 
instance, is produced by bacteria in the small and large intestines and is 
absorbed by enterocytes, epithelial cells that line the intestines. Based on our 
observations in Chapter 2, we hypothesized that bacteria in the intestines can 
utilize PAS for hydroxy-folate synthesis which may be the basis for PAS-
mediated gastrointestinal distress in humans. Indeed, we found that hydroxy-
folates, but not PAS, are cytotoxic to human cells. Furthermore, we determined 
that hydroxy-dihydrofolate can be utilized as a substrate by human dihydrofolate 
reductase at a reduced catalytic rate. We hypothesized that by blocking PAS 
incorporation into folates in the gut microbiota we could prevent PAS toxicity in 
vivo. By using sulfamethoxazole (SMX), a FolP inhibitor, as a chemical tool we 
were able to alleviate PAS toxicity in mice. Previous work has demonstrated that 
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SMX can antagonize the antitubercular activity of PAS in vitro. When we 
examined the interaction between PAS and SMX in a M. tuberculosis murine 
infection model we found that SMX could potently antagonize PAS activity in 
vivo. This antagonism was found to be mediated by alterations in pterin 
biosynthesis. Taken together, our study is the first to characterize the basis for 







Folate (vitamin B9), is required for the de novo biosynthesis of thymidylate, 
purines, coenzyme A and several amino acids. As such, this cofactor is essential 
for synthesis of new DNA, RNA and proteins in all actively growing cells. In 
humans, folate deficiency has pleotropic effects, particularly in rapidly dividing 
tissues including, bone marrow, gastrointestinal (GI), and central nervous system 
development. Therefore, folate metabolism is an attractive target for treating 
cancer.  
 
Humans lack many of the enzymes required to synthesize folates and must 
acquire folates from their diet or other sources. Most, if not all, human cells 
possess folate receptors which transport the cofactor into the cytosol. The 
primary system to acquire folates from the diet is in the duodenum and jejunum 
in the small intestine (Visentin et. al., 2014). Most bacteria must produce their 
own folates, and many bacteria of the human GI tract secrete folates that are 
accessible by enterocytes, epithelial cells that line the intestines. Once absorbed, 
these folates can be transported to other areas of the body.  
 
There are a number of solute carriers that possess the ability to transport folates. 
Two important solute carriers expressed by enterocytes include reduced folate 
carrier (RFC) and proton-coupled folate transporter (PCFT). Both RFC and PCFT 
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are specific for folates with distinct roles in transport. RFC is expressed in all 
tissues and cell lines on the both the apical and basolateral sides of the cell 
membrane (Wang et. al., 2001). RFC binds reduced folates at neutral pH with 
high affinity but has low affinity for folic acid (Visentin et. al., 2014). Furthermore, 
RFC binds most antifolic acid chemotherapeutic agents including methotrexate, 
pralatrexate, and premetrexed (Visentin et. al., 2014). RFC is the primary solute 
carrier used to absorb and export reduced folates from the intestines to other 
areas of the body (Wang et. al., 2001). In contrast to RFC, PCFT is expressed 
and localized only to the apical side of enterocytes in the small intestine and 
binds folic acid at acidic pH with high affinity (Qiu et. al., 2006). PCFT can bind 
folic acid at neutral pH with lower affinity, however, it cannot bind reduced folates 
(Qiu et. al., 2006). Although PCFT is able to bind some antifolates, it primarily 
binds premetrexed (Zhao et. al., 2008).  
 
Once folate is absorbed into the enterocyte, it can be utilized for one carbon 
metabolism, or it can be secreted via the basolateral membrane into the portal 
vein (Visentin et. al., 2014). While in the portal vein, folates travel to the liver by 
merging with the hepatic artery into the hepatic sinusoid. Folates travel to the 
hepatic vein and are transported to other areas of the body. Folates can also be 
absorbed by hepatocytes via folate receptors (specifically RFC) on the 
basolateral membrane. If folates are not utilized by the liver, they can be 
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secreted via the apical membrane into the bile canaliculus which drains into the 
small intestine.  
 
Chemotherapy often induces changes in the commensal bacteria of the GI tract 
as well as changes to the enterocytes (Keefe et. al., 1997). Side effects of many 
chemotherapeutic agents include severe enterocolitis, gastrointestinal 
ulcerations, diarrhea and anorexia from nutrient malabsorption (Pico and Avila-
Garavito, A, Naccache, 1998). Specifically, methotrexate (MTX) and other 
dihydrofolate reductase (DHFR) inhibitors at high concentration are known to 
cause mucositis, inflammation and ulcerations along mucosal membranes. 
Furthermore, these inhibitors are associated with increased intestinal 
permeability through alteration of tight junction formation (Beutheu Youmba et. 
al., 2012). Tight junctions are transmembrane multi-protein complexes that 
anchor the peripheral cellular membranes and maintains the intestinal barrier. 
Recently, MTX was found to modulate tight junction formation by causing 
alterations in expression of proteins that make up tight junctions (Beutheu 
Youmba et. al., 2012).  
 
para-Aminosalicylic acid (PAS) has been used clinically to treat tuberculosis (TB) 
for over 70 years. Unfortunately, treatment with PAS was often associated with 
severe GI distress. In the first clinical trial of PAS, 75% of patients reported 
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severe GI distress, and 20-25% reported nausea, vomiting and diarrhea (Erdei 
and Snell, 1948; Vallentin and Tronell, 1950). These side effects were often 
attributed to the presence of impurities introduced during synthesis or 
spontaneous deterioration of PAS (Mitchell et. al., 1954). In an effort to bypass 
the associated GI distress, PAS was given intravenously in Europe and was 
found to be more well-tolerated (Jones, 1954). With the advent of better tolerated 
and superior chemotherapeutics, PAS fell out of favor to treat TB in the late 
1960s. 
 
Use of PAS was revitalized with the emergence of multi-drug resistant strains of 
M. tuberculosis in the 1990s. To help prevent GI distress, PAS was reformulated 
into a delayed release gastro-resistance formulation. With this formulation, once 
the granules enter the small intestine, the coating is dissolved at neutral pH 
which allows for delayed release of PAS, so that the serum levels do not 
immediately peak. However, patients still must take 10-12 g of PAS per day to 
reach inhibitory levels in the lung. While this formulation represents an 
improvement, 20% of patients still discontinue PAS treatment due to GI distress. 
In response to the revitalization of PAS, there is a need for a better 




Previous work has shown that PAS is converted to hydroxy-dihydrofolate 
(hydroxy-DHF) via the folate biosynthesis pathway in M. tuberculosis 
(Chakraborty et. al., 2013; Zhao et. al., 2014; Zheng et. al., 2013). Results in 
chapter 2 indicate the same is true in several other bacterial species. Thus, we 
hypothesized that bacteria in the GI tract produce hydroxy-folates that might 
intoxicate gut enterocytes. Consistent with this model, cytotoxicity assays 
revealed that hydroxy-DHF and hydroxy-folate were toxic for HepG2 and Caco-2 
cells while PAS was not toxic. Further, it was found that human DHFR could 
utilize hydroxy-DHF as a substrate at a compromised rate relative to DHF, 
suggesting that hydroxy-folates can impair one-carbon metabolism in human 
cells. Since the first step of hydroxy-DHF synthesis requires dihydropteroate 
synthase (FolP) (Chakraborty et. al., 2013; Zhao et. al., 2014; Zheng et. al., 
2013), the FolP inhibitor sulfamethoxazole was found to be an antagonist of PAS 
toxicity in mice. These data indicate that PAS-mediated GI distress involves 
production of hydroxy-DHF by the gut microbiota.  
 
Previous work has shown that PAS activity can be antagonized in vitro in M. 
tuberculosis by SMX (Zheng et. al., 2013). In the present study, we determined 
that this antagonism also occurs in vivo using a mouse model of M. tuberculosis 
infection. Further, other FolP inhibitors were found to potently antagonize PAS 
susceptibility in M. tuberculosis. The mechanistic basis of antagonism by SMX 
was probed using strains deficient for synthesis of folate precursors, and it was 
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found that SMX-mediated PAS antagonism required flux through the pterin 
biosynthesis pathways. The data from this study can be used to discover novel 
mechanisms to prevent PAS toxicity. Furthermore, these data can be used to 
uncover novel antagonism mechanisms that can be used to inform drug 




Materials and Methods: 
Bacterial strains, media, and growth conditions 
All information regarding primers, plasmids, and bacterial can be found in Table 
3.1-3.3 
 
M. tuberculosis strains and Mycobacterium bovis BCG were grown at 37 ºC in 
either 7H9 broth (Difco) supplemented with 0.2% (vol/vol) glycerol (Fisher 
Scientific), 10% (vol/vol) oleic acid-albumin-dextrose-catalase (OADC) (Difco), 
and 0.05% (vol/vol) tyloxapol (Sigma-Aldrich) or 7H10 agar (Difco) supplemented 
with 0.2% glycerol and OADC.  
 
All antibiotics were added when appropriate to final concentrations of 50µg/mL 
for kanamycin, and 150 µg/mL for hygromycin. To eliminate PABA 
contamination, glassware was baked for a minimum of one hour at 180 ºC. PAS, 
PABA, trimethoprim (TMP), dapsone (DDS), and methotrexate (MTX) were 
purchased from Sigma and were dissolved in 100% DMSO (Sigma). 2'-Hydroxy-
7,8-dihydrofolate was synthesized as described in Chapter 2. Pterin-PAS was a 
gift from Dr. Richard Lee and hydroxy-folate was a gift from Dr. Courtney Aldrich. 




Cell Lines (Written by Dr. Elise Lamont) 
Hep-G2 cell (ATCC HB-8065) and Caco-2 cell (ATCC HTB-37) lines were 
purchased from the American Type Culture Collection (ATCC; Manassas, VA).  
Hep-G2 and Caco-2 cell lines were maintained in Minimal Essential Medium 
(MEM; Gibco, Waltham, MA) and Dulbecco’s Modified Eagle Medium (DMEM; 
Gibco), respectively. Media were supplemented with 10% (Hep-G2) or 20% 
(Caco-2) fetal bovine serum (FBS) and 1% penicillin/streptomycin (pen/strep) 
solution. Both cell lines were incubated at 37 oC in a humidified chamber 
containing 5% CO2. Medium was refreshed every 2 days. Once 70% confluency 
was achieved, cell lines were washed thrice using Dulbecco’s phosphate 
buffered saline (D-PBS) without calcium and magnesium (Gibco) and harvested 
with TrypLE™ express enzyme (1X; Gibco). Detached cells were subsequently 
used in cytotoxicity assays. 
 
Cytotoxicity assays (Written by Dr. Elise Lamont) 
Unless otherwise noted, cells were incubated at 37 oC in a humidified chamber 
containing 5% CO2. Hep-G2 and Caco-2 cells were seeded separately in tissue 
culture treated, flat-bottom 96 well plates at a density of 5.0 x 104 cells per well in 
antibiotic free media. The final volume per well was 100 μL. After cells were 
adhered to the well substrate overnight, cells were washed thrice with D-PBS 
and incubated with individual drugs and metabolites, methotrexate (MTX; 0-4,000 
μM), para-aminosalicylic acid (PAS; 0-4,000 μM), hydroxy-folate (0-500 μM), and 
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hydroxyl-dihydrofolate (0-500 μM) in a two-fold serial dilution using appropriate 
culture media. Cells were treated for up to 72 h and media containing appropriate 
drugs were replaced every 24 h. DMSO vehicle control was included for every 
time point. Cell survival after drug exposure was determined using previously 
established methods (Mosmann, 1983). Briefly, 200 μL of freshly made 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; 1 mg/mL; Sigma-
Aldrich, St. Louis, MO) in serum-free, phenol red-free MEM or DMEM was added 
to each well and incubated for 3 h. MTT solution was removed and formazan 
crystals were dissolved in 200 μL of isopropanol. Formazan dye was quantified at 
570 nm using the Synergy H1 microtiter plate reader (BioTek; Winooski, VT).  
Absorbance was normalized for background at OD650. Cell survival was 
calculated as the percentage absorbance of sample relative to no vehicle control.  
IC50 (half maximal inhibitory concentrations) values for each drug at all time 
points tested were calculated using GraphPad Prism (San Diego, CA) statistical 
software. All treatments were conducted in technical triplicate for each time point.  
All experiments were repeated thrice. 
 
Assessing PAS toxicity in mice 
Seven week old C57BL/6 mice were obtained from Jackson Laboratory (Bar 
Harbor, ME). Female mice (5 per treatment) were orally gavaged every day for 
two weeks with a vehicle control of phosphate buffered saline (PBS) (pH 7.2) or 
750 mg/kg para-aminosalicylic acid. Before the mice were gavaged, the cannula 
145 
 
was submerged in a 10% (weight/volume) sucrose (Fisher) solution. Fecal pellets 
(3-6) were collected from individual mice prior to initiation of treatment, after two 
weeks of treatment, and after a two week recovery following treatment. Mice 
were sacrificed and the small and large intestines were harvested and washed in 
PBS. 
 
Construction and purification of DHFRHuman 
Human DHFR isoform 1 cDNA was codon optimized and purchased as a gene 
block (Invitrogen) containing 5’ NdeI and 3’ BamHI cut sites. The gene block was 
digested with NdeI and BamHI and ligated into an already digested pET28b(+) 
(Novagen) using the same restriction enzymes. Expression and purification of 
DHFRHuman was performed as previously described (Tai et. al., 2002). Briefly, 
sequence-verified pET28b(+):DHFRHuman was used to transform competent E. 
coli BL21 (DE3) cells. E. coli BL21 pET28b(+):DHFRHuman was inoculated into 
Lysogeny Broth (LB) and grown overnight at 37 ºC. The cells were diluted 1:1000 
into fresh LB (4 L) and were grown until mid-exponential phase (optical density at 
600 nm (OD600) 0.4–0.6) at 37 ºC. Next, 1 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) (GoldBio) was added to induce protein expression 
at 37 ºC for 4 h. The cells were collected by centrifugation at 5,000 rpm 
(Beckman Coulter, Avanti JXN-30) at 4 ºC. The pellet was resuspended in 10 mL 
of lysis buffer (100 mM K2PO4 (pH 8.0) and 5 mM imidazole) and disrupted by 
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ultrasonication (Branson Sonifier 450) three times using 20 sec burst and 20 sec 
cooling (4 ºC). 10 mg chicken egg white lysozyme (MP Biomedicals, LLC) was 
added and incubated on ice for 30 min. The insoluble fraction was removed by 
centrifugation (Beckman Coulter, Avanti JXN-30) at 11,000 rpm at 4 ºC for 45 
min. The supernatant was applied to 1 ml Ni-NTA Agarose (Qiagen) equilibrated 
with lysis buffer. DHFRHuman was eluted using a step-wise gradient of 10 mL wash 
buffer containing increasing concentrations of imidazole (10 mM, 15 mM and 20 
mM). DHFRHuman was eluted with 5 mL of elution buffer (100 mM K2PO4 (pH 7.5) 
and 50 mM imidazole). Fractions containing pure DHFRHuman (>90% as judged by 
running samples on an SDS-PAGE gel) were pooled and using an ultra-
centrifugal filter concentrated (Millipore) in storage buffer (50 mM KPO4, 5 mM β-
mercaptoethanol, pH 7.3) to 2.5 mg/ml. The protein was stored at 4 ºC.  
 
Biochemical utilization of DHF and hydroxy-DHF 
All enzymatic assays were performed in flat bottom 96 well plates (Corning), with 
200 µl reaction volume, and measured in a BioTek Synergy H1 
spectrophotometer at 25 ºC. The enzymatic reactions were performed as 
previously described (White et. al., 2004). Enzyme assays were performed using 
5 nM enzyme in 50 mM KPO4, pH 7.3, 5 mM β-mercaptoethanol and 0.01% 
(vol/vol) Triton-X 100. The enzyme was preincubated with 67 µM of NADPH at 
room temperature for 5 min. The reaction was initiated with varying 
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concentrations of DHF or hydroxy-DHF. The decrease in absorbance 
corresponding to NADPH oxidation was monitored at 340 nm every 10 sec for 10 
min. The Km was determined from 4 independent experiments performed in 
biological triplicate and analyzed using GraphPad Prism software. 
 
Bacterial enumeration of M. tuberculosis infected mice during antitubercular oral 
gavage treatment 
Seven week old C57BL/6 mice were obtained from Jackson Laboratory (Bar 
Harbor, ME). Mice were infected with ~100 CFU of M. tuberculosis H37Rv using 
an inhalation exposure system (GlasCol) as previously described (Ramakrishnan 
et. al., 2016). The infection was established for 1 week. Following the 1 weeks 
incubation period, mice were gavaged daily for 13 days with vehicle (PBS), SMX 
(150 mg/kg), PAS (500 mg/kg or 750 mg/kg), and a combination of SMX (150 
mg/kg) and PAS (750 mg/mg). Before gavage, the cannula was submerged in 
10% (wt/vol) sucrose (Fisher) solution. Following each daily treatment mice were 
fed peanut butter. The peanut butter (PB2 powdered peanut butter) (Amazon) 
was suspended in 50:50 (weight/volume) of sterile water. Infected mice were 
euthanized by CO2 overdose. Bacterial CFU were enumerated by plating serially 
diluted lung, spleen, and liver homogenates on complete Middlebrook 7H10 agar 
containing 100 µg/ml cycloheximide. The CFU’s were enumerated after 3 to 4 
weeks of incubation at 37 °C. All animal protocols were reviewed and approved 
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by the University of Minnesota Institutional Animal Care and Use Committee and 
were conducted in accordance with recommendations in the National Institutes of 
Health Guide for the Care and Use of Laboratory Animals. The protocols, 
personnel and animals used were approved and monitored by the Institutional 
Animal Care and Use Committee.  
 
M. tuberculosis antagonism assays 
All assays were performed in round bottom 96-well plates (Corning) except 
where noted. Minimum inhibitory concentration (MIC90) is defined as the 
concentration to inhibit 90% of growth compared to a no drug control. Growth 
was assessed spectrophotometrically (OD600) (BioTek Synergy H1) or visually, 
when noted. All assays were performed in biological triplicate. 
 
M. tuberculosis H37Rv was grown to mid-exponential phase and subcultured to 
OD600 0.001 in 96 round bottom plates (Corning). The interactions between 
PABA and PAS, PAS and SMX, PAS and DDS, and pterin-PAS and SMX were 
evaluated using log2 serial dilutions. The MIC was determined visually after 14 
days of static incubation at 37 ºC. The interactions between TMP and PAS, using 
log2 serial dilutions, was performed in M. tuberculosis H37Rv grown to mid-
exponential phase and subcultured to OD600 0.01 in inkwell bottles at 37 ºC, with 
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shaking. The MIC90 of TMP and PAS was measured spectrophotometrically 
(GENESYS 20, Thermo Fisher) after 14 days.  
 
M. tuberculosis H37Rv ΔpabB was constructed as described in Chapter 2. M. 
tuberculosis H37Rv ΔpabB was grown in 7H9 medium containing 1µg/mL of 
PABA to mid-exponential phase and subcultured to OD600 0.001 in 7H9 media 
containing 100ng/mL of PABA in round bottom 96-well plates (Corning). The 
interactions between PAS and SMX was performed using log2 serial dilutions. 
The MIC was determined visually after 14 days of static incubation at 37 ºC. 
 
M. bovis BCG and M. bovis BCG ftsH::himar1 was grown in 7H9 medium to mid-
exponential phase and subcultured to OD600 0.001 in 7H9 media in round bottom 
96-well plates (Corning). The interactions between PAS and SMX was performed 
using log2 serial dilutions. The MIC90 was determined in a BioTek Synergy H1 
spectrophotometer after 14 days of static incubation at 37 ºC.  
 
Statistical analysis 
Number of mice required to produce results with statistical significance were 
determined by a power calculation. A sample size of n≥4 was used detect a 10-
fold (1-log10) difference in CFU between groups, assuming standard deviations of 
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35-40% of sample mean, with a type 1 error rate (α) of 0.05% to achieve a 90% 
power (Chow et. al., 2008). A student’s unpaired t test (two tailed) was used for 
comparison between vehicle and treatment groups. p-values were calculated 
using GraphPad Prism 5.0 software (GraphPad Software, Inc.). p ≤ 0.05 was 





Exploring PAS toxicity in humans and in a murine model 
Many patients discontinue PAS chemotherapy because of severe GI distress. 
We have replicated the PAS associated GI toxicity in a mouse model. Mice were 
treated daily for 14 days, via oral gavage with PAS (750mg/kg). Mice treated with 
PAS had a 60% mortality rate (Figure 3.1). The fecal pellets in the PAS treatment 
group were loose, moist, and smaller than the vehicle control fecal pellets (Figure 
3.2). After a two week recovery, the size of the fecal pellets from the PAS 
treatment group returned to the same size as from the vehicle group, however, 
the pellets were still loose and moist (Figure 3.2). Upon examining the small and 
large intestines from mice of the PAS treatment group, both the small and large 
intestine exhibited inflammation and hemorrhaging that was absent in the vehicle 
treatment group (Figure 3.3).  
 
Based on the observation that bacteria can utilize PAS as a source of folates, we 
hypothesized that bacteria in the human GI tract were producing a hydroxy-folate 
species that was causing PAS toxicity. To test this hypothesis, we performed 
cytotoxicity assays using HepG2 cells (hepatocytes) that are the canonical cell 
line to test cytotoxicity. We also used Caco-2 cells that are intestinal epithelial 
cells. Cytotoxicity assays were performed using PAS, hydroxy-DHF and hydroxy-
folate. PAS exhibited no cytotoxicity at physiologically relevant concentrations in 
152 
 
HepG2 and Caco-2 cells (IC50 1270 ± 9 µM and 1230 ± 6 µM, respectively) 
(Table 3.4 and 3.5). Hydroxy-DHF did show some cytotoxicity in HepG2 and 
Caco-2 cells (IC50 343 ± 4 µM and 370 ± 5 µM, respectively) (Table 3.4 and 3.5). 
Interestingly, we found that hydroxy-folate is cytotoxic in both HepG2 and Caco-2 
cells (IC50 35 ± 5 µM and 44 ± 5 µM, respectively) at similar to concentrations to 
MTX (IC50 7.2 ± 4.7 µM and 12 ± 6 µM, respectively), a known human-DHFR 
inhibitor (Table 3.4 and 3.5). We found that purified human-DHFR could use 
hydroxy-DHF as a suboptimal substrate (Km 0.16 µM) compared to the native 
substrate, DHF (Km 1.26 µM ) (Figure 3.4, Table 3.6).  
 
FolP inhibitors antagonize the antitubercular activity of PAS 
Since PAS toxicity was mediated by bioactivation of PAS into hydroxy-DHF or 
hydroxy-folate, we hypothesized toxicity could be prevented by blocking PAS 
bioactivation. To test this hypothesis we co-treated PAS with SMX because SMX 
blocks FolP, the first enzyme required to convert PAS into hydroxy-
dihydropteroate. TB infected mice were given vehicle control, SMX (150 mg/kg), 
PAS (500 mg/kg or 750 mg/kg), and SMX and PAS (150 mg/kg and 750mg/kg, 
respectively) for 13 days. The mice in the vehicle control and SMX treatment 
group showed a 100% survival rate (Figure 3.5). Mice in the PAS 500 mg/kg 
group showed an 80% survival rate and mice in the PAS 750 mg/kg group 
showed a 38% survival rate (Figure 3.5).The mice in the PAS-SMX (PAS 750 
153 
 
mg/kg and SMX 150 mg/kg) treatment groups showed an 87% survival rate 
(Figure 3.5). These observations demonstrate that SMX can antagonize PAS-
mediated toxicity. 
 
Following treatment of the TB infected mice, lung, spleen, and liver were 
harvested to determine bacterial burden. The vehicle control and SMX treatment 
groups showed similar bacterial burden in lung liver and spleen (Figure 3.5). PAS 
treatment was able to reduce the burden of M. tuberculosis in the lung of mice 
and virtually eliminated appearance of bacilli (below limit of detection) in spleen 
and liver (Figure 3.5). Interestingly, non-mycobacterial growth was observed on 
liver homogenate plates from the PAS and PAS-SMX treatment groups (Figure 
3.6), consistent with the hypothesis that PAS treatment disrupts barrier function 
of the intestines. Co-treatment with SMX antagonized PAS antitubercular activity 
and resulted in an increased in bacterial burden in lung, liver and spleen that was 
statistically indistinguishable from the vehicle control and SMX treatment groups 
(Figure 3.5).  
 
These observations are consistent with previous work that has shown PAS can 
be antagonized by SMX in vitro (Figure 3.7 and 8) (Zheng et. al., 2013). We 
extended this study to the diaminophenylsulfone, dapsone, (DDS) and found that 
DDS can antagonize the antitubercular activity of PAS (Figure 3.7 and 3.8). 
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Trimethoprim (TMP) had no interaction when with PAS in vitro (Figure 3.7 and 
3.8).  
 
The mechanistic basis for SMX antagonism of PAS 
To explore the mechanism of SMX-mediated antagonism of PAS, we tested the 
hypothesis that SMX might prevent PAS bioactivation to hydroxy-DHF. We used 
pterin-PAS (PtePAS) an oxidized form of hydroxy-dihydropteroate to bypass the 
need for FolP (Howe et. al., 2018). Thus, co-treatment with PtePAS and SMX 
should yield either no interaction or a synergistic interaction similar to co-
treatment with SMX and TMP. Counter to our expectation, PtePAS activity was 
antagonized by SMX (Figure 3.7 and 3.8). Since SMX treatment has previously 
been shown to increase PABA production in bacteria, we reasoned that SMX is 
causing an increase in PABA biosynthesis and, thereby, driving antagonism of 
PAS (Minato et. al., 2018). We created a deletion in the gene pabB, encoding 
amino-deoxychrosimate synthase. Previous work has shown that strains lacking 
pabB in M. tuberculosis are PABA auxotrophs and can only grow with 
supplemental PABA (Thiede et. al., 2016). We found that SMX could still 
antagonize PAS in the M. tuberculosis ΔpabB strain (Figure 3.7 and 3.8). This 
data suggests that SMX antagonism of PAS is not mediated by PAS bioactivation 




Previous studies have shown that FolA inhibitors can also modulate pterin 
biosynthesis (Minato et. al., 2018). We next tested the hypothesis that PAS is 
causing an increase in pterin production, using a strain containing a transposon 
disruption in 3’ end of ftsH, a gene encoding a transmembrane protease. 
ftsH::himar1 is directly upstream (150 bp) of the start codon for folE, encoding 
FolE.  FolE is required for the first committed step of pterin biosynthesis (Fischer 
et. al., 2003). The insertion is predicted to be in the ribosome binding site for the 
pterin biosynthesis operon. When we examined if SMX could antagonize PAS in 
the ftsH::himar1 mutant we found that antagonism was greatly diminished, 
relative to that for the wild type strain (Figure 3.9). Taken together, this data 
suggests the mechanistic basis for SMX antagonism of PAS is mediated through 





Hydroxy-folates, not PAS, are highly cytotoxic 
PAS causes GI distress in humans which can result in patient non-compliance. 
During PAS treatment in mice, the GI tract showed inflammation and even some 
bleeding in the small and large intestine compared to the vehicle control (Figure 
3.3). Previous work in mice, showed MTX treatment also led to an increase in 
inflammatory cytokines and the loss of tight junction formation in intestinal 
epithelial cells (Beutheu Youmba et. al., 2012). Therefore, it is possible that PAS 
is acting by a similar mechanism and is causing inflammation and ultimately 
reducing tight junction integrity. Furthermore, it was noted that PAS treatment led 
to a more wet stool compared to controls. Changes in stool integrity could also 
be indictive of GI disturbances either to the microbiota or to epithelial cells. 
Currently, a microbiome study is underway to determine bacterial changes 
(diversity and abundance) in mice treated with vehicle control, PAS, TMP/SMX 
co-treatment, and PAS/SMX co-treatment.  
 
Based on the observation that bacteria can utilize PAS in the synthesis of folates, 
we hypothesized that bacteria in the human gut were producing a hydroxy-folate 
species resulting in PAS associated toxicity. Although it was previously thought 
that PAS is responsible for the cytotoxicity, we have demonstrated that PAS is 
not cytotoxic (Table 3.4 and 3.5). Interestingly, hydroxy-folate is cytotoxic at 
similar concentrations to a known cytotoxic chemotherapeutic agent, MTX (Table 
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3.4 and 3.5). Hydroxy-DHF was found to be slightly cytotoxic (Table 3.4 and 3.5). 
It is difficult to assess hydroxy-DHF toxicity because the half-life under an 
ambient atmosphere is about 6 hours (Dawadi et. al., 2017). Since the GI tract is 
anaerobic, it is possible that hydroxy-DHF is more stable and could exert more 
cytotoxic effects under physiological conditions.  
 
To determine if hydroxy-DHF showed any inhibitory activity against DHFR in 
humans, we purified DHFRHuman and measured its ability to catalyze reduction of 
DHF or hydroxy-DHF. We found that DHFRHuman could utilize both DHF and 
hydroxy-DHF as a substrate. Taken together, these data suggest that bacteria in 
the GI tract could be incorporating PAS in folate synthesis and secreting hydroxy-
folate species. Based on the cytotoxicity assays, a hydroxy-folate species could 
be absorbed into enterocytes. Although hydroxy-DHF does not inhibit 
DHFRHuman, it could be inhibitory somewhere downstream in one-carbon 
metabolism. Furthermore, enterocytes require a large amount of folate for rapid 
cellular growth and maintenance. Since DHFRHuman could not utilize hydroxy-
dihydrofolate as efficiently as dihydrofolate, impaired folate reduction could 
impede cellular processes requiring folates.   
 
There are many experiments that could solidify the hypothesis that the microbiota 
of mice is producing a toxic byproduct during PAS treatment. One future 
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experiment would be to treat gnotobiotic mice with a vehicle control, PAS, and 
MTX. Gnotobiotic mice are born germ-free; therefore, these mice should not 
succumb to PAS toxicity. Another experiment would be to treat mice with PAS 
and perform liquid chromatography mass spectrometry/mass spectrometry. This 
would allow us to determine the hydroxylated folate specie(s) secreted during 
PAS treatment.  
 
Furthermore, since treatment with MTX depolarizes tight junctions, other follow 
up experiments would be to determine if tight junction integrity is affected during 
PAS treatment. Two experiments to test this hypothesis would be to perform 
transepithelial/transendothelial electrical resistance assay to indirectly measure 
tight junction integrity during treatment with vehicle control, MTX, PAS, and 
hydroxy-folate (Srinivasan et. al., 2015). Another experiment would be to treat 
mice with vehicle, MTX, PAS, and hydroxy-folate harvest the small and large 
intestines and perform immunostaining against tight junction associated proteins 
zonula occludens-1, occludin, and claudin-1 (Beutheu Youmba et. al., 2012). If 
the GI microbiota are indeed traversing from the lumen into the lamina propria, 
blood from PAS treated mice could be tested for lipopolysaccharides, a 
component of bacterial cell wall. 
 
SMX antagonizes the toxicity and activity of PAS. 
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Many patients discontinue treatment with PAS because of the severe side effects 
namely GI distress. We treated TB infected mice with a vehicle control, SMX 
(150 mg/kg), PAS (750 mg/kg), PAS (500 mg/kg), and SMX and PAS (150 mg/kg 
and 750 mg/kg). A low dose-PAS treatment (500mg/kg) had a higher percent 
survival (Figure 1b) suggesting that PAS toxicity is dose dependent. PAS and 
SMX (high dose-750 mg/kg and 150 mg/kg, respectively) co-treatment resulted in 
increased (87%) survival. Since SMX prevents PAS incorporation into the folate 
biosynthesis pathway it is likely that PAS mediated toxicity is due to a 
hydroxylated folate species produced. Taken together, these data suggests that 
PAS toxicity is dose dependent and toxic metabolite is a product of PAS 
incorporation in the folate biosynthesis pathway.  
 
Following treatment of the M. tuberculosis infected mice, we harvested the lung, 
spleen, and liver and measured colony forming units. Although we had some 
bacterial growth in the spleen of PAS treated mice. We tested the colonies for 
resistance to PAS by plating them on high concentrations of PAS. We found 
these colonies were resistant to PAS, compared to colonies on plates from the 
vehicle control (data not shown). Strikingly, SMX (150 mg/kg)/PAS (500 mg/kg) 
co-treatment allowed for the unrestricted growth of M. tuberculosis in the lungs of 
mice and allowed for the dissemination of M. tuberculosis from the lung into the 
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spleen and liver (Figure 3.5). Taken together, this data suggests that addition of 
SMX antagonizes the anti-mycobacterial activity of PAS.  
 
Furthermore, we noticed evidence of non-mycobacterial growth in the liver and in 
some of the spleens in the mice treated with PAS, and some with PAS and SMX 
co-treatment (Figure 3.6). This growth was absent in the vehicle and SMX 
treatment groups. As described previously some DHFR inhibitors can impair tight 
junction formation, we speculate that perhaps hydroxy-DHF/folate produced 
during PAS treatment can also cause impaired tight junction formation. 
Depolarization of tight junctions can lead to enterocyte cell death, impaired 
barrier function and sepsis. The tissue homogenates from the in vivo study could 
also be used and 16S rRNA sequenced to determine if any GI bacteria are 
represented. 
 
Although we were able to antagonize PAS GI toxicity by co-treatment with SMX, 
we found that SMX also antagonized the antitubercular activity of PAS in vivo. 
This observation supports previous work that has suggested PAS can be 
antagonized by SMX (Zheng et. al., 2013). We extended this study to DDS and 
found that DDS can antagonize the antitubercular activity of PAS. TMP did not 
alter the PAS MIC. As described in Chapter 2, HIV/AIDS infected individuals are 
prescribed SMX and TMP for lifetime prophylactic therapy. When SMX is not well 
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tolerated DDS is prescribed. SMX and DDS were found to antagonize the 
antitubercular activity of PAS. Therefore, HIV/TB co-infected individuals who are 
prescribed SMX or DDS to protect against opportunistic infections are at risk for 
treatment failure if using PAS to treat for TB infection. Furthermore, the 
observations in Chapter 2 suggest that PAS can antagonize the activity of SMX 
and DDS in treating numerous bacterial infections. Taken together, the 
combination of SMX/DDS and PAS to treat both TB and opportunistic infections 
needs to be reevaluated. 
 
The mechanistic basis for SMX antagonism of PAS 
To understand the mechanism of SMX mediated antagonism we hypothesized 
that SMX is preventing PAS bioactivation to hydroxy-DHF. To test this hypothesis 
we used pterin-PAS (PtePAS) an oxidized form of hydroxy-dihydropteroate, to 
bypass the need for PAS conversion to hydroxy-dihydropteroate (Howe et. al., 
2018). Interestingly, PtePAS activity was antagonized by SMX (Figure 3.7 and 
3.8). This suggests that SMX mediated antagonism of PAS does not occur by 
preventing PAS bioactivation.  
 
Since SMX treatment has previously been shown to increase PABA production in 
bacteria, we reasoned that SMX is causing an increase in PABA biosynthesis 
and, thereby, antagonism of PAS (Minato et. al., 2018). We tested if SMX could 
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antagonize PAS in M. tuberculosis H37Rv ΔpabB and found it could still 
antagonize (Figure 3.7 and 3.8). This data suggests that while SMX could be 
causing an increase in PABA, the amount of PABA produced is not enough to 
antagonize the activity of PAS. Therefore, the mechanistic basis of SMX 
mediated antagonism of PAS is not through an increase in PABA biosynthesis. 
 
When used in combination, TMP and SMX (co-trimoxazole) exhibit highly 
synergistic antimicrobial activity. For several decades it was presumed that the 
basis for synergy between SMX and TMP was exclusively due to the ability of 
SMX to prevent DHF synthesis and enhance the ability of TMP to inhibit FolA 
(Bushby and Hitchings, 1968; Minato et. al., 2018; Wormser et. al., 1982). While 
this model explains how SMX is able to enhance microbial susceptibility to TMP, 
it is not sufficient to explain the ability of TMP to enhance susceptibility of 
microbes to SMX (Harvey, 1978). It was recently demonstrated that TMP 
treatment results in depletion of DHPPP through impairment of GTP synthesis 
and is the basis for potentiation of SMX susceptibility (Minato et. al., 2018). The 
folate biosynthesis pathway exhibits a cyclic nature that enables the potent 
synergy between SMX and TMP (Minato et. al., 2018). Therefore, we 
hypothesized that SMX was modulating pterin biosynthesis. We had previously 
isolated strain with a transposon disruption in 3’ end of ftsH, a gene encoding a 
transmembrane protease(Howe et. al., 2018). Directly downstream of ftsH is folE, 
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a gene encoding FolE required for the first committed step of pterin biosynthesis. 
We found that SMX could no longer antagonize PAS compared to the parent 
strain in the ftsH mutant. Multiple attempts have been made to create deletions in 
either folE or folBK; however, these have not been successful. Currently, more 
work is underway to determine if SMX increases pterin biosynthesis in the parent 
strain compared to the ftsH::himar1 strain using both qPCR and metabolomics. 
Taken together these data suggest that SMX mediated antagonism of PAS 








Table 3.1. Oligonucleotides used in this study 
Primer 
name 
Primer sequence1 Source Restriction 
enzyme 
pabB_Mtb 



























    
1Underline corresponds to the restriction enzyme cut site. All primers are written in 5’ to 3’ orientation 
 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    






Table 3.2. Plasmids used in this study.  
Plasmid Relevant characteristics Source 
pET28b+ Bacterial high copy plasmid for protein overexpression 
containing C- and N-terminal 6X histidine tags 




pET28b+ containing DHFRHuman with an N-terminal 6x-
histidine tag, Kanr  
This work 
phAE159 Phasmid used for specialized transduction, Penr (Bardarov et. 
al., 2002) 
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Table 3.3. Strains used in this study   
Strain Name Relevant characteristics Source 
E. coli   
 DH5α Cloning strain Lab stock 
 BL21 (DE3) Protein purification strain Lab stock 
 pET28b-DHFR-
human 
BL21 containing pET28b-DHFR-human for overexpression 
of FolAMtb, Kanr 
This work 
M. tuberculosis    
 H37Rv Wild-type strain Lab stock 
 ΔpabB H37Rv pabB::hygro-sacB cassette, Hygror This work 
M. bovis   
 BCG Wild-type strain Lab stock 
 BCG 
ftsH::himar1 
BCG with a himar1 transposon insertion at position 2155 at 





Table 3.4. Cytotoxicity assays, in HepG2 cells, of MTX, PAS, hydroxy-
dihydrofolate, and hydroxy-folate. 
 IC50 (µM) 
Drug 24 h 48 h 72 h 
MTX 823±3 58.2±0.4 7.2±4.7 
PAS 1850±10 1480±14 1270±9 
Hydroxy-DHF NA 426±4 343±4 





Table 3.5. Cytotoxicity assays, in Caco-2 cells, of MTX, PAS, hydroxy-
dihydrofolate, and hydroxy-folate. 
 IC50 (µM) 
Drug 24hr 48hr 72hr 
MTX 813±12 62±5 12±6 
PAS 1850±16 1410±12 1230±6 
Hydroxy-DHF NA 497±4 370±5 




Table 3.6. Mechaelis-Menten kinetics of dihydrofolate and hydroxy-DHF 
Organism DHF (Km) Hydroxy-DHF (Km) 










Figure 3.1. Kaplan-Meier kill curve from treatment with PAS. Specific 
pathogen free C57Bl/6 mice were treated via oral gavage with either a 
vehicle control (PBS) or 750 mg/kg PAS. The mice were treated every 
day for 14 days. Mice were assessed daily and examined for signs of 
distress including shortness of breath, withdrawal from littermates, and 









































a b c d 
Figure 3.2. Fecal pellets from vehicle and PAS treated mice. Specific 
pathogen free C57Bl/6 mice were treated via oral gavage with either a 
vehicle control (PBS) or 750 mg/kg PAS. The mice were treated every 
day for 14 days. After the treatment the mice were left undisturbed to 
allow for any recovery in the microbiome to occur. a) and b) fecal pellets 
post treatment of vehicle and PAS, respectively c) and d) fecal pellets 
after a 2 week recovery of vehicle and PAS, respectively. 
Post treatment Recovery 














Figure 3.3. Small intestine and cecum from vehicle and PAS treated mice. 
Specific pathogen free C57Bl/6 mice were treated via oral gavage with 
either a vehicle control (PBS) or 750 mg/kg PAS. The mice were treated 
every day for 14 days. After the treatment the mice were euthanized by 
CO2 overdose. Vehicle control a) small and b) cecum b). PAS treatment c) 







Figure 3.4. DHF and hydroxy-DHF can be utilized as substrates for DHFRHuman. 
DHF or hydroxy-DHF utilization was measured in the presence of DHF or 
hydroxy-DHF using purified recombinant DHFR. The experiment was 
performed in technical triplicate four times. The error bars represent standard 















































  Figure 3.5. SMX antagonizes the anti-tubercular activity of PAS. Analysis of 
C57Bl/6 mice infected with 100 CFU of M. tuberculosis H37Rv. The infection 
was established for 1 week and the mice were treated for 13 days via oral 
gavage with vehicle control, SMX, PAS, and SMX/PAS using an acute 
infection model. a) Kaplan-Meier survival analysis. b) Bacterial burden was 
enumerated in the lung, spleen, and liver, in mice following treatment. The 
limit of detection (100 CFU) is marked by dotted red line. **p<0.05, 
***p<0.0001, NS (not significant). 
176 
 
  a b 
Figure 3.6. Bacterial growth on liver homogenates. These plates are a 
representative of growth found on plates containing liver homogenates 
from pictures taken. The plates represent SMX/PAS co-treatment at 






















1.56 0 µg mL-1 PABA 
1.56 0 µg mL
-1 SMX 
32 0 µg mL
-1 DDS 
250 0 µg mL
-1 TMP 
Figure 3.7. FolP inhibitors antagonize the anti-tubercular activity of PAS. 
in vitro interactions between PAS and PABA, PAS and SMX, PAS and 
DDS, PtePAS and SMX in M. tuberculosis H37Rv and H37Rv ΔpabB. 
































































































































































































































































































Figure 3.8. FolP inhibitors antagonize the anti-tubercular activity of PAS. 
in vitro Interactions between PAS and PABA, PAS and SMX, PAS and 
DDS, PtePAS and SMX in M. tuberculosis H37Rv and H37Rv ΔpabB. 
Strains were grown in 7H9 with appropriate supplementations at 37 ºC for 
2 weeks. The data represents the minimum concentration of drug 
required to inhibit growth in varying concentrations. Data shown 
represent average of three independent experiments. Error bars 



























































































































Figure 3.9. SMX antagonizes the anti-tubercular activity of PAS in M. 
bovis BCG but not in M. bovis BCG ftsH::himar1. a) In vitro fold change 
in PAS MIC during SMX treatment. b) M. bovis BCG and c) M. bovis 
BCG ftsH::himar1. Strains were grown in 7H9 with appropriate 
supplementations at 37 ºC for 2 weeks. The data represents the 
minimum concentration of drug required to inhibit growth in varying 
concentrations. Data shown represent average of three independent 
experiments. Error bars represent standard deviation. Data shown 
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The treatment regimen for Mycobacterium tuberculosis involves lengthy, 
intensive drug therapy that causes severe side-effects. The antimicrobial para-
aminosalicylic acid (PAS) is used to treat drug resistant M. tuberculosis 
infections. Despite the use of PAS to treat M. tuberculosis for over 70 years, the 
biochemical mechanisms which govern PAS susceptibility and resistance in M. 
tuberculosis are incomplete. In this study we set out to determine novel PAS 
resistance mutations. We identified mutations in folC and thyA. We showed folC 
PAS resistant mutants had an increase in expression of para-aminobenzoic acid 
(PABA) biosynthesis genes. We found that disrupting PABA biosynthesis genes 
resulted in hypersusceptibility to sulfa-drugs and PAS. Furthermore, disruptions 
in PABA biosynthesis resulted in restoration of PAS susceptibility in folC mutant 





Resistance to para-aminosalicylic acid (PAS) was described shortly after its 
introduction into the clinic. Therefore, PAS was prescribed in combination with 
other antitubercular drugs to suppress the emergence of drug resistance. PAS 
has been discontinued as a first-line agent in treating Mycobacterium 
tuberculosis due to its toxicity and the advent of better tolerated drugs. Currently, 
PAS is primarily used to treat drug resistant strains of M. tuberculosis, but 
remains a primary chemotherapeutic agent for treating tuberculosis in southeast 
Asia. With the increase incidence of drug-resistant strains of M. tuberculosis a 
new effort has focused on determining the mechanistic basis for PAS resistance 
(WHO, 2018).  
 
PAS is a structural analog of the folate precursor metabolite para-aminobenzoic 
acid (PABA). PAS only differs from PABA by the presence of a hydroxyl-group in 
the ortho-position to the carboxylic acid. PAS was thought to disrupt folate 
biosynthesis based on the observation that exogenous PABA could antagonize 
PAS inhibition of M. tuberculosis growth(Youmans et. al., 1947). The folate 
biosynthesis pathway is composed of three enzymes: dihydropteroate synthase 
(FolP), dihydrofolate synthase (FolC), and dihydrofolate reductase (FolA). FolP is 
an essential enzyme required for the condensation of para-aminobenzoic acid 
and 6-hydroxymethyl-7,8-dihydropterin pyrophosphate to form dihydropteroate 
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(DHP). FolC is required to ligate glutamate to DHP via ATP to produce 
dihydrofolate (DHF). FolA catalyzes the NADPH-dependent reduction of DHF to 
tetrahydrofolate (THF). 
 
Initially, PAS was thought to act as a FolP inhibitor similar to 
sulfonamides(Youmans et. al., 1947). However, no cross-resistance between 
PAS and sulfonamides in M. tuberculosis was observed(Yegian and Long, 1951). 
In contrast to sulfonamides, PAS only weakly inhibited purified FolP enzymatic 
activity and was later demonstrated to be converted to a hydroxylated version of 
DHP, hydroxy-DHP (Chakraborty et. al., 2013; Zhao et. al., 2014; Zheng et. al., 
2013). FolC was found to catalyze the glutamylation of hydroxy-DHP to hydroxy-
DHF. This suggested that FolC is not the target of bioactivated PAS and the 
target was likely downstream within the folate pathway (Chakraborty et. al., 2013; 
Zhao et. al., 2014; Zheng et. al., 2013). Indeed, it was predicted and later 
confirmed that hydroxy-DHF could potently inhibit FolA(Chakraborty et. al., 2013; 
Dawadi et. al., 2017; Zheng et. al., 2013).  
 
To date, few folA missense mutations associated with PAS resistance have been 
reported(Myllykallio et. al., 2002). It is presumed that mutations in the FolA active 
site can be highly deleterious to the overall enzyme function. Thus, it could be 
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rare for folA point mutations to confer resistance to PAS without compromising 
FolA enzymatic activity.  
 
Resistance to PAS exclusively arises through the occurrence of spontaneous 
mutations in genes related to folate synthesis and metabolism. To date, PAS 
resistance mutations have been identified in folC, ribD, and thyA (Mathys et. al., 
2009; Zhang et. al., 2015; Zhao et. al., 2014).  
 
Mutations in folC are the most prevalent mutations identified in PAS resistant 
clinical isolates(Mathys et. al., 2009; Zhang et. al., 2015). folC mutations typically 
map to positions corresponding to substrate binding and nucleoside binding 
pockets of the ATP binding domain in FolC(Mathys et. al., 2009; Zhang et. al., 
2015; Zhao et. al., 2014). Both of these positions are essential for proper 
enzymatic function. Purified recombinant FolC variants from resistant strains had 
reduced enzymatic activity (10 to 20% of wild type activity)(Zhao et. al., 2014). 
These variants were analyzed for the ability to glutamylate hydroxy-DHP to 
hydroxy-DHF; however, no detectable hydroxy-DHF was observed (Zhao et. al., 
2014). Similarly, PAS resistant M. tuberculosis folC mutant strains were found to 
produce substantially less hydroxy-DHF than the wild type control(Zhao et. al., 
2014). Thus, it has been hypothesized that folC-linked PAS resistance occurs via 




Another common PAS resistance mechanism involves loss-of-function mutations 
in thyA, encoding a non-essential thymidylate synthase (ThyA). In M. 
tuberculosis ThyA is responsible for the 5,10-methylene-tetrahydrofolate 
dependent conversion of dUMP to dTMP (Mathys et. al., 2009; Zhang et. al., 
2015; Zhao et. al., 2014). When functional, ThyA releases DHF that must be re-
reduced in order to be utilized in folate metabolism. M. tuberculosis encodes an 
alternate thymidylate synthase (ThyX, encoded by thyX) that regenerates THF 
from 5,10-methylene-THF following catalysis (Myllykallio et. al., 2002). Thus, in 
contrast to ThyA, ThyX places limited demand of FolA for maintaining reduced 
folate pools. In other bacterial pathogens that do not encode a ThyX ortholog, 
loss-of-function mutations in thyA lead to attenuation due to a resulting thymine 
auxotrophy (Cersini et. al., 1998; Kok et. al., 2001). M. tuberculosis thyA loss-of-
function mutants are not compromised for fitness growth and survival in vivo due 
to the compensatory role of ThyX(Fivian-Hughes et. al., 2012; Maisani et. al., 
2017). 
 
One study recently described five independent PAS resistant clinical isolates 
containing a deletion of the folA-thyA coding sequence(Moradigaravand et. al., 
2016). These strains were 26 times more resistant to PAS than susceptible 
control strains. Many bacteria encode a short-chain dehydrogenase/ reductase 
(FolM, encoded by folM)(Pribat et. al., 2009). In these bacteria, FolM has the 
ability to reduce DHF to THF. M. tuberculosis does not encode a FolM ortholog 
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that would be expected to compensate for loss of FolA activity. Instead, this 
compensation likely comes from a weak DHF reductase activity that is catalyzed 
by the 5-amino-6-(5-phosphoribosylamino)uracil reductase (encoded by ribD, 
RibD) that normally functions in riboflavin synthesis(Salcedo et. al., 2001; Zhao 
et. al., 2014). Consistent with this model, ribD promoter mutations have been 
described that confer PAS resistance and were shown to render folA as non-
essential in M. tuberculosis(Zhang et. al., 2015; Zhao et. al., 2014).  
 
PAS is prone to exclusion from the cytoplasm by the action of efflux pumps. 
Overexpression of the major facilitator superfamily protein Tap (encoded by 
rv1258c, Rv1258c) in Mycobacterium bovis BCG conferred resistance to 
PAS(Ramón-García et. al., 2012a). Furthermore, overexpression of Tap in M. 
tuberculosis and M. bovis BCG conferred resistance to a variety of other 
antimicrobial agents that do not target folate biosynthesis including streptomycin, 
vancomycin, and tetracycline(Aínsa et. al., 1998; Ramón-García et. al., 2012b; 
Siddiqi et. al., 2004). 
 
As described in Chapter 3, the folate biosynthesis pathway has a cyclic nature. 
FolP inhibitors such as sulfamethoxazole (SMX) increase PABA biosynthesis and 
could be modulating 6-hydroxymethyl-7,8-dihydropterin pyrophosphate 
biosynthesis(Minato et. al., 2018). We hypothesize one mechanism of PAS 
resistance is by increasing PABA biosynthesis causing intrinsic resistance to 
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PAS. To test this hypothesis, M. tuberculosis mutants that were resistant to PAS 
were isolated. PABA biosynthesis gene expression in the PAS resistant mutants 
were measured. Finally, disruptions in PABA biosynthesis were created to 
determine if PAS activity could be potentiated and restored in the PAS resistant 
mutants. 
 
This study found that folC mediated resistant to PAS could occur through an 
increase in PABA biosynthesis causing PAS resistance. PAS susceptibility could 
be restored by disrupting PABA biosynthesis. These data suggest PABA 















Materials and methods: 
Bacterial strains, media, and growth conditions 
All information regarding primers, plasmids, and bacterial can be found in Table 
4.1-4.3 
 
M. tuberculosis strains were grown at 37ºC in either 7H9 broth (Middlebrook) 
supplemented with 0.2% (wt/vol) glycerol (Fisher Scientific), 10% (vol/vol) oleic 
acid-albumin-dextrose-catalase (OADC) (Middlebrook), and 0.05% (vol/vol) 
tyloxapol (Sigma-Aldrich) or 7H10 agar (Middlebrook) supplemented with 0.2% 
glycerol and 10% OADC. For experiments using M. tuberculosis mc27000, media 
were supplemented with 50 µg/mL of pantothenate (Sigma). 
 
All antibiotics were added when appropriate to final concentrations of 50 µg/mL 
for kanamycin, and 150 µg/mL for hygromycin. PABA free mediumwere created 
by baking glassware for a minimum of one hour at 180ºC and using PABA free 
reagents. PAS, PABA, trimethoprim (TMP), dapsone (DDS), and methotrexate 
(MTX) were purchased from Sigma and were dissolved in 100% DMSO (Sigma). 
Isoniazid was purchased from Sigma and dissolved in water. 
 
Identification of thyA or folC PAS resistance alleles 
PAS resistant mutants were previously isolated from M. tuberculosis H37Ra 
(Zhao et. al., 2014) were streaked onto 7H10 containing 1 µg/mL of PAS and 
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incubated at 37ºC for 3-4 weeks. The genomic DNA from the PAS resistant 
colonies were isolated and the folC and thyA genes were amplified using PCR 
using primers described in table 4.1. The resulting PCR product was purified 
(Qiagen) and was sequenced using the previously mentioned primers. 
Corresponding mutations were mapped onto the crystallized FolC (PDB: 2VOR) 
and ThyA (PDB: 4FOG)(Young et. al., 2008). Molecular graphics and analyses 
were performed with UCSF Chimera, developed by the Resource for 
Biocomputing, Visualization, and Informatics at the University of California, San 
Francisco(Pettersen et. al., 2004).  
 
Minimum inhibitory concentration determination using PAS resistant isolates 
PAS minimum inhibitory concentration (MIC90) is defined as the amount of drug 
required to inhibit 90% of bacterial growth compared to the no drug control using 
the log2 dilution method. All strains were grown in inkwell bottles, with aeration, at 
37ºC. The MIC90 was determined spectrophotometrically (OD600) (GENESYS 20, 
Thermo Fisher) and was measured at 7 and 14 days, except when noted. The 
MIC90 was determined in biological triplicate for each strain. 
 
qPCR of PABA and folate biosynthesis pathways of PAS resistance isolates 
M. tuberculosis strains PAS6, PAS7, and PAS10 were grown to mid-exponential 
phase (OD600 0.4-0.6) and subcultured to OD 0.3 in 7H9 complete medium for 24 
hr at 37ºC with aeration. The cells were harvested by centrifugation (4,000 x g, 
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10 min, 4°C). The total RNA was extracted using TRIzol (Invitrogen, CA) with 
0.1% polyacryl carrier (Molecular Research Center, Inc.) by bead beating with 
0.1-mm zirconia beads (BioSpec Products). The total RNA was treated with 
Turbo DNase (Invitrogen). cDNA was synthesized and quantitative PCR was 
performed using QuantiFast SYBR Green RT-PCR (Qiagen). qPCR primers to 
amplify internal regions of the genes of interest (trpG, pabB, folP, folC, folA, thyA, 
and sigA) were designed with similar annealing temperatures (58 to 60°C) using 
Primer3(Koressaar and Remm, 2007; Untergasser et. al., 2012). Quantitative 
RT-PCR mixtures were prepared in technical triplicate using 2 SYBR green 
master mix, 1µM each primer, and 1 ng RNA. Reactions were run on a 
LightCycler 480 (Roche). The following real-time cycler conditions were used: 
reverse transcription 50ºC for 10min; PCR activation step 95°C for 5 min; 40 two-
step cycles, denaturation 95°C for 10 sec; combined annealing/extension 60°C 
for 30 sec; with data collected once per cycle during the extension phase; and 
one cycle of 95°C for 5 s, 65°C for 1 min, and 97°C with a ramp rate of 0.11°C/s 
for generation of melting curves. Cycle threshold values (Cp) were normalized to 
Cp sigA values and were normalized to the parent strain wild-type control. qPCRs 
of folC mutants were performed in biological triplicate and thyA mutants were 
performed in biological singlet.  
 




A transposon mutagenesis screen was performed on M. tuberculosis mc27000 
(Kriakov et. al., 2003) to identify strains that were auxotrophic for PABA. 
Briefly, transposon mutagenized strains were isolated on supplemented 7H10 
agar medium containing 10 μg/ml PABA. Five thousand independent colonies 
were picked and patched to supplemented 7H10 with or without 10 μg/ml 
PABA (Sigma). Mutant strains that were unable to grow on the PABA-free 
medium were purified and rescreened to confirm PABA auxotrophy. Genomic 
DNA from mutant strains that showed a PABA auxotrophic phenotype was 
extracted and transposon insertion sites were determined as previously 
described (Rubin et. al., 1999). 
 
M. tuberculosis H37Ra ΔpabB was constructed as described in Chapter 2, 
except M. tuberculosis H37Ra was used instead of M. tuberculosis H37Rv. 
 
M. tuberculosis H37Ra was used as a template for constructing pabC and 
pabB complementation plasmids. Both genes were amplified by PCR, the pabB 
gene was digested with NcoI and HindIII, the pabC gene was digested with 
HindIII and EcoRI. The resulting PCR product for pabC was ligated into an a 
previously digested pJT6a, modified from pTIC6a using same restriction 
enzymes (Glover et. al., 2007). The resulting PCR product for pabB was 
ligated into an already digested pMV306 plasmid using the same restriction 
enzymes(Stover et. al., 1992). The resulting plasmids were propagated in E. 
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coli DH5α and were sequenced verified. Once plasmids were sequence 
verified they were electroporated into the corresponding M. tuberculosis 
strains, the resulting colonies were evaluated by colony PCR to confirm the 
presence of the plasmid.  
 
 Phenotypic validation of PABA auxtrophs  
M. tuberculosis mc27000 pabC::himar1 was grown in medium containing 10 
ng/mL PABA to mid-exponential phase (OD600 0.4-0.6) and washed three times 
in PABA free 7H9 medium. The bacterium was subcultured to OD600 0.01 in 
PABA free complete 7H9 medium with or without 10 µg/mL and was incubated 
with aeration at 37ºC. The OD600 was measured every two to three days as 
indicated.  
 
M. tuberculosis H37Ra ΔpabB was grown in 7H9 medium containing 10 ng/mL of 
PABA to mid-exponential phase and washed three times in 7H9 PABA free 
medium. The bacterium was subcultured to OD600 0.01 in 7H9 medium with or 
without 10 µg/mL of PABA. The cultures were incubated with aeration at 37ºC. 
The OD600 was measured every two to three days as indicated.  
 
A kill curve was generated by growing M. tuberculosis H37Ra ΔpabB in 7H9 
medium containing 10 ng/mL of PABA to mid-exponential phase and washed 
three times in 7H9 PABA free medium. The bacterium was subcultured to OD600 
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0.01 in 7H9 PABA free medium. The cultures were incubated with aeration at 
37ºC. Every 7, 14, 21, and 28 day aliquots were taken and plated for colony 
enumeration on 7H10 complete medium with 10 µg/mL PABA. The colonies were 
counted after 3-4 weeks of growth at 37ºC.  
 




PAS resistance mutations primarily map to folC and thyA 
Recent findings show that M. tuberculosis PAS resistant clinical isolates 
frequently have mutations that map to folate biosynthesis and metabolism, 
namely to thyA and folC(Mathys et. al., 2009; Zhang et. al., 2015; Zhao et. al., 
2014). thyA encodes a thymidylate synthase that converts dUMP to dTMP with 
the concomitant conversion of 5,10-methylene-tetrahydrofolate to dihydrofolate. 
folC encodes dihydrofolate synthase, an essential enzyme required for the 
glutamylation of 7,8-dihydropteroate (DHP) to 7,8-dihydrofolate (DHF). To further 
investigate molecular mechanisms for PAS resistance, we selected for resistant 
strains and performed genotypic characterization. Of eight PAS resistant strains 
that were analyzed, only two were found to have mutations in folC (FolC E153A) 
(Figure 4.1). These isolates had PAS MIC90 of 1.2 µg/ml and 4.8 µg/ml (Table 
4.4). Five strains were found to have mutations in thyA and corresponded to the 
following positions in the predicted protein S54A, L7V, N134K, H147N, and 
G15D (Table 4.4 and Figure 4.2). thyA mutations had a PAS MIC90 ranging from 
9.6 µg/ml to 19.2 µg/ml (Table 4.4). One strain did not have mutations in folC or 
thyA and had the greatest resistance to PAS with a MIC90 of 38.4 µg/ml (Table 
4.4).  
 




Previous work has demonstrated that dihydrofolate reductase inhibitors can 
cause an increase in PABA biosynthesis through a feedback mechanism(Minato 
et. al., 2018). Based on our previous study of FolC variants associated with PAS 
resistance, we hypothesized that the folC mutants would have compromised 
DHF synthesis. This defect could result in M. tuberculosis synthesizing more 
PABA and folates for growth, thereby out competing PAS incorporation. To test 
this hypothesis, we performed qPCR on representative PAS resistant thyA and 
folC mutants in the absence of PAS. We found the folC PAS resistant strains 
PAS7 and PAS10 had higher expression of trpG, pabB, folP, folA, and thyA 
(roughly 4, 9, 2, 3, and 10 fold respectively) (Figure 4.3). The thyA PAS resistant 
strain PAS6 had increased gene expression of pabB and thyA (roughly 3 and 3 
fold, respectively) (Figure 4.3).  
 
Disruption in PABA biosynthesis genes potentiates activity of PAS and 
structurally related antifolates 
Mutations in folC cause an increase in both PABA and folate biosynthesis. 
Therefore, we hypothesized disruptions in PABA biosynthesis would re-sensitize 
the folC resistant mutants to PAS. First we performed a transposon screen to 
identify transposon disruptions that would lead to PABA auxotrophy. Our screen 
yielded a transposon insertion in pabC, encoding PabC an amino-
deoxychorismate lyase. M. tuberculosis mc27000 pabC::himar1 was a strict 
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auxotroph on 7H10 plates in the absence of PABA (data not shown). In liquid 
medium the strain could grow, albeit at a reduced rate, compared to the wild-type 
and complemented control (Figure 4.4).  
 
Next, we determined the MIC90 of PAS, FolP inhibitors (SMX, STZ, DDS), MTX, 
TMP, and isoniazid in M. tuberculosis mc27000 pabC::himar1. PAS and all FolP 
inhibitors tested showed enhanced activity against M. tuberculosis mc27000 
pabC::himar1 relative to the parental control (Table 4.5). Neither TMP or MTX 
showed any change in MIC90 for M. tuberculosis mc27000 pabC::himar1 (Table 
4.5). Isoniazid, a M. tuberculosis cell wall inhibitor, showed no changes in MIC90 
for  M. tuberculosis mc27000 pabC::himar1 (Table 4.5). 
 
pabB deletion confers PABA auxotrophy and restores PAS susceptibility in folC 
mutants 
Although M. tuberculosis mc27000 pabC::himar1 showed enhanced susceptibility 
to antifolates such as PAS and sulfa-drugs, it is not a PABA auxotroph. We 
hypothesized the protein upstream of PabC in the PABA synthesis pathway, 
PabB an amino-deoxychorismate synthase, encoded by pabB, would be 
essential for PABA synthesis. Indeed M. tuberculosis H37Ra ΔpabB could not 
grow in the absence of PABA, unless pabB was supplied in trans (Figure 4.5). 
Furthermore, M. tuberculosis H37Ra ΔpabB could be chemically complimented 
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with the addition of exogenous PABA (Figure 4.5). Interestingly, M. tuberculosis 
H37Ra ΔpabB lost viability as early as 7 days without exogenously 
supplemented PABA (Figure 4.6). 
 
PABA is a known antagonist of PAS. Since M. tuberculosis H37Ra ΔpabB cannot 
grow in the presence of exogenous PABA, we performed a dose response with 
varying concentrations of PABA and determined the MIC90 of PAS. In M. 
tuberculosis H37Ra, the PAS MIC90 increased with increasing concentrations of 
supplemental PABA. This trend was also observed in the M. tuberculosis H37Ra 
ΔpabB; however, the PAS MIC90 was much lower than the parent strain in the 
presence of 1 ng/ml and 10 ng/ml of PABA (Figure 4.7).  
 
To test if we could restore PAS susceptibility in folC mutants we created a pabB 
deletion in M. tuberculosis PAS7. M. tuberculosis PAS7 also exhibited a dose 
response increase in the PAS MIC90 in the presence of increasing concentrations 
of PABA (Figure 4.7). This trend was also observed in the M. tuberculosis PAS7 
ΔpabB (Figure 4.7). Notably, the PAS MIC90 of M. tuberculosis PAS7 ΔpabB was 
near the wild-type drug susceptible parent strain in the presence of 1 ng/ml and 
10 ng/ml (Figure 4.7). Furthermore, the PAS MIC90 of M. tuberculosis PAS7 
ΔpabB was restored to that of the parent drug resistant strain in the presence of 




Characterization of PAS resistant strains 
We isolated PAS resistant laboratory strains of M. tuberculosis in an effort to 
discover novel resistance mechanisms. The PAS MIC90 of these strains were 
determined and eight were found to be resistant to PAS. Of these strains, 2 were 
found to have mutations in folC, 5 were found to have mutation in thyA, and one 
did not have mutations that mapped to folC or thyA. The mutations that mapped 
to folC were found within the active site and resulted in a non-synonymous 
change from charged, glutamic acid to non-polar alanine. These mutations have 
been described previously(Zhao et. al., 2014). Interestingly, both folC strains had 
mutations in the same location; however, the MIC90 were different. This suggests 
that there could be a secondary mutation somewhere else in the genome and 
warrants further investigation. 
 
FolC E153A mediated PAS resistance could occur by preventing binding of 
hydroxy-DHP. Specifically, hydroxy-DHP could form hydrogen bonding or salt 
bridges via glutamic acid in the native enzyme that is not required for binding 
DHP. These interactions would be abolished in the presence of alanine. This 
hypothesis would be difficult to test since hydroxy-DHP is only stable for about 
3hrs in ambient oxygen. FolC has a very slow catalytic turnover and previous 
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FolC enzymatic assays require 24hrs to determine enzymatic activity (Dawadi et. 
al., 2017; Zhao et. al., 2014).  
 
Treatment with FolA inhibitors leads to folate starvation in E. coli. We have 
recently shown that treatment with FolA inhibitors resulted in increased 
production of PABA, in E. coli(Minato et. al., 2018). FolC E153A mutants had 
reduced enzymatic activity (~20% of wild-type) utilizing the native substrate, 
DHP(Zhao et. al., 2014). Since FolC mutants had reduced enzymatic activity, we 
hypothesized that the FolC mutants could be limited for folates. These FolC 
mutants could be synthesizing more PABA to compensate for the reduced 
enzymatic activity of FolC E153A.  
 
In contrast to PAS resistant folC mutant strains, thyA mutant strains were the 
most prevalent and changes corresponded to the active site residues (S54A and 
H147N) as well as residues outside of the active site (L7V, G15D, and N134K). 
ThyA H147N has already been described as a molecular mechanism of 
resistance to PAS(Zhao et. al., 2014). Mutations in ThyA G15 have been 
described (G15R); however, G15D represents a novel mutation. We also 
described 3 novel ThyA mutations (S54A, L7V, N134K). Interestingly, all 
mutations in thyA had the greatest PAS resistance (MIC90 9.6-19.6 µg/ml) 
compared to mutations in folC (MIC90 1.2-4.8 µg/ml). Furthermore, we noticed 
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some of thyA mutants had a growth defect. This suggests that thyA mediated 
PAS resistance mechanisms are different than folC mediated PAS resistance. 
 
In addition, we isolated one mutant that did not have any mutations that mapped 
to thyA or folC. This strain had the highest PAS resistance out of all of the 
mutants. We have whole genome sequenced this strain and are awaiting 
sequencing results.  
 
PABA biosynthesis genes are upregulated in folC mutants 
During treatment with FolA inhibitors PABA levels are increased(Minato et. al., 
2018). We hypothesized that folC mutants are not able to produce enough 
folates causing an increase in PABA biosynthesis genes. To test this hypothesis, 
we performed qPCR on the folC and thyA mutants in the absence of PAS. We 
found that the folC mutants had increased expression of PABA and folate 
biosynthesis genes. thyA mutants only had increased expression of folA and 
thyA biosynthesis genes. This also suggests the mechanistic basis for folC 
mediated PAS resistance is different than thyA. Specifically, that folC causes an 
increase in PABA and folate biosynthesis. Since it appears that thyA increases 
folA and its own expression, we hypothesize that thyA mediated resistance is 




Targeting PABA biosynthesis sensitizes M. tuberculosis to folP inhibitors and 
PAS 
We hypothesized we could restore susceptibility to PAS by creating a disruption 
in PABA biosynthesis in PAS resistant folC mutants. First we performed a 
transposon mutagenesis screen for a PABA auxotrophic phenotype. We isolated 
a mutant strain with a transposon insertion in pabC that could only grow in the 
presence of PABA on solid medium. Unfortunately, this strain, M. tuberculosis 
mc27000 pabC::himar1 could still grow in the absence of PABA in liquid culture. 
Since pabC encodes an amino-deoxychorismate lyase requiring water to 
eliminate pyruvate, it is possible that this hydrolysis could occur in the absence of 
PabC. 
 
M. tuberculosis mc27000 pabC::himar1 was tested for susceptibility to a variety of 
folate biosynthesis inhibitors including and was hypersusceptible to all 
sulfonamides tested as well as DDS and PAS. There was no change in TMP, 
MTX and isoniazid susceptibility. As discussed in Chapter 3, sulfonamides, as 
well as DDS and PAS can be antagonized by exogenous PABA; therefore, this 
hypersusceptibility is likely due to the decrease in intrinsic PABA production. As 
discussed in Chapter 3, PABA does not antagonize TMP. Since M. tuberculosis 
does not encode a folate transporter, it is unlikely that MTX was transported into 




Although we were anticipating the pabC mutant would be a PABA auxotroph, we 
assessed if a deletion in pabB would result in complete PABA auxotrophy. 
Indeed, a deletion in pabB resulted in a complete PABA auxotrophy. Since the 
strain could not grow in the absence of PABA, we assessed if a deletion in pabB 
was bacteriostatic or bactericidal. We found that a deletion in pabB is 
bactericidal. Therefore, pabB represents a novel drug target in treating M. 
tuberculosis.  
 
Since PABA limitation is bactericidal for M. tuberculosis H37Ra ΔpabB, we 
added exogenous PABA in order to assess the PAS MIC. Even in the presence 
of exogenous PABA, M. tuberculosis H37Ra ΔpabB was hypersusceptible to 
PAS. The PAS MIC90 was restored to the drug-susceptible wild-type level when 
pabB was deleted in a folC E153A strain. Taken together this data suggest that 
the folC mutants synthesize more PABA resulting in antagonism of PAS.  
 
In M. tuberculosis, (-)-abyssomicin C is a known PabB inhibitor and is 
bactericidal(Freundlich et. al., 2010). A future study could investigate treating M. 
tuberculosis with (-)-abyssomicin C in combination with PAS, sulfonamides, and 
DDS. We anticipate that the combination of (-)-abyssomicin C would have a 
synergistic effect. Furthermore, co-treating folC PAS resistant strains with (-)-





Table 4.1. Oligonucleotide primers used in this study. 
Primer 
name 
Primer sequence1 Source Restriction 
enzyme 





CCTACCGGGAGATCGAGCCG This work NA 
folC seq 
rev 





CGCCGCGCTTGCATCGCCCGCT This work NA 
thyA seq 
rev 
TGTCGCTTGAGCCCAGATCA This work NA 
trpG qPCR 
for 
ACGGTGTCCAGTTCCATCC This work NA 
trpG qPCR 
rev 
GTGTCGTCTTGCGTCCATC This work NA 
pabB 
qPCR for 
GGGTACTGGCGTGTCTGGAA This work NA 
pabB 
qPCR rev 
CGAACCCGTCGATGAAGAAG This work NA 
folP qPCR 
for 
TGCCCAGATGGTCAACGA This work NA 
folP qPCR 
rev 
ATCAACACCCACGGCACA This work NA 
folC qPCR 
for 
AAGGCGGGCATCATCACT This work NA 
folC qPCR 
rev 
AGCAGCACCTCCATGACCTT This work NA 
folA qPCR 
for 
ATTCGCTGCCGGCTAAAG This work NA 
folA qPCR 
rev 
TCGAGTGAACCGACAACCTC This work NA 
thyA qPCR 
for 
GTTTCCCGCTGCTCACTACC This work NA 
thyA qPCR 
rev 
GCCTGTATCACTTGCCCATTC This work NA 
sigA qPCR 
for 
CGACGAAGACCACGAAGACC  This work NA 
sigA qPCR 
rev 


























TTTTTT CCATGG ACG CCG AGC GTG CTT 
TTC CTA CT 
This work NcoI 
pMV306-
pabB rev 
TTTTTT AAGCTT CTA CCG CAC TTT GCT GGC 
TAA CC 
This work HindIII 
pJT6a-
pabC for 
TTTTTT AAGCTT ATG TTG AGG CAG ACG 
GGC GT 
This work HindIII 
pJT6a-
pabC rev 
TTTTTT GAATTC TCA CCG GTC GCT GAC AAT 
AGC 
This work EcoRI 






Table 4.2. Plasmids used in this study.
Plasmid Relevant characteristics Source 
p0004S Plasmid used for allelic exchange, Hygror, sacB (Baughn et. al., 
2010) 
phAE159 Phasmid used for specialized transduction, Penr (Bardarov et. 
al., 2002) 
pMV306 Mycobacteria integrating vector, Kanr (Stover et. al., 
1992) 
pMV306-pabB pMV306 containing pabB and 150bp upstream of 
pabB, Kanr 
This work 
pJT6a Modified pTIC6a (Glover et. al., 2007), replacing the 
Kanr cassette with hygror, tet inducible  
This work 
pJT6a-pabC pJT6a containing pabC under tet inducible expression. This work 
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Table 4.3. Strains used in this study. 
Strain Name Relevant characteristics Source 
E. coli   
 DH5α Cloning strain Lab stock 
M. tuberculosis    
 H37Ra Wild-type attenuated strain derived from H37Rv Lab stock 
 PAS6 H37Ra PASr ThyA S54A This work 
 PAS7 H37Ra PASr FolC E153A This work 
 PAS10 H37Ra PASr FolC E153A This work 
 PAS39 H37Ra PASr ThyA L7V This work 
 PAS47 H37Ra PASr ThyA N134K This work 
 PAS48 H37Ra PASr ThyA H147N This work 
 PAS54 H37Ra PASr ThyA G15D This work 
 PAS57 H37Ra PASr unknown mutation This work 
 ΔpabB H37Ra pabB::hygro-sacB cassette, Hygror This work 
 ΔpabB-pMV306-
pabB 
ΔpabB containing pPV306-pabB, Kanr, Hygror  This work 
 PAS7ΔpabB PAS7 containing ΔpabB, Hygror This work 
 mc27000 H37Rv ΔRD1 ΔpanCD  (Sambandan 
et. al., 2008) 
 mc27000 
pabC::Tn 










Table 4.4. Characterization of PAS resistant strains of M. tuberculosis H37Ra. 
Strain PAS MIC901 
(µg/mL) 
folC mutation thyA mutation 
H37Ra 0.3 WT WT 
PAS6 9.6 WT S54A 
PAS7 4.8 E153A WT 
PAS10 1.2 E153A WT 
PAS392 9.6 WT L7V 
PAS472 ≥9.6 WT N134K 
PAS48 9.6 WT H147N 
PAS542 19.2 WT G15D 
PAS572 38.4 WT WT 
1Defined by the minimum concentration of PAS to inhibit 90% of growth 
compared to a no drug control after two weeks. 




Table 4.5. Minimum inhibitory concentration (MIC1) of various antifolates in M. 
tuberculosis mc27000 pabC::Tn. 
 
1MIC90 defined as minimum amount of drug required to inhibit 90% of growth 














PAS 0.3 ≤0.000234 ≥1000 
Sulfamethoxazole 8 ≤1 ≥8 
Sulfathiazole 4 ≤0.06 ≥64 
Dapsone 64 ≤0.13 ≥512 
Trimethoprim ≥512 ≥512 1 
Methotrexate ≥512 ≥512 1 






























Proposed dihydropteroate binding pocket 
E153A ADP 
Figure 4.1. Structural consequences of FolC mutations. The FolC mutation 
described in Table 4.3 was mapped using PDB file 2VOR. The ADP and the 

































































Figure 4.2. Structural consequences of ThyA mutations inside and outside 
of the active site. ThyA mutations found within the active site a) and outside 
of the active site b) are described in Table 4.3 and were mapped using PDB 
file 4FOG. The substrate binding pocket is shown with 5-































































Figure 4.3. PABA and folate biosynthesis genes are upregulated in folC 
PAS resistant mutants but not in thyA PAS resistant mutants. M. 
tuberculosis H37Ra was grown to mid-exponential phase (OD 0.4-0.8) in 
7H9 complete medium. The RNA was extracted and PABA and folate 
biosynthesis gene expression was measured. The RNA expression level 
represented is relative to H37Ra. folC data represents the average and 
standard deviation of three independent replicated. thyA data represents the 




















H37Ra ΔpabB mc27000 C::Tn 
mc27000 pabC::Tn 
pJT6a-pabC 
 0 5 10 
Time (days) 
Figure 4.4. mc27000 pabC::Tn is a bradytroph in liquid medium. 
mc27000, mc27000 pabC::Tn, and mc27000 pabC::Tn-pJT6a-pabC 
were grown in 7H9 supplemented with 1 ng/ml PABA. The cells were 
diluted in 7H9 PABA free medium and grown in 37ºC with agitation. 
OD600 measured at indicated time points. Data represents average of 
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Figure 4.5. H37Ra ΔpabB is a PABA auxotroph. H37Ra, H37Ra 
ΔpabB, and H37Ra ΔpabB-pMV306-pabB were grown in 7H9 
supplemented with 1 ng/ml PABA. The cells were diluted in 7H9 a) 
PABA free medium or b) supplemented with 10 µg/ml PABA and 
grown in 37ºC with agitation. OD600 measured at indicated time 
points. Data represents average of three biological replicates with 
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Figure 4.6. H37Ra ΔpabB is bacteriocidal. H37Ra and H37Ra ΔpabB 
were grown in 7H9 supplemented with 1 ng/ml PABA. The cells were 
diluted in 7H9 PABA free medium grown in 37ºC with agitation. CFU’s 
were enumerated every 7 days for 21 days. Data represents average 
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Figure 4.7. Restoration of susceptibility to PAS in folC mutant. M. 
tuberculosis strains were in 7H9 containing 1 ng/mL PABA and subcultured 
in varying concentrations of PABA and the PAS. The minimum inhibitory 
concentration (MIC90) required to inhibit 90% growth was determined after 
two weeks of growth. Data represents three biological replicates with 














para-Aminosalicylic acid selectively inhibits Mycobacterium tuberculosis 
dihydrofolate reductase 
Many antimicrobial agents have off target effects such as inhibition of commensal 
bacteria and impairment of human cells. This facet of drug action can present a 
problem in the context of the human gastrointestinal (GI) microbiota. It has long 
been known that this consortium of microbes provides protection from 
opportunistic gut pathogens through competition. Recently, there have been 
multiple studies showing the human GI microbiota is also important for 
development and maintenance of an effective and appropriate immune 
response(Belkaid and Hand, 2014; Cianci et. al., 2018; Levy et. al., 2017). 
Perturbations or loss of diversity within the GI microbiota have been shown to 
dampen the immune response to several pathogens(Belkaid and Hand, 2014; 
Cianci et. al., 2018; Levy et. al., 2017). For example, perturbations in the 
microbiota can promote virulence of the opportunistic pathogen, Clostridium 
difficile, leading to pseudomembranous colitis (Bien et. al., 2013). To prevent off 
target effects on the host and beneficial microbiota, there is an increased need to 
develop drugs that selectively inhibit a pathogen of interest. 
 
para-Aminosalicylic acid (PAS) has been in clinical use for treatment of 
tuberculosis for over 70 years. Previous work suggests that PAS targets the 
folate biosynthesis pathway, specifically by inhibiting dihydrofolate reductase 
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(FolA) in Mycobacterium tuberculosis (Chakraborty et. al., 2013; Dawadi et. al., 
2017; Youmans et. al., 1947; Zhao et. al., 2014; Zheng et. al., 2013). 
Interestingly, PAS has shown no activity against any other bacterial species that 
has been evaluated (Ivanovics et. al., 1948; Ragaz, 1948; Sievers, 1946; Tobie 
and Jones, 1949; Wyss, 1943). We built upon these studies and demonstrated 
that PAS is converted to hydroxy-dihydrofolate (DHF) that subsequently inhibits 
FolA. Until this study, it was unclear why other bacteria do not show PAS 
susceptibility. Possible resistance mechanisms to PAS included lack of uptake, 
exclusion, inactivation, failure to synthesize hydroxy-DHF and lack of inhibition of 
FolA by hydroxy-DHF. Using biochemical assays, we determined that hydroxy-
DHF does not inhibit FolA from other bacterial species that we tested. Rather, 
FolA from other microbes is able to utilize hydroxy-DHF as a suitable substrate 
for reduction to hydroxy-tetrahydrofolate. Importantly, we found that these other 
microbes were able to utilize PAS in lieu of PABA in folate synthesis and these 
PAS-containing folates could be used as a cofactor for one carbon metabolism. 
Thus, we conclude that PAS selectivity is endowed with a specific structural 
feature of the M. tuberculosis FolA. Interestingly, the broad spectrum FolA 
inhibitor trimethoprim (TMP) has poor activity against M. tuberculosis(Dias et. al., 
2014). This suggests that FolA could be exploited as a selective target for 
inhibiting M. tuberculosis. These observations will be instrumental in 
development of more potent next generation FolA inhibitors that maintain 





There are two hypotheses that could account for PAS selectivity for the M. 
tuberculosis FolA. First, based on our studies, FolAMtb Q28 is responsible for 
forming an additional hydrogen bond with hydroxy-DHF. This hydrogen bond is 
absent in FolAE.coli. Second, the active site in FolAMtb is much smaller and more 
hydrophilic compared to FolAE.coli that is larger and more hydrophobic. These 
differences could be utilized to create more potent and selective FolAMtb inhibitor. 
One such modification could involve making the hydroxy-group on PAS more 
electronegative. Replacing the hydroxyl group with a fluorine or chlorine is 
predicted to allow for stronger hydrogen bond interactions. Another potential 
approach would be to modify the hydroxyl group on PAS to make it a bulky 
functional group, such as replacing it with an acetyl group. However, protein 
structural studies of FolAMtb and FolAEc complexed with hydroxy-folate need to be 
completed before any meaningful structure-based discovery campaigns can be 
performed.  
 
The mechanistic basis for para-aminosalicylic acid toxicity and resulting 
antagonism by sulfa-drugs  
PAS is primarily used to treat drug resistant strains of M. tuberculosis, due to its 
severe side effects. The main side effect is GI distress, causing many patients to 
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discontinue treatment. Historically, physicians have attributed GI distress to the 
presence of impurities due to instability of PAS or toxic compounds that arose 
during synthesis(Mitchell et. al., 1954). We determined that bacteria of the GI 
tract can utilize PAS to produce a cytotoxic hydroxylated folate species, such as 
hydroxy-DHF and hydroxy-folate. We hypothesize that hydroxylated folates 
cause the depolarization of tight junctions. The collapse of tight junctions allows 
for bacteria in the GI tract to transverse into the lamina propria resulting in 
sepsis. Our data strongly suggest that to avoid GI distress, PAS should not be 
given orally in its current dosage or in the current form. For PAS to be used as a 
well-tolerated antitubercular agent it should be modified such that it is not utilized 
or accessible by GI bacteria.  
 
In an attempt to counter this toxicity, we co-treated mice with SMX to prevent 
PAS incorporation into hydroxy-folates in the GI tract. This approach prevented 
toxicity but also demonstrated that SMX can antagonize the antitubercular 
activity of PAS. Our data suggest that this antagonism was mediated by 
increased flux through pterin biosynthesis. While these observations indicate that 
SMX cannot be used to mitigate GI distress caused by PAS, they do provide 
proof of concept that PAS-mediated GI distress can be mitigated through 




Alternative mechanisms to reduce PAS toxicity 
Another mechanism to reduce PAS GI distress may be to orally administer high 
doses of folinic acid. Folinic acid, also known as leucovorin, is a 5-formyl 
derivative of tetrahydrofolate and is used with treatment regimens involving drugs 
that target the folate pathway in humans. Both the cancer chemotherapeutic 
agent methotrexate (MTX) and the antiprotozoan drug pyrimethamine are given 
orally and are associated with GI distress and toxicity. To counter this toxicity 
these drugs are typically prescribed with folinic acid (Goldman and Matherly, 
1987). Co-treating with folinic acid prevents some off-target effects of MTX by 
allowing some synthesis of purines and pyrimidines to occur.  
 
PAS toxicity could also be reduced by administering pro-drug formulations that 
enable selective release only at the site of infection. This approach would prevent 
PAS from being taken up by other bacteria and prevent off target effects. One 
such strategy that has been used in treating cancer involves conjugating drugs to 
tumor specific antibodies that are taken up via receptor mediated 
endocytosis(Dan et. al., 2018). The antibody-drug conjugate is trafficked to the 
lysosome where the acidic pH catalyzes release the drug(Ekins, 2014). There 
are currently two FDA approved antibody-drug conjugates(Ornes, 2013). Using 
this knowledge, we could design PAS-antibody conjugates that selectively target 
macrophages. A similar approach would be to conjugate PAS to a nanoparticle 
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that can be readily phagocytosed by macrophages (Rattan et. al., 2017). Drug 
delivery by nanoparticles has been used to target cancer cells and macrophages 
(Rattan et. al., 2017). Another potential selective release approach could utilize a 
beta-lactam-PAS conjugate that can only be cleaved by M. tuberculosis specific 
beta-lactamase(Majewski et. al., 2016). Beta-lactamases are secreted proteins, 
therefore the PAS-conjugates would be cleaved to release PAS only in the 
vicinity of M. tuberculosis.  Feasibility of these targeted delivery approaches 
would be dependent upon achieving a critical concentration of PAS at the site of 
infection. 
 
Other PAS implications for human health 
Sulfonamides are used to treat a wide array of bacterial, fungal and protozoan 
infections. Importantly, SMX is given as prophylactic therapy to prevent 
opportunistic infections in HIV-positive individuals. The data presented in this 
dissertation can be used to inform physicians of possible drug-drug interactions 
between sulfonamides and PAS. 
 
In certain areas of the world HIV-TB co-infections are common. According to the 
WHO roughly 200,000 people are co-infected with HIV-TB(WHO, 2018). Thus, it 
is likely that a subset of patients have been prescribed SMX for prophylactic HIV-
therapy and PAS to treat MDR-TB. Since co-treatment with SMX antagonized the 
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activity of PAS in our in vitro and in vivo studies, we propose that PAS and SMX 
co-treatment needs to be reevaluated in a clinical setting.  
 
Further, since hydroxy-folates could be causing toxicity in other areas of the 
body, research focused on measuring hydroxy-folates in the blood stream are 
warranted. As a folate-rich diet is critical to support normal fetal development in 
pregnant women, hydroxy-folates found within the circulatory system could pose 
a complication in this population. If hydroxy-folates can cross the placental 
barrier they could cause neural defects or other developmental disorders in the 
fetus. While it is possible that this danger could be mitigated by co-administering 
PAS and folinic acid, safety of PAS treatment in pregnant women should be 
evaluated. 
 
Recently, associations have been made between development of autism and 
mutations in the gene for MTHFR, methylenetetrahydrofolate reductase(Boris et. 
al., 2004). In humans, MTHFR converts 5,10-methylenetetrahydrofolate and 
NADPH to 5-methyltetrahydrofolate and NADP+. 5,10-methyltetrahydrofolate is 
the methyl donor for synthesis of methionine from homocysteine via methionine 
synthase. Pregnant women who carry the MTHFR C677T polymorphism have a 
higher chance of having a child with autism(Boris et. al., 2004). Furthermore, 
infants who are homozygous for this polymorphism are at a higher risk for 
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developing autism and may be given folinic acid as a preventive measure (Boris 
et. al., 2004). Although a causal association between mutations in MTHFR and 
autism is still controversial, there are speculations that it may occur via impaired 
folate metabolism (Boris et. al., 2004; Raghavan et. al., 2018; Sener et. al., 
2014). Thus, if hydroxy-folates impair folate metabolism, PAS treatment in 
pregnant women could contribute to autism or other disorders in the developing 
fetus. As folates are abundant in breast milk, it may be beneficial to co-administer 
folinic acid to nursing women taking PAS. A systematic study of the impact of 
PAS on fetal and childhood development in pregnant or breastfeeding women is 
essential to address this important concern. 
 
Final Conclusions 
My dissertation is the first to determine that PAS selectively inhibits M. 
tuberculosis dihydrofolate reductase enzyme and subsequently, the folate 
biosynthetic pathway. It was further shown that using PAS and sulfonamides 
together prevented both drugs from working correctly against M. tuberculosis or 
against in other bacterial species. The results generated from this work will be 
used to inform the current clinical practices in combination therapy and foster a 
paradigm shift in the treatment regimen administered to HIV TB co-infected 
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